[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Euro Diagnostica AB\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":187},{"warningLetters":4,"total":186},[5,31,50,67,91,114,132,150,167],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},21693,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-10-06T04:00:00Z\">10\u002F06\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-09-01T04:00:00Z\">09\u002F01\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdiagnostics-llc-730301-09012026\">O.N. Diagnostics, LLC\u003C\u002Fa>","Center for Devices and Radiological Health","Medical Device Reporting\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Shui Wong\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>O.N. Diagnostics, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1936 University Ave, Ste 280\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Berkley\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94704\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS 730301\u003C\u002Fp>\u003Cp>9\u002F1\u002F2026\u003C\u002Fp>\u003Cp>Dear Ms. Wong,\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Berkley, CA, from March 12-17, 2026, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures (or markets) the VirtuOst and VirtuOst Vertebral Fracture Assessment (VFA) software products. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. The VirtuOst and VirtuOst VFA software products are device software functions because they analyze medical images for use in the diagnosis of existing vertebral fractures and the management of osteoporosis. As such, your firm has responsibility for maintaining full compliance with all applicable pre- and post-market requirements associated with these device software functions.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection revealed that the VirtuOst VFA 3.0.0 is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device as described and marketed. The VirtuOst VFA 3.0.0 is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution this device with changes or modifications in the device that could significantly affect the safety or effectiveness of the device without submitting a new premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(i).\u003C\u002Fp>\u003Cp>Specifically, the VirtuOst VFA was cleared under K171435 with the following indications: VirtuOst VFA uses sagittal sections from a spine-containing CT scan, with or without contrast enhancement, to visualize and measure vertebral deformities, classify the type and grade of any existing vertebral fracture, and from this identify patients at high risk of a future osteoporosis-related fracture. This information can be interpreted by a physician to diagnose existing vertebral fractures and to manage patients for osteoporosis.\u003C\u002Fp>\u003Cp>A review of the Software Version Control Log and “3.0.0 Release Notes” dated June 11, 2024, shows that a new machine learning algorithm was introduced for vertebral landmarking. A new model trained on different data, with different architecture, or optimized for a different objective may perform differently across patient populations, imaging equipment types, or clinical settings. This new feature fundamentally changes how the device performs, fails, and affects patients in ways that go beyond what was originally cleared and therefore the feature must be adequately validated. Inadequate validation of this new feature may lead to a device that is unable to perform clinically as expected, which may result in patient harm such as missed or inadequate diagnosis, absence or delay of results, leading to missing, inaccurate, or delayed patient assessment. It can also lead to incorrect patient management due to misinterpretation of device output or overreliance on device output for radiological image interpretation. Thus, a new premarket notification is required.\u003C\u002Fp>\u003Cp>Additionally, the VirtuOst VFA 3.0.0 version involves two other changes that each independently raise significant regulatory concerns. First, the device has migrated from a desktop application to a web-based architecture, which introduces network-exposed attack surfaces, authentication vulnerabilities, and other cybersecurity risks inherent to internet-accessible platforms. As your firm acknowledged during the inspection, the change from a desktop application to a web-based architecture expanded the “cyberattack surface area.” Second, the technology platform has been migrated from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> only, which necessitates comprehensive re-verification and re-validation of the entire software codebase, including changes to third-party libraries and dependencies. FDA has not reviewed your device's Software Bill of Materials (SBOM) or documentation of third-party components affected by this migration.\u003C\u002Fp>\u003Cp>Each of these changes could significantly affect the safety or effectiveness of the device by introducing new software and cybersecurity risks. Furthermore, these changes require a new premarket notification pursuant to 21 CFR 807.81(a)(3)(i).\u003C\u002Fp>\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>Our office requests that O.N. Diagnostics cease any activities that result in the misbranding or adulteration of the VirtuOst VFA 3.0.0, such as the commercial distribution of the device for the uses discussed above.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality Management System Regulation Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality Management System Regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. We received a response from Dr. Kopperdahl, Director of Research and Development, dated April 1, 2026, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to document procedures for corrective actions and take action to eliminate the cause of nonconformities in order to prevent recurrence, as required by ISO 13485:2016, Clause 8.5.2.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Review of your CAPA procedure, DOC: SOP-017, and related records found:\u003C\u002Fp>\u003Cp>A. Failure to take necessary corrective actions without undue delay. For example:\u003C\u002Fp>\u003Cp>i. Within CAPA-0080, procedural updates from four other CAPA records identified as necessary to eliminate the cause of nonconformities and prevent their recurrence were not made for over a year and a half.\u003C\u002Fp>\u003Cp>ii. Additionally, your organization was made aware of the underlying issue related to the need to update your \u003Cstrong>(b)(4)\u003C\u002Fstrong> software three times over three years. Although CAPA-0088 was opened the day before our inspection began to address this three yearlong software issue, it was unsigned (even to demonstrate opening a new record) and no corrective actions had been identified or initiated within the record.\u003C\u002Fp>\u003Cp>B. Failure to clearly define the requirements to evaluate the need for action to ensure that nonconformities do not recur. For example:\u003C\u002Fp>\u003Cp>i. Your procedure allows use of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> ticket instead of a corrective action when there are “Individual and sporadic instances of issues that need correction do not require a CAPA”. This is one reason for some of the untimely corrective actions discussed in item A above. The procedure needs to more clearly define when a \u003Cstrong>(b)(4)\u003C\u002Fstrong> ticket may be used vs. opening a CAPA to ensure corrective action is taken appropriately.\u003C\u002Fp>\u003Cp>ii. Your organization has changed the requirements used to evaluate the need for action \u002F determine when a corrective action is necessary. CAPA-0083 included a corrective action to update to your CAPA procedure. Your findings stated the language governing when a CAPA should be opened was too broad and did not include the potential for process based CAPAs to be opened. The language targeted for update stated, “In general, a CAPA investigation will be initiated for any quality problem that is a non-conformance with respect to medical device requirements that has an associated safety hazard.”\u003C\u002Fp>\u003Cp>Therefore, in revision 11 released 10\u002F2\u002F2024, your organization implemented a change to “narrow the CAPA triggers and place more emphasis on systemic or recurring issues”. This update also included allowance to document other issues as a \u003Cstrong>(b)(4)\u003C\u002Fstrong> ticket, as previously mentioned above. These changes altered the threshold of when to open a CAPA from a safety hazard focus to systemic issues and allowed more flexibility to handle “individual and sporadic instances” through the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system. In doing so, it appears your procedure now lacks clarity for when it is necessary to open a corrective action, based on risk.\u003C\u002Fp>\u003Cp>Additionally, the impact of these changes was not evaluated prior to implementation. To maintain the integrity of the QMS, all changes must be evaluated to determine their potential impact on it. This evaluation must be conducted before implementing the change.\u003C\u002Fp>\u003Cp>C. Failure to require documentation of verification of effectiveness following corrective action implementation.\u003C\u002Fp>\u003Cp>The procedure allows closure after “A failure investigation has been completed, a corrective action has been defined and implemented, and the effectiveness of the implemented action has been evaluated.”\u003C\u002Fp>\u003Cp>Within CAPA-0080, the record includes verification of implementation, but not of effectiveness. There is no developed plan to determine how to verify effectiveness or a place to do so within the form, only a yes \u002F no checkbox.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response regarding items 1A and C above and conclude that it is not adequate. We understand your intent is to update the CAPA procedure to “strengthen requirements for effectiveness verification, including predefined acceptance criteria and sufficient prospective evidence, to ensure nonconformities do not recur”, as well as train staff, conduct a retrospective review to include performing additional analysis where necessary, and document findings. You anticipate an overall timeline of 90 days to complete all these steps (early August 2026). The CAPA documenting these actions will be closed when 100% of CAPAs over a six-month period and at least three CAPAs have demonstrated correct implementation of the revised procedure. This overall approach seems reasonable, however your response is inadequate because the requirement of ensuring necessary corrective actions are taken without undue delay has not been addressed to complete necessary procedural updates, and no records were provided for evidence of implementation of corrective actions.\u003C\u002Fp>\u003Cp>Your response related to item 1B states you intend to require documented risk assessments prior to implementation as part of change control procedures, establish criteria for when a change is ‘critical’ or ALARP, create a new form for this assessment following ISO 14971, train staff, perform a retrospective review of QMS changes over the last six months and act on those that meet new criteria, and summarize findings. You estimate all these actions to take about 90 days (early August 2026) and state this CAPA will be closed if no recurrence over a six-month period defined as failure to identify critical process changes or perform risk assessments of those changes. The adequacy of your response to item 1B cannot be determined as no records were provided for evidence of implementation of corrective actions.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to adequately document procedures to ensure that purchased product conforms to specified purchasing information and plan the monitoring and re-evaluation of suppliers, as required by 21 CFR 820, ISO 13485: 2016 Clause 7.4.1.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>For example: the procedural requirements in your organization’s Purchasing Controls procedure, rev 11, concerning how your firm will re-evaluate and conduct monitoring and trending of suppliers \u002F vendors is vague. Specifically, none of these give details of when action should be taken. For example, the procedure mentions re-evaluation frequency will be every \u003Cstrong>(b)(4)\u003C\u002Fstrong> which maybe increased based on the criticality, but gives no specific criteria or examples of when this should occur. Regarding monitoring the procedure, it discusses “periodic progress reports and incremental deliverables” but doesn’t explain when they should be run or how those will be assessed. The extent of monitoring should be commensurate with the risk of the device, or impact on the device or QMS. The procedure also mentions trending of vendor performance but contains no limits or criteria stating when action might be necessary.\u003C\u002Fp>\u003Cp>This was discussed during your recent inspection, but as it was not cited in the 483, your response did not address this violation.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Our inspection (also) revealed that your firm has failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>For example, during the inspection, your organization presented the document titled “Complaint Management Procedure”, SOP-014, Revision 15, dated January 15, 2026, as its guidance for MDR reporting. Specifically, the purpose and scope of the procedure highlights that the SOP is intended to address the requirements of 21 CFR 803. However, after reviewing the procedure, the following deficiencies were noted:\u003C\u002Fp>\u003Cp>1. Your procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1).\u003C\u002Fp>\u003Cp>a. Your procedure does not include adequate definitions of what constitutes a reportable event under 21 CFR Part 803. The fact that the procedure does not include definitions from 21 CFR 803.3 for the terms “become aware” and “caused or contributed”, and the definition described in 21 CFR 803.20(c)(1) for the term “reasonably suggests”, may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\u003Cp>b. Your procedure’s definition of “serious injury” is not consistent with 21 CFR 803.3(w) and will not allow you to correctly identify complaints as reportable events.\u003C\u002Fp>\u003Cp>Specifically, DC03055, MDR Reportability Review Memorandum 4 the regulatory definition includes both injury and illness, whereas the procedure limits the definition to injury only.\u003C\u002Fp>\u003Cp>2. Your procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the procedure does not include:\u003C\u002Fp>\u003Cp>a. Instructions for submitting information that corresponds generally to the format of Form FDA 3500A, including how you will ensure that all information reasonably known to you is submitted for each event. Specifically, which types of information corresponding generally to the format of Form 3500A will need to be submitted, including the information in your firm’s possession when the initial report is filed and any required information later obtained that was not available when the initial report is filed.\u003C\u002Fp>\u003Cp>b. Instructions for complying with the 21 CFR 803.12(a) requirement to submit reports to FDA in an electronic format that the FDA can process, review, and archive.\u003C\u002Fp>\u003Cp>3. Your organization’s MDR event files do not contain all documentation of its deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable under 21 CFR Part 803, as required under 21 CFR 803.18(b)(1)(i). Specifically, although Sections 2.2 and 2.3 of the procedure describe documentation requirements, your firm’s ONG-FRM-007 Event Report reviewed for Event 0047 did not demonstrate implementation of these requirements for reportability determination.\u003C\u002Fp>\u003Cp>A device is deemed to be misbranded under section 501(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information respecting a device required by or under section 519 of the Act, 21 U.S.C. § 360i, including adverse event reports required under CFR Part 803.\u003C\u002Fp>\u003Cp>Your firm’s response dated April 1, 2026, does not address the procedural deficiencies, given that such deficiencies were not cited on the FDA 483.\u003C\u002Fp>\u003Cp>We also note your organization’s SOP-014 procedure includes references to baseline reports in Section 4.4. Baseline reports are no longer required, and we recommend that all references to a Baseline Report be removed from your firm’s MDR procedure; see: 73 Federal Register Notice 53686, dated September 17, 2008.\u003C\u002Fp>\u003Cp>Additionally, we recommend your organization establish an active Electronic Submission Gateway Next Generation (ESG NextGen) production account for the electronic submission of MDR reports. FDA verified that, as of April 24, 2026, your firm does not have such an account. Information about the ESG NextGen can be found at: Electronic Submissions Gateway Next Generation (ESG NextGen) | FDA.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality Management System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Jeff Wooley at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 730301” when replying. If you have any questions about the contents of this letter, please contact: Lauren Priest at Lauren.Priest@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nShui Wong\n\nRecipient Title\n\nCEO\n\nO.N. Diagnostics, LLC\n\n1936 University Ave, Ste 280\n\nBerkley, CA 94704\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS 730301\n9\u002F1\u002F2026\nDear Ms. Wong,\nDuring an inspection of your firm located in Berkley, CA, from March 12-17, 2026, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures (or markets) the VirtuOst and VirtuOst Vertebral Fracture Assessment (VFA) software products. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. The VirtuOst and VirtuOst VFA software products are device software functions because they analyze medical images for use in the diagnosis of existing vertebral fractures and the management of osteoporosis. As such, your firm has responsibility for maintaining full compliance with all applicable pre- and post-market requirements associated with these device software functions.\nUnapproved Device Violation(s)\nOur inspection revealed that the VirtuOst VFA 3.0.0 is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device as described and marketed. The VirtuOst VFA 3.0.0 is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution this device with changes or modifications in the device that could significantly affect the safety or effectiveness of the device without submitting a new premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(i).\nSpecifically, the VirtuOst VFA was cleared under K171435 with the following indications: VirtuOst VFA uses sagittal sections from a spine-containing CT scan, with or without contrast enhancement, to visualize and measure vertebral deformities, classify the type and grade of any existing vertebral fracture, and from this identify patients at high risk of a future osteoporosis-related fracture. This information can be interpreted by a physician to diagnose existing vertebral fractures and to manage patients for osteoporosis.\nA review of the Software Version Control Log and “3.0.0 Release Notes” dated June 11, 2024, shows that a new machine learning algorithm was introduced for vertebral landmarking. A new model trained on different data, with different architecture, or optimized for a different objective may perform differently across patient populations, imaging equipment types, or clinical settings. This new feature fundamentally changes how the device performs, fails, and affects patients in ways that go beyond what was originally cleared and therefore the feature must be adequately validated. Inadequate validation of this new feature may lead to a device that is unable to perform clinically as expected, which may result in patient harm such as missed or inadequate diagnosis, absence or delay of results, leading to missing, inaccurate, or delayed patient assessment. It can also lead to incorrect patient management due to misinterpretation of device output or overreliance on device output for radiological image interpretation. Thus, a new premarket notification is required.\nAdditionally, the VirtuOst VFA 3.0.0 version involves two other changes that each independently raise significant regulatory concerns. First, the device has migrated from a desktop application to a web-based architecture, which introduces network-exposed attack surfaces, authentication vulnerabilities, and other cybersecurity risks inherent to internet-accessible platforms. As your firm acknowledged during the inspection, the change from a desktop application to a web-based architecture expanded the “cyberattack surface area.” Second, the technology platform has been migrated from (b)(4) to (b)(4) only, which necessitates comprehensive re-verification and re-validation of the entire software codebase, including changes to third-party libraries and dependencies. FDA has not reviewed your device's Software Bill of Materials (SBOM) or documentation of third-party components affected by this migration.\nEach of these changes could significantly affect the safety or effectiveness of the device by introducing new software and cybersecurity risks. Furthermore, these changes require a new premarket notification pursuant to 21 CFR 807.81(a)(3)(i).\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nOur office requests that O.N. Diagnostics cease any activities that result in the misbranding or adulteration of the VirtuOst VFA 3.0.0, such as the commercial distribution of the device for the uses discussed above.\nQuality Management System Regulation Violation(s)\nThis inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality Management System Regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Dr. Kopperdahl, Director of Research and Development, dated April 1, 2026, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to document procedures for corrective actions and take action to eliminate the cause of nonconformities in order to prevent recurrence, as required by ISO 13485:2016, Clause 8.5.2.\nReview of your CAPA procedure, DOC: SOP-017, and related records found:\nA. Failure to take necessary corrective actions without undue delay. For example:\ni. Within CAPA-0080, procedural updates from four other CAPA records identified as necessary to eliminate the cause of nonconformities and prevent their recurrence were not made for over a year and a half.\nii. Additionally, your organization was made aware of the underlying issue related to the need to update your (b)(4) software three times over three years. Although CAPA-0088 was opened the day before our inspection began to address this three yearlong software issue, it was unsigned (even to demonstrate opening a new record) and no corrective actions had been identified or initiated within the record.\nB. Failure to clearly define the requirements to evaluate the need for action to ensure that nonconformities do not recur. For example:\ni. Your procedure allows use of a (b)(4) ticket instead of a corrective action when there are “Individual and sporadic instances of issues that need correction do not require a CAPA”. This is one reason for some of the untimely corrective actions discussed in item A above. The procedure needs to more clearly define when a (b)(4) ticket may be used vs. opening a CAPA to ensure corrective action is taken appropriately.\nii. Your organization has changed the requirements used to evaluate the need for action \u002F determine when a corrective action is necessary. CAPA-0083 included a corrective action to update to your CAPA procedure. Your findings stated the language governing when a CAPA should be opened was too broad and did not include the potential for process based CAPAs to be opened. The language targeted for update stated, “In general, a CAPA investigation will be initiated for any quality problem that is a non-conformance with respect to medical device requirements that has an associated safety hazard.”\nTherefore, in revision 11 released 10\u002F2\u002F2024, your organization implemented a change to “narrow the CAPA triggers and place more emphasis on systemic or recurring issues”. This update also included allowance to document other issues as a (b)(4) ticket, as previously mentioned above. These changes altered the threshold of when to open a CAPA from a safety hazard focus to systemic issues and allowed more flexibility to handle “individual and sporadic instances” through the (b)(4) system. In doing so, it appears your procedure now lacks clarity for when it is necessary to open a corrective action, based on risk.\nAdditionally, the impact of these changes was not evaluated prior to implementation. To maintain the integrity of the QMS, all changes must be evaluated to determine their potential impact on it. This evaluation must be conducted before implementing the change.\nC. Failure to require documentation of verification of effectiveness following corrective action implementation.\nThe procedure allows closure after “A failure investigation has been completed, a corrective action has been defined and implemented, and the effectiveness of the implemented action has been evaluated.”\nWithin CAPA-0080, the record includes verification of implementation, but not of effectiveness. There is no developed plan to determine how to verify effectiveness or a place to do so within the form, only a yes \u002F no checkbox.\nWe reviewed your firm’s response regarding items 1A and C above and conclude that it is not adequate. We understand your intent is to update the CAPA procedure to “strengthen requirements for effectiveness verification, including predefined acceptance criteria and sufficient prospective evidence, to ensure nonconformities do not recur”, as well as train staff, conduct a retrospective review to include performing additional analysis where necessary, and document findings. You anticipate an overall timeline of 90 days to complete all these steps (early August 2026). The CAPA documenting these actions will be closed when 100% of CAPAs over a six-month period and at least three CAPAs have demonstrated correct implementation of the revised procedure. This overall approach seems reasonable, however your response is inadequate because the requirement of ensuring necessary corrective actions are taken without undue delay has not been addressed to complete necessary procedural updates, and no records were provided for evidence of implementation of corrective actions.\nYour response related to item 1B states you intend to require documented risk assessments prior to implementation as part of change control procedures, establish criteria for when a change is ‘critical’ or ALARP, create a new form for this assessment following ISO 14971, train staff, perform a retrospective review of QMS changes over the last six months and act on those that meet new criteria, and summarize findings. You estimate all these actions to take about 90 days (early August 2026) and state this CAPA will be closed if no recurrence over a six-month period defined as failure to identify critical process changes or perform risk assessments of those changes. The adequacy of your response to item 1B cannot be determined as no records were provided for evidence of implementation of corrective actions.\n2. Failure to adequately document procedures to ensure that purchased product conforms to specified purchasing information and plan the monitoring and re-evaluation of suppliers, as required by 21 CFR 820, ISO 13485: 2016 Clause 7.4.1.\nFor example: the procedural requirements in your organization’s Purchasing Controls procedure, rev 11, concerning how your firm will re-evaluate and conduct monitoring and trending of suppliers \u002F vendors is vague. Specifically, none of these give details of when action should be taken. For example, the procedure mentions re-evaluation frequency will be every (b)(4) which maybe increased based on the criticality, but gives no specific criteria or examples of when this should occur. Regarding monitoring the procedure, it discusses “periodic progress reports and incremental deliverables” but doesn’t explain when they should be run or how those will be assessed. The extent of monitoring should be commensurate with the risk of the device, or impact on the device or QMS. The procedure also mentions trending of vendor performance but contains no limits or criteria stating when action might be necessary.\nThis was discussed during your recent inspection, but as it was not cited in the 483, your response did not address this violation.\nMedical Device Reporting (MDR) Violation(s)\nOur inspection (also) revealed that your firm has failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17.\nFor example, during the inspection, your organization presented the document titled “Complaint Management Procedure”, SOP-014, Revision 15, dated January 15, 2026, as its guidance for MDR reporting. Specifically, the purpose and scope of the procedure highlights that the SOP is intended to address the requirements of 21 CFR 803. However, after reviewing the procedure, the following deficiencies were noted:\n1. Your procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1).\na. Your procedure does not include adequate definitions of what constitutes a reportable event under 21 CFR Part 803. The fact that the procedure does not include definitions from 21 CFR 803.3 for the terms “become aware” and “caused or contributed”, and the definition described in 21 CFR 803.20(c)(1) for the term “reasonably suggests”, may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\nb. Your procedure’s definition of “serious injury” is not consistent with 21 CFR 803.3(w) and will not allow you to correctly identify complaints as reportable events.\nSpecifically, DC03055, MDR Reportability Review Memorandum 4 the regulatory definition includes both injury and illness, whereas the procedure limits the definition to injury only.\n2. Your procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the procedure does not include:\na. Instructions for submitting information that corresponds generally to the format of Form FDA 3500A, including how you will ensure that all information reasonably known to you is submitted for each event. Specifically, which types of information corresponding generally to the format of Form 3500A will need to be submitted, including the information in your firm’s possession when the initial report is filed and any required information later obtained that was not available when the initial report is filed.\nb. Instructions for complying with the 21 CFR 803.12(a) requirement to submit reports to FDA in an electronic format that the FDA can process, review, and archive.\n3. Your organization’s MDR event files do not contain all documentation of its deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable under 21 CFR Part 803, as required under 21 CFR 803.18(b)(1)(i). Specifically, although Sections 2.2 and 2.3 of the procedure describe documentation requirements, your firm’s ONG-FRM-007 Event Report reviewed for Event 0047 did not demonstrate implementation of these requirements for reportability determination.\nA device is deemed to be misbranded under section 501(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information respecting a device required by or under section 519 of the Act, 21 U.S.C. § 360i, including adverse event reports required under CFR Part 803.\nYour firm’s response dated April 1, 2026, does not address the procedural deficiencies, given that such deficiencies were not cited on the FDA 483.\nWe also note your organization’s SOP-014 procedure includes references to baseline reports in Section 4.4. Baseline reports are no longer required, and we recommend that all references to a Baseline Report be removed from your firm’s MDR procedure; see: 73 Federal Register Notice 53686, dated September 17, 2008.\nAdditionally, we recommend your organization establish an active Electronic Submission Gateway Next Generation (ESG NextGen) production account for the electronic submission of MDR reports. FDA verified that, as of April 24, 2026, your firm does not have such an account. Information about the ESG NextGen can be found at: Electronic Submissions Gateway Next Generation (ESG NextGen) | FDA.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality Management System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Jeff Wooley at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 730301” when replying. If you have any questions about the contents of this letter, please contact: Lauren Priest at Lauren.Priest@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","O.N. Diagnostics, LLC","diagnostics-llc-730301-09012026","2026-10-14T12:31:16.41489+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdiagnostics-llc-730301-09012026","2026-11-17T01:02:03.701861+00:00","Warning Letter","Issued","2026-10-06","730301","Medical Devices","Shui Wong","2026-10-14T12:33:05.323+00:00","VIA Electronic Mail","2026-09-01",{"id":32,"raw":33,"subject":37,"body_html":38,"body_text":39,"firm_name":40,"letter_id":41,"created_at":42,"fei_number":19,"letter_url":43,"updated_at":44,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":46,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":47,"body_fetched_at":48,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":49,"medical_device_id":19,"response_letter_date":19},2276,[34,35,36,11,37,13,13,13],"\u003Ctime datetime=\"2022-12-27T14:20:00Z\">12\u002F27\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-10-06T04:00:00Z\">10\u002F06\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fempowered-diagnostics-llc-638164-10062022\">Empowered Diagnostics LLC\u003C\u002Fa>","Unapproved Products Related to the Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Rick J. Hennessey\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Empowered Diagnostics LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3341 W. McNab Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pompano Beach\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33069\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:rick@empdx.net\"> rick@empdx.net\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS# 638164\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>October 6, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Hennessey:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located at 3341 W. McNab Rd., Pompano Beach, Florida on February 3 through February 25, 2022, investigators from the United States Food and Drug Administration (FDA) determined that your firm is a medical device manufacturer and distributor of the CovClear COVID-19 Rapid Antigen Tests and the ImmunoPass COVID-19 Neutralizing Antibody Rapid Tests (hereinafter collectively referred to as “COVID-19 Test Kits”). Based on our review, your COVID-19 Test Kits are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that these COVID-19 Test Kits have been distributed in the U.S. without marketing approval, clearance, or authorization from FDA. Accordingly, the products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C §331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>Your ImmunoPass COVID-19 Neutralizing Antibody Rapid Tests and certain configurations of your CovClear COVID-19 Rapid Antigen Tests are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because labeling distributed with these products included statements that these products are authorized for use under an Emergency Use Authorization (EUA). These statements create a false impression that your products have been approved or authorized for emergency use by FDA and are misleading. As discussed above, none of your COVID-19 Test Kits have been approved, cleared, or authorized for emergency use by FDA.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed a product that is intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>. In addition, the guidance titled “\u003Cstrong>Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)\u003C\u002Fstrong>”\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System Regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. The violations observed are cited below.\u003C\u002Fp>\n\n\u003Cp>We received your responses dated March 18, 2022; April 8, 2022; April 15, 2022; and April 29, 2022, concerning our investigator(s) observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm on February 28, 2022. We address your responses below.\u003C\u002Fp>\n\n\u003Cp>Your response dated March 18, 2022, indicated that you are a small start-up seeking to market and distribute COVID-19 devices under Emergency Use Authorization in the United States. Your response references the FDA guidance document, “\u003Cem>Emergency Use Authorization of Medical Products and Related Authorities, Guidance for Industry and other Stakeholders\u003C\u002Fem>” issued January 2017 and that FDA may waive cGMPs on a case-by-case basis, and your response goes on to list some examples for products similar to your COVID-19 testing products. The guidance document that you have referenced also states “\u003Cem>FDA generally expects that EUA products will be produced, stored, and distributed in compliance with CGMPs; however, limits or waivers may be granted in an EUA on a case-by-case basis, after consideration of the circumstances and of any alternative proposed approach\u003C\u002Fem>.” However, as the devices which were distributed have not been granted EUA authorization, no such waiver of cGMPs has been granted to your firm.\u003C\u002Fp>\n\n\u003Cp>The violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish and maintain design control procedures in order to ensure that specified design requirements of the device are met, as required by 21 CFR 820.30(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm did not establish design control procedures prior to the distribution of the CovClear COVID-19 Rapid Antigen Tests. For example, Design validation activities and\u002For their documentation for the release of the CovClear Rapid Antigen Test were inadequate. The IFU document COVCLEAR SARS-COV-2 RAPID ANTIGEN TEST, LIT 900-027 REV 1, (not dated), states in the DIRECT TEST SWAB PROCEDURE section (p. 4) to “read results within 3-20 minutes.” All the CovClear design verification and validation documentation reviewed revealed the time for reading the test results at 20 minutes.\u003C\u002Fp>\n\n\u003Cp>You must establish and maintain procedures to ensure that specified design requirements are met, this would include validating the device design to include reading results for the specified timeframe. If a user reads the results prior to the validated time, an incorrect diagnosis may result. Your design controls should ensure that the device’s specifications meet the intended use. Your response indicates that you have developed design control procedures that are compliant with the regulation. A follow-up inspection will be necessary to evaluate the effectiveness of your corrective actions.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to adequately establish and implement corrective and preventive action procedures, as required by 21 CFR 820.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, during review of your corrective action activities, your firm indicated that an internal audit \u002F gap analysis was conducted by a third-party auditor from May 20-24, 2021 that revealed major nonconformances to your quality system. Your Quality Department indicated that no systematic investigation to identify root causes of these reported issues or to identify similar quality issues was conducted; no corrective action plan was defined to systematically address the root causes; and no effectiveness verifications were conducted to address the deficiencies identified by the third-party auditor.\u003C\u002Fp>\n\n\u003Cp>Your response indicates that you have developed procedures that are to be compliant with the regulation and have conducted training. A follow-up inspection will be necessary to evaluate the effectiveness of your corrective actions.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your procedure QP 822, CUSTOMER FEEDBACK AND COMPLAINT HANDLING, Revision A, Effective June 22, 2020 until June 29, 2021 (Revision B) was inadequate in that the procedure did not include the requirement for complaints to be evaluated to determine whether the complaint is reportable. Additionally, a review of your complaint handling activities revealed that the contact phone number provided in your IFUs was directed to a commercial phone answering system monitored by the Marketing Department. There was no documentation of any follow-up with callers to determine if the inquiries constituted complaints. There were two notification transcriptions dated October 7, 2021 and October 14, 2021 that appeared to require further investigation and were not forwarded to QA for investigation or evaluation of reportability.\u003C\u002Fp>\n\n\u003Cp>We acknowledge you have revised your procedure and have conducted training. A follow-up inspection will need to be conducted to evaluate the implementation and the effectiveness of your corrective actions.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to adequately establish procedures for finished device acceptance, as required by 21 CFR 820.80(d).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, Manufacturing Batch Record, MBR 900-005, Final QC Testing for Antigen Test which covers production lot number 02-365-03, lot size 1,270 kits\u002F 50 test strips with expiration dates of February 14, 2021 and June 2022 did not demonstrate the lot met the acceptance criteria for release, and this lot was distributed to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Your response indicates you have identified the root cause to be inadequate procedures lacking clearly defined acceptance criteria in the final QC testing MBR. You indicate you have updated the procedures, forms, and acceptance criteria, and have conducted training. Lot 02-365-03 was subject of the recall and product destruction will be documented within a CAPA. FDA witnessed the destruction on June 30, 2022. The implementation and effectiveness of your corrective actions will be reviewed during your follow-up inspection.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to adequately establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, you did not ensure that your suppliers perform contracted processes that impact CovClear’s performance and effectiveness in a manner that guarantees your quality specifications are consistently met.\u003C\u002Fp>\n\n\u003Cp>A. The packaging process for the CovClear Rapid Antigen Test’s individually foil-wrapped configuration performed by your contract packager was not adequately validated to ensure that finished product will meet performance specifications during transportation, storage and use.\u003C\u002Fp>\n\n\u003Cp>B. Your firm indicated the Machinery Acceptance Declaration, approved August 5, 2021, used by your contract packager as the validation documentation, does not include any operating parameters, processing limits, component \u002F raw material (foil) identification, nor does it demonstrate the validation accounted for potential process variations introduced by differences in operators or packaging material lots, or how the documentation applies to the CovClear packaging.\u003C\u002Fp>\n\n\u003Cp>Your response indicates that you have retained new regulatory and legal advisors and that you have developed purchasing control procedures that are compliant with the regulation. A follow-up inspection will verify the effectiveness of your corrective actions.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to adequately establish and maintain document control procedures, as required by 21 CFR 820.40.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your IFU document COVCLEAR SARS-COV-2 RAPID ANTIGEN TEST, LIT 900-027 REV 1, (not dated), and your marketing materials were observed to: lack the approval signature and date, the review for adequacy, and the change control within the quality system; and contain incorrect authorization status and or intended use for the CovClear Rapid Antigen Test.\u003C\u002Fp>\n\n\u003Cp>Your response indicates that you have identified the root cause and have taken corrective actions including: personnel changes and conducting a recall. You indicate that you are in compliance with the regulations. A follow-up inspection is necessary to determine the effectiveness or your corrective actions.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations. Other federal agencies may take your compliance history into account when considering the award of federal contracts. Should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-request-review-FDAs-decision-not-issue-certain-export-certificates-devices\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-request-review-FDAs-decision-not-issue-certain-export-certificates-devices\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Note, there are two response time frames specified. You should take immediate action to address any of the violations relating to your firm’s sale or distribution of the COVID-19 Test Kits and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address any of these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulentcoronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulentcoronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the distribution of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>Please also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter related to Quality Systems. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\u003C\u002Fp>\n\n\u003Cp>This response should be sent via email to: Melissa Michurski, Director of Compliance Branch, at \u003Cstrong>oradevices2firmresponse@fda.hhs.gov. Refer to CMS # 638164\u003C\u002Fstrong> when replying.\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, \u003Cstrong>ORA Division Compliance Officer\u003C\u002Fstrong> at demetria.lueneburg@fda.hhs.gov \u003Cstrong>or 612-758-7210\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to correct any violations and bring your products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTimothy T. Stenzel, M.D., Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT7: Office of In Vitro Diagnostics\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Blake Bevill, M.S.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Devices and Radiological Health\u003Cbr>\nDivision 2 Central\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Accessible at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\u003C\u002Fa>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nRick J. Hennessey\n\nRecipient Title\n\nCEO\n\nEmpowered Diagnostics LLC\n\n3341 W. McNab Rd\n\nPompano Beach, FL 33069\n\nUnited States\n\nrick@empdx.net\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS# 638164\n\nOctober 6, 2022\n\nDear Mr. Hennessey:\n\nDuring an inspection of your firm located at 3341 W. McNab Rd., Pompano Beach, Florida on February 3 through February 25, 2022, investigators from the United States Food and Drug Administration (FDA) determined that your firm is a medical device manufacturer and distributor of the CovClear COVID-19 Rapid Antigen Tests and the ImmunoPass COVID-19 Neutralizing Antibody Rapid Tests (hereinafter collectively referred to as “COVID-19 Test Kits”). Based on our review, your COVID-19 Test Kits are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nOur inspection revealed that these COVID-19 Test Kits have been distributed in the U.S. without marketing approval, clearance, or authorization from FDA. Accordingly, the products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C §331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nYour ImmunoPass COVID-19 Neutralizing Antibody Rapid Tests and certain configurations of your CovClear COVID-19 Rapid Antigen Tests are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because labeling distributed with these products included statements that these products are authorized for use under an Emergency Use Authorization (EUA). These statements create a false impression that your products have been approved or authorized for emergency use by FDA and are misleading. As discussed above, none of your COVID-19 Test Kits have been approved, cleared, or authorized for emergency use by FDA.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed a product that is intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”4 provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\n\nOur inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System Regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. The violations observed are cited below.\n\nWe received your responses dated March 18, 2022; April 8, 2022; April 15, 2022; and April 29, 2022, concerning our investigator(s) observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm on February 28, 2022. We address your responses below.\n\nYour response dated March 18, 2022, indicated that you are a small start-up seeking to market and distribute COVID-19 devices under Emergency Use Authorization in the United States. Your response references the FDA guidance document, “Emergency Use Authorization of Medical Products and Related Authorities, Guidance for Industry and other Stakeholders” issued January 2017 and that FDA may waive cGMPs on a case-by-case basis, and your response goes on to list some examples for products similar to your COVID-19 testing products. The guidance document that you have referenced also states “FDA generally expects that EUA products will be produced, stored, and distributed in compliance with CGMPs; however, limits or waivers may be granted in an EUA on a case-by-case basis, after consideration of the circumstances and of any alternative proposed approach.” However, as the devices which were distributed have not been granted EUA authorization, no such waiver of cGMPs has been granted to your firm.\n\nThe violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain design control procedures in order to ensure that specified design requirements of the device are met, as required by 21 CFR 820.30(a).\n\nSpecifically, your firm did not establish design control procedures prior to the distribution of the CovClear COVID-19 Rapid Antigen Tests. For example, Design validation activities and\u002For their documentation for the release of the CovClear Rapid Antigen Test were inadequate. The IFU document COVCLEAR SARS-COV-2 RAPID ANTIGEN TEST, LIT 900-027 REV 1, (not dated), states in the DIRECT TEST SWAB PROCEDURE section (p. 4) to “read results within 3-20 minutes.” All the CovClear design verification and validation documentation reviewed revealed the time for reading the test results at 20 minutes.\n\nYou must establish and maintain procedures to ensure that specified design requirements are met, this would include validating the device design to include reading results for the specified timeframe. If a user reads the results prior to the validated time, an incorrect diagnosis may result. Your design controls should ensure that the device’s specifications meet the intended use. Your response indicates that you have developed design control procedures that are compliant with the regulation. A follow-up inspection will be necessary to evaluate the effectiveness of your corrective actions.\n\n2. Failure to adequately establish and implement corrective and preventive action procedures, as required by 21 CFR 820.100(a).\n\nSpecifically, during review of your corrective action activities, your firm indicated that an internal audit \u002F gap analysis was conducted by a third-party auditor from May 20-24, 2021 that revealed major nonconformances to your quality system. Your Quality Department indicated that no systematic investigation to identify root causes of these reported issues or to identify similar quality issues was conducted; no corrective action plan was defined to systematically address the root causes; and no effectiveness verifications were conducted to address the deficiencies identified by the third-party auditor.\n\nYour response indicates that you have developed procedures that are to be compliant with the regulation and have conducted training. A follow-up inspection will be necessary to evaluate the effectiveness of your corrective actions.\n\n3. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\n\nSpecifically, your procedure QP 822, CUSTOMER FEEDBACK AND COMPLAINT HANDLING, Revision A, Effective June 22, 2020 until June 29, 2021 (Revision B) was inadequate in that the procedure did not include the requirement for complaints to be evaluated to determine whether the complaint is reportable. Additionally, a review of your complaint handling activities revealed that the contact phone number provided in your IFUs was directed to a commercial phone answering system monitored by the Marketing Department. There was no documentation of any follow-up with callers to determine if the inquiries constituted complaints. There were two notification transcriptions dated October 7, 2021 and October 14, 2021 that appeared to require further investigation and were not forwarded to QA for investigation or evaluation of reportability.\n\nWe acknowledge you have revised your procedure and have conducted training. A follow-up inspection will need to be conducted to evaluate the implementation and the effectiveness of your corrective actions.\n\n4. Failure to adequately establish procedures for finished device acceptance, as required by 21 CFR 820.80(d).\n\nSpecifically, Manufacturing Batch Record, MBR 900-005, Final QC Testing for Antigen Test which covers production lot number 02-365-03, lot size 1,270 kits\u002F 50 test strips with expiration dates of February 14, 2021 and June 2022 did not demonstrate the lot met the acceptance criteria for release, and this lot was distributed to customers in the United States.\n\nYour response indicates you have identified the root cause to be inadequate procedures lacking clearly defined acceptance criteria in the final QC testing MBR. You indicate you have updated the procedures, forms, and acceptance criteria, and have conducted training. Lot 02-365-03 was subject of the recall and product destruction will be documented within a CAPA. FDA witnessed the destruction on June 30, 2022. The implementation and effectiveness of your corrective actions will be reviewed during your follow-up inspection.\n\n5. Failure to adequately establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50.\n\nSpecifically, you did not ensure that your suppliers perform contracted processes that impact CovClear’s performance and effectiveness in a manner that guarantees your quality specifications are consistently met.\n\nA. The packaging process for the CovClear Rapid Antigen Test’s individually foil-wrapped configuration performed by your contract packager was not adequately validated to ensure that finished product will meet performance specifications during transportation, storage and use.\n\nB. Your firm indicated the Machinery Acceptance Declaration, approved August 5, 2021, used by your contract packager as the validation documentation, does not include any operating parameters, processing limits, component \u002F raw material (foil) identification, nor does it demonstrate the validation accounted for potential process variations introduced by differences in operators or packaging material lots, or how the documentation applies to the CovClear packaging.\n\nYour response indicates that you have retained new regulatory and legal advisors and that you have developed purchasing control procedures that are compliant with the regulation. A follow-up inspection will verify the effectiveness of your corrective actions.\n\n6. Failure to adequately establish and maintain document control procedures, as required by 21 CFR 820.40.\n\nSpecifically, your IFU document COVCLEAR SARS-COV-2 RAPID ANTIGEN TEST, LIT 900-027 REV 1, (not dated), and your marketing materials were observed to: lack the approval signature and date, the review for adequacy, and the change control within the quality system; and contain incorrect authorization status and or intended use for the CovClear Rapid Antigen Test.\n\nYour response indicates that you have identified the root cause and have taken corrective actions including: personnel changes and conducting a recall. You indicate that you are in compliance with the regulations. A follow-up inspection is necessary to determine the effectiveness or your corrective actions.\n\nYour firm should take prompt action to address any violations. Other federal agencies may take your compliance history into account when considering the award of federal contracts. Should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-request-review-FDAs-decision-not-issue-certain-export-certificates-devices.\n\nNote, there are two response time frames specified. You should take immediate action to address any of the violations relating to your firm’s sale or distribution of the COVID-19 Test Kits and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address any of these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at: https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulentcoronavirus-disease-2019-covid-19-products. Once you have taken actions to address the distribution of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nPlease also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter related to Quality Systems. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\n\nThis response should be sent via email to: Melissa Michurski, Director of Compliance Branch, at oradevices2firmresponse@fda.hhs.gov. Refer to CMS # 638164 when replying.\n\nIf you have any questions about the contents of this letter, please contact: Demetria Lueneburg, ORA Division Compliance Officer at demetria.lueneburg@fda.hhs.gov or 612-758-7210.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to correct any violations and bring your products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D.\n\nDirector\n\nOHT7: Office of In Vitro Diagnostics\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nBlake Bevill, M.S.\n\nProgram Division Director\n\nOffice of Medical Devices and Radiological Health\n\nDivision 2 Central\n\n__________________________\n\n1 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\n\n4 Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload","Empowered Diagnostics LLC","empowered-diagnostics-llc-638164-10062022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fempowered-diagnostics-llc-638164-10062022","2026-10-26T08:08:35.475486+00:00","2022-12-27","638164","Rick J. Hennessey","2026-08-20T01:20:47.784+00:00","2022-10-06",{"id":51,"raw":52,"subject":56,"body_html":57,"body_text":58,"firm_name":59,"letter_id":60,"created_at":42,"fei_number":19,"letter_url":61,"updated_at":62,"action_type":22,"case_status":23,"posted_date":63,"marcs_cms_no":64,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":65,"body_fetched_at":66,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":45,"medical_device_id":19,"response_letter_date":19},2127,[53,54,55,11,56,13,13,13],"\u003Ctime datetime=\"2023-04-18T13:20:00Z\">04\u002F18\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-12-27T05:00:00Z\">12\u002F27\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-american-diagnostics-llc-643203-12272022\">North American Diagnostics, LLC\u003C\u002Fa>","Medical Device\u002FAdulterated\u002FMisbranded\u002FLacks PMA and\u002For 510(k)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Elizabeth A. Lashinsky\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>North American Diagnostics, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>618 Ridgewood Ave., Suite 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Holly Hill\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>32117\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ealash52@gmail.com\"> ealash52@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS# 643203\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDecember 27, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Lashinsky:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations, North American Diagnostics, LLC (“North American,” “you,” or “your firm”), located at 618 Ridgewood Ave, Suite 100, Holly Hill, Florida on five dates from June 14 through 23, 2022. During this inspection, FDA investigators determined that your firm is a manufacturer and distributor of SARS-CoV-2 antigen rapid test kits under the names ORAL RAPID SARS-CoV-2 Antigen Rapid test kits, SDI LABS SARS-CoV-2 Antigen Rapid Test Kit, North American Diagnostics SARS-CoV-2 Antigen Rapid Test Kit, Skippack Medical Labs SARS-CoV-2 Antigen Rapid Test (Colloidal Gold), and Spectrum DX Lab SARS-CoV-2 Antigen Rapid test kits (hereafter referred to as “COVID-19 Test”). Based on our review, your COVID-19 Test is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, it is a device under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that your COVID-19 test has been distributed in the United States (U.S.). without marketing approval, clearance, or authorization from FDA. Indeed, in your response dated July 6, 2022, concerning our investigators’ observations noted on the Form FDA 483 List of Inspectional Observations, that was issued to your firm, you acknowledged that you had “improperly distributed into commerce” COVID-19 test kits. Accordingly, your product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your product is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of this product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C §331(a).\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed a product that is intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>. In addition, the guidance titled “\u003Cstrong>Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)\u003C\u002Fstrong>” provides FDA’s review priorities and enforcement policies regarding novel coronavirus (COVID-19) tests.\u003C\u002Fp>\n\n\u003Cp>This inspection also revealed that your COVID-19 test is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. The violations observed include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish and maintain design control procedures in order to ensure that specified design requirements of the device are met, as required by 21 CFR 820.30(a).\u003C\u002Fstrong> Specifically, your firm did not establish design control procedures prior to the manufacture and distribution of your COVID-19 test.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to develop, conduct, control, and monitor production processes to ensure the device conforms to its specifications, as required by 21 CDR 820.70.\u003C\u002Fstrong> Specifically, your firm has not established production processes controls for your COVID-19 test, for any production and process changes, environmental control requirements, personnel requirements, contamination control requirements, manufacturing material requirements, or automated processes requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to adequately ensure that the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a).\u003C\u002Fstrong> Specifically, your firm has not conducted process validations for those processes that your firm cannot fully verify in the manufacture of your COVID-19 Test.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish procedures for acceptance activities, as required by 21 CFR 820.80.\u003C\u002Fstrong> Specifically, your firm has not established 1) receiving acceptance activities for any components used to manufacture your COVID-19 Test, 2) in-process acceptance activities for any process critical to the functionality and\u002For intended use of the device, 3) final acceptance activities.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fstrong> Specifically, your firm has not established procedures, instructions, or processes to identify, investigate, and correct problems that are observed and to prevent recurrence of issues.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR 820.160(a).\u003C\u002Fstrong> Specifically, your firm does not have procedures for control and distribution of your COVID-19 Test.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\u003C\u002Fstrong> Specifically, your firm received information indicating that the reagent packed in plastic tubes with screw-on caps were leaking. it is not clear how this complaint was received, reviewed, or evaluated; your firm has not established procedures to handle complaints, you have not kept records of any complaints received or investigated or evaluated to determine whether the complaint represents an event which is required to be reported to FDA under part 803.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to establish an organizational structure to ensure that devices are designed and produced in accordance 21 CFR part 820.20(b).\u003C\u002Fstrong> Specifically, you have not established an organizational structure that defines the responsibilities and authority, resources, management representative, management review, quality planning and quality system procedures in accordance with good manufacturing practices set forth in the Quality System Regulation.\u003Cbr>\n\u003Cbr>\nOur inspection also revealed that you have failed to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17. Specifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements. Notably, during the inspection, your firm acknowledged that it does not have any MDR procedures. A device is deemed to be misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, which includes adverse event reports required under 21 CFR Part 803, respecting the device.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response dated July 6, 2022. In the response, your firm noted that you do not have certain “corrective action to propose” because you have “not manufactured test kits at the Holly Hill facility since July 2021,” and that you do “not plan to manufacture rapid antigen test kits in the near future.” However, as the manufacturer of those previously distributed devices your firm is still required under 21 CFR 803 to develop, maintain, and implement MDR procedures and ensure timely reporting of reportable events involving any device that you manufactured, even if you subsequently cease manufacturing or marketing the device. As such, your firm has an obligation to report adverse events.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations. Failure to adequately address the matters discussed in this letter may result in legal action being initiated by the FDA without further notice. These actions may include, but are not necessarily limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-request-review-fdas-decision-not-issue-certain-export-certificates-devices\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-request-review-fdas-decision-not-issue-certain-export-certificates-devices\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Note, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to\u003C\u002Fstrong> COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale or distribution of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>Please also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter, in particular with respect to MDR procedures and reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Melissa Michurski, Director of Compliance Branch, at oradevices2firmresponse@fda.hhs.gov. \u003Cstrong>Refer to CMS # 643203\u003C\u002Fstrong> when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, \u003Cstrong>ORA Division Compliance Officer\u003C\u002Fstrong> at demetria.lueneburg@fda.hhs.gov \u003Cstrong>or 612-758-7210\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of any violations at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTimothy T. Stenzel, M.D., Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT7: Office of In Vitro Diagnostics\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003Cbr>\nBlake Bevill, M.S.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Devices and Radiological Health\u003Cbr>\nDivision 2 Central\u003C\u002Fp>\n\n\u003Cp>______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-%20emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national- emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nElizabeth A. Lashinsky\n\nRecipient Title\n\nOwner\n\nNorth American Diagnostics, LLC\n\n618 Ridgewood Ave., Suite 100\n\nHolly Hill, FL 32117\n\nUnited States\n\nealash52@gmail.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS# 643203\n\nDecember 27, 2022\n\nDear Ms. Lashinsky:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations, North American Diagnostics, LLC (“North American,” “you,” or “your firm”), located at 618 Ridgewood Ave, Suite 100, Holly Hill, Florida on five dates from June 14 through 23, 2022. During this inspection, FDA investigators determined that your firm is a manufacturer and distributor of SARS-CoV-2 antigen rapid test kits under the names ORAL RAPID SARS-CoV-2 Antigen Rapid test kits, SDI LABS SARS-CoV-2 Antigen Rapid Test Kit, North American Diagnostics SARS-CoV-2 Antigen Rapid Test Kit, Skippack Medical Labs SARS-CoV-2 Antigen Rapid Test (Colloidal Gold), and Spectrum DX Lab SARS-CoV-2 Antigen Rapid test kits (hereafter referred to as “COVID-19 Test”). Based on our review, your COVID-19 Test is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people, and thus, it is a device under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h).\n\nOur inspection revealed that your COVID-19 test has been distributed in the United States (U.S.). without marketing approval, clearance, or authorization from FDA. Indeed, in your response dated July 6, 2022, concerning our investigators’ observations noted on the Form FDA 483 List of Inspectional Observations, that was issued to your firm, you acknowledged that you had “improperly distributed into commerce” COVID-19 test kits. Accordingly, your product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your product is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of this product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C §331(a).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed a product that is intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)” provides FDA’s review priorities and enforcement policies regarding novel coronavirus (COVID-19) tests.\n\nThis inspection also revealed that your COVID-19 test is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. The violations observed include:\n\n1. Failure to establish and maintain design control procedures in order to ensure that specified design requirements of the device are met, as required by 21 CFR 820.30(a). Specifically, your firm did not establish design control procedures prior to the manufacture and distribution of your COVID-19 test.\n\n2. Failure to develop, conduct, control, and monitor production processes to ensure the device conforms to its specifications, as required by 21 CDR 820.70. Specifically, your firm has not established production processes controls for your COVID-19 test, for any production and process changes, environmental control requirements, personnel requirements, contamination control requirements, manufacturing material requirements, or automated processes requirements.\n\n3. Failure to adequately ensure that the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a). Specifically, your firm has not conducted process validations for those processes that your firm cannot fully verify in the manufacture of your COVID-19 Test.\n\n4. Failure to establish procedures for acceptance activities, as required by 21 CFR 820.80. Specifically, your firm has not established 1) receiving acceptance activities for any components used to manufacture your COVID-19 Test, 2) in-process acceptance activities for any process critical to the functionality and\u002For intended use of the device, 3) final acceptance activities.\n\n5. Failure to establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm has not established procedures, instructions, or processes to identify, investigate, and correct problems that are observed and to prevent recurrence of issues.\n\n6. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR 820.160(a). Specifically, your firm does not have procedures for control and distribution of your COVID-19 Test.\n\n7. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). Specifically, your firm received information indicating that the reagent packed in plastic tubes with screw-on caps were leaking. it is not clear how this complaint was received, reviewed, or evaluated; your firm has not established procedures to handle complaints, you have not kept records of any complaints received or investigated or evaluated to determine whether the complaint represents an event which is required to be reported to FDA under part 803.\n\n8. Failure to establish an organizational structure to ensure that devices are designed and produced in accordance 21 CFR part 820.20(b). Specifically, you have not established an organizational structure that defines the responsibilities and authority, resources, management representative, management review, quality planning and quality system procedures in accordance with good manufacturing practices set forth in the Quality System Regulation.\n\nOur inspection also revealed that you have failed to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17. Specifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements. Notably, during the inspection, your firm acknowledged that it does not have any MDR procedures. A device is deemed to be misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, which includes adverse event reports required under 21 CFR Part 803, respecting the device.\n\nWe reviewed your firm’s response dated July 6, 2022. In the response, your firm noted that you do not have certain “corrective action to propose” because you have “not manufactured test kits at the Holly Hill facility since July 2021,” and that you do “not plan to manufacture rapid antigen test kits in the near future.” However, as the manufacturer of those previously distributed devices your firm is still required under 21 CFR 803 to develop, maintain, and implement MDR procedures and ensure timely reporting of reportable events involving any device that you manufactured, even if you subsequently cease manufacturing or marketing the device. As such, your firm has an obligation to report adverse events.\n\nYour firm should take prompt action to address any violations. Failure to adequately address the matters discussed in this letter may result in legal action being initiated by the FDA without further notice. These actions may include, but are not necessarily limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-request-review-fdas-decision-not-issue-certain-export-certificates-devices.\n\nNote, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale or distribution of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nPlease also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter, in particular with respect to MDR procedures and reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\n\nYour firm’s response should be sent to: Melissa Michurski, Director of Compliance Branch, at oradevices2firmresponse@fda.hhs.gov. Refer to CMS # 643203 when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, ORA Division Compliance Officer at demetria.lueneburg@fda.hhs.gov or 612-758-7210.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of any violations at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D.\n\nDirector\n\nOHT7: Office of In Vitro Diagnostics\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nBlake Bevill, M.S.\n\nProgram Division Director\n\nOffice of Medical Devices and Radiological Health\n\nDivision 2 Central\n\n______________________________\n\n1 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national- emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","North American Diagnostics, LLC","north-american-diagnostics-llc-643203-12272022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-american-diagnostics-llc-643203-12272022","2026-10-26T08:09:34.512211+00:00","2023-04-18","643203","Elizabeth A. Lashinsky","2026-08-20T01:09:41.813+00:00",{"id":68,"raw":69,"subject":75,"body_html":76,"body_text":77,"firm_name":78,"letter_id":79,"created_at":80,"fei_number":19,"letter_url":81,"updated_at":82,"action_type":22,"case_status":23,"posted_date":83,"marcs_cms_no":84,"product_type":85,"closeout_date":19,"issuing_office":86,"recipient_name":87,"body_fetched_at":88,"delivery_method":89,"recipient_title":19,"reference_number":19,"action_taken_date":90,"medical_device_id":19,"response_letter_date":19},1965,[70,71,72,73,74,13,13,13],"\u003Ctime datetime=\"2023-08-01T13:20:00Z\">08\u002F01\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-07-20T04:00:00Z\">07\u002F20\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fiso-tex-diagnostics-inc-655666-07202023\">Iso-Tex Diagnostics, Inc.\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations II ","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u003Cbr \u002F>\r\n","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail Return Confirmation Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Megan M. Maloney\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FQuality Assurance\u002FRegulatory Affairs\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Iso-Tex Diagnostics, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1511 County Road 129\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Alvin\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>77511\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations II \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>DATE: 7\u002F20\u002F2023\u003C\u002Fp>\n\n\u003Cp>Case #: 655666\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Maloney:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Iso-Tex Diagnostics, Inc., FEI 1626310, at 1511 County Road 129 Alvin, TX, from January 30, 2023, to February 10, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your March 2, 2023, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to have buildings used in the manufacture, processing, packing, or holding of drug products of a suitable size, construction, and location to facilitate cleaning, maintenance, and proper operations (21 CFR&nbsp;\u003C\u002Fstrong>\u003Cstrong>211.42(a)). Your firm also failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas, and an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions (21 CFR 211.42(c)(10)(iv) &amp; (v)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your deficient facility design, equipment suitability, and environmental conditions significantly increased contamination risk to drugs intended to be sterile.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate Design and Control of Facility Conditions\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You failed to ensure that cleanrooms are properly designed and constructed of materials that allow for the ease of cleaning and disinfection. For example, our investigators observed:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The door of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> connection to your aseptic processing cleanroom and gowning room was in disrepair and unable to fully close.\u003C\u002Fli>\n\t\u003Cli>Foreign particulates hanging from two ceiling HEPA Filters within your aseptic processing cleanroom.\u003C\u002Fli>\n\t\u003Cli>Inadequately sealed fluorescent light fixtures in aseptic processing cleanrooms.\u003C\u002Fli>\n\t\u003Cli>Exposed electrical lightbulb sockets and an emergency light within aseptic processing cleanroom without a cover.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cem>Inadequate Monitoring and Control of Environmental Conditions\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You failed to ensure that your facility is designed, controlled, and maintained to prevent lower quality air from entering and contaminating your aseptic processing cleanrooms, resulting in departures from your established limits throughout your clean rooms. For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Since at least December 1, 2022, negative differential pressure was frequently documented between your sterile drug processing cleanroom containing aseptic processing hoods and the adjacent gowning room, that allows for lower quality of air to move into your aseptic processing cleanroom. You lacked investigations into these recurring excursions.\u003C\u002Fli>\n\t\u003Cli>From at least August 10, 2022, you failed to maintain the relative humidity below \u003Cstrong>(b)(4)\u003C\u002Fstrong> as established in your “Environmental Quality and Control Program” procedure. Your relative humidity data reveals repetitive and extended excursions. For example, in aseptic processing cleanroom \u003Cstrong>(b)(4)\u003C\u002Fstrong>, from January 15, 2023, starting at 7:40pm, and ending January 18, 2023, at 7:10pm, the relative humidity ranged from 60.1 to 94.8%, and averaged 73.5%. Upon request for additional information on April 26, 2023, you did not provide any investigations into the excursions. You were also unable to provide procedures, use logs, or qualification documentation for a \u003Cstrong>(b)(4)\u003C\u002Fstrong> dehumidifier operating in gowning cleanroom, suite \u003Cstrong>(b)(4)\u003C\u002Fstrong>, used to control relative humidity. Your use of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> dehumidifier in a cleanroom indicates a poorly designed HVAC system.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Aseptic processes should be designed to minimize exposure of sterile articles to potential contamination hazards, including, but not limited to, variation in environmental conditions. It is vital for rooms of higher air cleanliness to have a substantial positive pressure differential relative to adjacent rooms of lower air cleanliness. A suitable facility monitoring system is critical to maintain appropriate environmental conditions throughout all of your cleanrooms. All deviations from established limits should be appropriately investigated to rapidly detect atypical changes that can compromise the facility’s environment. Prompt detection of an emerging problem is essential to preventing contamination of your aseptic production operations.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you fail to address systemic issues to ensure your facility is suitable for the aseptic processing for sterile drugs. You also do not provide meaningful evidence that your manufacturing environment is under an ongoing state of control.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o All human interactions within the ISO 5 area\u003Cbr>\n&nbsp; &nbsp; o Equipment placement and ergonomics\u003Cbr>\n&nbsp; &nbsp; o Air quality in the ISO 5 area and surrounding room\u003Cbr>\n&nbsp; &nbsp; o Facility layout\u003Cbr>\n&nbsp; &nbsp; o Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\u003C\u002Fli>\n\t\u003Cli>A thorough, independent assessment, and corrective action and preventive action (CAPA) for your pressure differential system and environmental temperature and humidity conditions. Include a comprehensive evaluation of monitoring, recording, alarm documentation, deviation investigation, data retention and overall system control in your assessment. Provide a CAPA that includes, but is not limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o The state of control of air balance between clean areas and adequacy of integration of each of the HVAC systems\u003Cbr>\n&nbsp; &nbsp; o Documentation for all alarms, irrespective of the length or location of the event, and retention of this data\u003Cbr>\n&nbsp; &nbsp; o Remediated procedures for investigating deviations from established limits, including but not limited to specific provisions for handling instances in which a pressure reversal occurs\u003Cbr>\n&nbsp; &nbsp; o Remediated facility monitoring systems that will rapidly detect atypical changes of pressure, temperature, and humidity, in your cleanrooms simultaneously\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\u003C\u002Fli>\n\t\u003Cli>A detailed risk assessment addressing the hazards posed by distributing drug products with potential contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\n\t\u003Cli>Complete investigations into all batches with potential microbial contamination. The investigations should detail your findings regarding the root causes of the contamination.\u003C\u002Fli>\n\t\u003Cli>All microbial test methods and specifications used to analyze each of your drug products.\u003C\u002Fli>\n\t\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\n\t\u003Cli>Your complete investigation into failed cleanroom certification study data relating to air changes. Include all original and corrected calculations regarding air changes, the location of all air inlets and exhaust outlets in the room, and a detailed description of the BSC design (e.g., intake of air) and its position in the room. You should also provide an independent assessment of the investigation, and the adequacy of air changes in all of your cleanrooms, by a qualified consult.\u003C\u002Fli>\n\t\u003Cli>Smoke studies that evaluate the suitability of your biological safety cabinets (BSC) used for the aseptic manufacturing of your drug products.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003Cbr>\n\u003Cbr>\nYour firm manufactures sterile radiopharmaceutical drug products that are aseptically filled. You failed to have appropriate gowning for aseptic production of sterile injectable drug products. For example, investigators observed your production personnel:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>With exposed facial skin and hair entering your ISO 5 production environment while performing aseptic manual filling of Volumex I-131, Lot # V230102-1107.\u003C\u002Fli>\n\t\u003Cli>On multiple instances, failing to disinfect their sterile gloves before returning to the ISO 5 area.\u003C\u002Fli>\n\t\u003Cli>Use poor sterile gowning behavior and practices (e.g., sterile gown touched the floor while donning the gowning).\u003C\u002Fli>\n\t\u003Cli>Gowning without using suitable sterile gloves.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm’s failure to ensure that personnel gown appropriately and strictly adhere to acceptable aseptic procedures significantly increases the risk of drug product contamination.\u003C\u002Fp>\n\n\u003Cp>In addition, your production staff and equipment (e.g., active air monitor, analytical balance printer) blocked the path of unidirectional airflow in your ISO 5 production environment during filling operations of Volumex I-131, Lot # V230102-1107.\u003Cbr>\nUnidirectional airflow design is used to protect sterile equipment surfaces, container- closures, and drug product, and should not be obstructed by personnel or equipment. Disruption of unidirectional air in the critical area poses a significant risk to product sterility.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you do not commit to conducting a retrospective review of drug product manufactured under these conditions for potential quality and safety impact. Additionally, your response does not include supporting documentation of CAPA activities.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also, describe the frequency of quality unit oversight (e.g., audit) during aseptic processing and supporting operations.\u003C\u002Fli>\n\t\u003Cli>A thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\u003C\u002Fli>\n\t\u003Cli>A gowning qualification program that establishes, both initially and on a periodic basis, the capability of an individual to adequately don the complete sterile gown in an aseptic manner.\u003C\u002Fli>\n\t\u003Cli>Details regarding how you will establish adequate gowning, training, gowning qualification, and supervision on an ongoing basis.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our investigators observed inadequately controlled laboratory reagents (i.e., inadequate labeling), as well as expired testing materials. The use of uncontrolled and expired testing materials may impact the validity of your testing results used to support the release of your drug products.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you do not conduct or commit to conducting an investigation to determine product impact nor do you commit to determining whether your corrective actions require extension to other related procedures.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Additional Guidance on Aseptic Processing\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Repeat Violations and Observations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In a previous warning letter, 2011-DAL-WL-03, issued on December 3, 2010, and previous inspections ending on January 31, 2018, July 10, 2015, and September 12, 2011, FDA cited similar CGMP violations and observations. You proposed specific remediation for these violations and observations in your responses. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of all CAPAs before you pursue resolution of your firm’s compliance status (i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b).\u003Cbr>\nThis also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\n\n\u003Cp>Correct all violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to case # \u003Cstrong>655666.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Please electronically submit your reply, on company letterhead, to Rebecca Asente, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov, and copy Ronda Loyd-Jones, Director, Compliance Branch, at ronda.loyd-jones@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, you may contact Rebecca Asente via phone at (504) 846-6104 or email at Rebecca.asente@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Monica R. Maxwell\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations, Division II\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail Return Confirmation Requested\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMegan M. Maloney\n\nRecipient Title\n\nPresident\u002FQuality Assurance\u002FRegulatory Affairs\n\nIso-Tex Diagnostics, Inc.\n\n1511 County Road 129\n\nAlvin, TX 77511\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations II\n\nUnited States\n\nDATE: 7\u002F20\u002F2023\n\nCase #: 655666\n\nWARNING LETTER\n\nDear Ms. Maloney:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Iso-Tex Diagnostics, Inc., FEI 1626310, at 1511 County Road 129 Alvin, TX, from January 30, 2023, to February 10, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your March 2, 2023, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to have buildings used in the manufacture, processing, packing, or holding of drug products of a suitable size, construction, and location to facilitate cleaning, maintenance, and proper operations (21 CFR 211.42(a)). Your firm also failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas, and an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions (21 CFR 211.42(c)(10)(iv) & (v)).\n\nYour deficient facility design, equipment suitability, and environmental conditions significantly increased contamination risk to drugs intended to be sterile.\n\nInadequate Design and Control of Facility Conditions\n\nYou failed to ensure that cleanrooms are properly designed and constructed of materials that allow for the ease of cleaning and disinfection. For example, our investigators observed:\n\nThe door of your (b)(4) connection to your aseptic processing cleanroom and gowning room was in disrepair and unable to fully close.\n\nForeign particulates hanging from two ceiling HEPA Filters within your aseptic processing cleanroom.\n\nInadequately sealed fluorescent light fixtures in aseptic processing cleanrooms.\n\nExposed electrical lightbulb sockets and an emergency light within aseptic processing cleanroom without a cover.\n\nInadequate Monitoring and Control of Environmental Conditions\n\nYou failed to ensure that your facility is designed, controlled, and maintained to prevent lower quality air from entering and contaminating your aseptic processing cleanrooms, resulting in departures from your established limits throughout your clean rooms. For example:\n\nSince at least December 1, 2022, negative differential pressure was frequently documented between your sterile drug processing cleanroom containing aseptic processing hoods and the adjacent gowning room, that allows for lower quality of air to move into your aseptic processing cleanroom. You lacked investigations into these recurring excursions.\n\nFrom at least August 10, 2022, you failed to maintain the relative humidity below (b)(4) as established in your “Environmental Quality and Control Program” procedure. Your relative humidity data reveals repetitive and extended excursions. For example, in aseptic processing cleanroom (b)(4), from January 15, 2023, starting at 7:40pm, and ending January 18, 2023, at 7:10pm, the relative humidity ranged from 60.1 to 94.8%, and averaged 73.5%. Upon request for additional information on April 26, 2023, you did not provide any investigations into the excursions. You were also unable to provide procedures, use logs, or qualification documentation for a (b)(4) dehumidifier operating in gowning cleanroom, suite (b)(4), used to control relative humidity. Your use of a (b)(4) dehumidifier in a cleanroom indicates a poorly designed HVAC system.\n\nAseptic processes should be designed to minimize exposure of sterile articles to potential contamination hazards, including, but not limited to, variation in environmental conditions. It is vital for rooms of higher air cleanliness to have a substantial positive pressure differential relative to adjacent rooms of lower air cleanliness. A suitable facility monitoring system is critical to maintain appropriate environmental conditions throughout all of your cleanrooms. All deviations from established limits should be appropriately investigated to rapidly detect atypical changes that can compromise the facility’s environment. Prompt detection of an emerging problem is essential to preventing contamination of your aseptic production operations.\n\nYour response is inadequate because you fail to address systemic issues to ensure your facility is suitable for the aseptic processing for sterile drugs. You also do not provide meaningful evidence that your manufacturing environment is under an ongoing state of control.\n\nIn response to this letter, provide:\n\nA comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\n\no All human interactions within the ISO 5 area\n\no Equipment placement and ergonomics\n\no Air quality in the ISO 5 area and surrounding room\n\no Facility layout\n\no Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\n\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\n\nA thorough, independent assessment, and corrective action and preventive action (CAPA) for your pressure differential system and environmental temperature and humidity conditions. Include a comprehensive evaluation of monitoring, recording, alarm documentation, deviation investigation, data retention and overall system control in your assessment. Provide a CAPA that includes, but is not limited to:\n\no The state of control of air balance between clean areas and adequacy of integration of each of the HVAC systems\n\no Documentation for all alarms, irrespective of the length or location of the event, and retention of this data\n\no Remediated procedures for investigating deviations from established limits, including but not limited to specific provisions for handling instances in which a pressure reversal occurs\n\no Remediated facility monitoring systems that will rapidly detect atypical changes of pressure, temperature, and humidity, in your cleanrooms simultaneously\n\nA comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\n\nA detailed risk assessment addressing the hazards posed by distributing drug products with potential contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\n\nComplete investigations into all batches with potential microbial contamination. The investigations should detail your findings regarding the root causes of the contamination.\n\nAll microbial test methods and specifications used to analyze each of your drug products.\n\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n\nYour complete investigation into failed cleanroom certification study data relating to air changes. Include all original and corrected calculations regarding air changes, the location of all air inlets and exhaust outlets in the room, and a detailed description of the BSC design (e.g., intake of air) and its position in the room. You should also provide an independent assessment of the investigation, and the adequacy of air changes in all of your cleanrooms, by a qualified consult.\n\nSmoke studies that evaluate the suitability of your biological safety cabinets (BSC) used for the aseptic manufacturing of your drug products.\n\n2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n\nYour firm manufactures sterile radiopharmaceutical drug products that are aseptically filled. You failed to have appropriate gowning for aseptic production of sterile injectable drug products. For example, investigators observed your production personnel:\n\nWith exposed facial skin and hair entering your ISO 5 production environment while performing aseptic manual filling of Volumex I-131, Lot # V230102-1107.\n\nOn multiple instances, failing to disinfect their sterile gloves before returning to the ISO 5 area.\n\nUse poor sterile gowning behavior and practices (e.g., sterile gown touched the floor while donning the gowning).\n\nGowning without using suitable sterile gloves.\n\nYour firm’s failure to ensure that personnel gown appropriately and strictly adhere to acceptable aseptic procedures significantly increases the risk of drug product contamination.\n\nIn addition, your production staff and equipment (e.g., active air monitor, analytical balance printer) blocked the path of unidirectional airflow in your ISO 5 production environment during filling operations of Volumex I-131, Lot # V230102-1107.\n\nUnidirectional airflow design is used to protect sterile equipment surfaces, container- closures, and drug product, and should not be obstructed by personnel or equipment. Disruption of unidirectional air in the critical area poses a significant risk to product sterility.\n\nYour response is inadequate because you do not commit to conducting a retrospective review of drug product manufactured under these conditions for potential quality and safety impact. Additionally, your response does not include supporting documentation of CAPA activities.\n\nIn response to this letter, provide:\n\nYour plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also, describe the frequency of quality unit oversight (e.g., audit) during aseptic processing and supporting operations.\n\nA thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\n\nA gowning qualification program that establishes, both initially and on a periodic basis, the capability of an individual to adequately don the complete sterile gown in an aseptic manner.\n\nDetails regarding how you will establish adequate gowning, training, gowning qualification, and supervision on an ongoing basis.\n\n3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\n\nOur investigators observed inadequately controlled laboratory reagents (i.e., inadequate labeling), as well as expired testing materials. The use of uncontrolled and expired testing materials may impact the validity of your testing results used to support the release of your drug products.\n\nYour response is inadequate because you do not conduct or commit to conducting an investigation to determine product impact nor do you commit to determining whether your corrective actions require extension to other related procedures.\n\nIn response to this letter, provide a comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\nAdditional Guidance on Aseptic Processing\n\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\n\nRepeat Violations and Observations at Facility\n\nIn a previous warning letter, 2011-DAL-WL-03, issued on December 3, 2010, and previous inspections ending on January 31, 2018, July 10, 2015, and September 12, 2011, FDA cited similar CGMP violations and observations. You proposed specific remediation for these violations and observations in your responses. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of all CAPAs before you pursue resolution of your firm’s compliance status (i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b).\n\nThis also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nCorrect all violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour written notification should refer to case # 655666.\n\nPlease electronically submit your reply, on company letterhead, to Rebecca Asente, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov, and copy Ronda Loyd-Jones, Director, Compliance Branch, at ronda.loyd-jones@fda.hhs.gov.\n\nIf you have questions regarding the contents of this letter, you may contact Rebecca Asente via phone at (504) 846-6104 or email at Rebecca.asente@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMonica R. Maxwell\n\nProgram Division Director\n\nOffice of Pharmaceutical Quality Operations, Division II","Iso-Tex Diagnostics, Inc.","iso-tex-diagnostics-inc-655666-07202023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fiso-tex-diagnostics-inc-655666-07202023","2026-10-26T08:09:01.407758+00:00","2023-08-01","655666","Drugs","Division of Pharmaceutical Quality Operations II","Megan M. Maloney","2026-08-20T00:50:01.064+00:00","Via Electronic Mail Return Confirmation Requested","2023-07-20",{"id":92,"raw":93,"subject":98,"body_html":100,"body_text":101,"firm_name":102,"letter_id":103,"created_at":80,"fei_number":19,"letter_url":104,"updated_at":105,"action_type":22,"case_status":106,"posted_date":107,"marcs_cms_no":108,"product_type":26,"closeout_date":109,"issuing_office":110,"recipient_name":111,"body_fetched_at":112,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":113,"medical_device_id":19,"response_letter_date":19},1661,[94,95,96,97,98,13,99,13],"\u003Ctime datetime=\"2024-01-09T14:20:00Z\">01\u002F09\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-11-07T05:00:00Z\">11\u002F07\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdeymed-diagnostic-sro-671076-11072023\">Deymed Diagnostic s.r.o.\u003C\u002Fa>","&quot;OHT5: Office of Neurological and Physical Medicine Devices, Office of Product Evaluation and Quality&quot;","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdeymed-diagnostic-sro-671076-08062025\">\u003Ctime datetime=\"2025-08-12T04:00:00Z\">08\u002F12\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Kamil Holub\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Deymed Diagnostic s.r.o.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Kudrnacova 533\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hronov\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>54931\u003C\u002Fspan> \u003Cspan>Nachod CZ\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Czechia\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@deymed.com\"> info@deymed.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>\"OHT5: Office of Neurological and Physical Medicine Devices, Office of Product Evaluation and Quality\"\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\nCMS # 671076\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nCC: valsa@deymed.com\u003C\u002Fp>\n\n\u003Cp>November 7, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Kamil Holub:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm Deymed Diagnostic s.r.o., located in Hronov, Nachod, Czech Republic on July 24, 2023, through July 27, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures a variety of Class II, non-sterile, products: 1) BrainFeedback Pro and 2) TruScan LT. Your firm also contract manufactures the following Class II, non-sterile, product: 1) DuoMAG NL. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu>&nbsp;(CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>We received two responses from Mr. Kamil Holub, Chief Executive Officer (CEO) of Deymed Diagnostic s.r.o. dated August 17, 2023, and September 15, 2023, addressing our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain adequate design control procedures to control the design of the device in order to ensure that specified requirements are met, as required by 21 CFR 820.30(a)\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm’s Design and Development Procedure, Document #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, states that the purpose of this procedure is to describe control of product development from establishing of requirements on product till transfer to production and following product changes. However, your firm has yet to subject the Class II BrainFeedback PRO to the design control process. Your firm has been shipping these units to the United States (U.S.) since 2015.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses dated August 17, 2023, and September 15, 2023, and concluded that your firm’s response is not adequate. In your responses, you submitted documentation of your corrective action plan and remediation progress to-date. We acknowledge that your firm opened “CAPA2023\u002F04 BrainFeedback Pro USA Design Controls”, revised \u003Cstrong>(b)(4)\u003C\u002Fstrong> Design and Development Procedure so that it specifies design inputs and outputs and a design verification and validation plan, completed personnel training on the new procedures and processes and discontinued the sale of the BrainFeedback Pro in the U.S. In your response dated September 15, 2023, your firm indicates that there are several corrective actions in progress, including but not limited to the following: 1) Test the BrainFeedback Pro for electrical safety according to the latest revision of IEC 60601-1, 2) Make a gap analysis for remaining US devices (TruScan Neurofeedback and DuoMag NL), 3) Complete the Design History File (DHF) for BrainFeedback Pro, 4) Delete BrainFeedback Pro proprietary name in FDA Unified Registration and Listing Systems (FURLS) Database and 5) Delete Unique Device Identifier (UDI) 08592566001017 from the Global Unique Device Identification (GUDID) Database. However, as of October 31, 2023, it does not appear that your firm has deleted its entry in the GUDID Database, and it is not clear what your firm intends to do to ensure that BrainFeedback Pro devices that were previously sold in the US are in compliance with the Quality System Regulation. For this reason, your firm’s response is inadequate.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain adequate procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a)\u003C\u002Fp>\n\n\u003Cp>Specifically, under Section 2.4.1 (page 2) of your firm’s Customer Complaints Procedure - Doc #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, a complaint is defined as follows:\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Complaint – …written, electronic or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, usability, safety, or performance of a medical device that has been released from the organization’s control or related to a service that affects the performance of such medical devices, according to ISO 13485.\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>…any written, electronic, or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or performance of a device after it is released for distribution, according to FDA 21 CFR Part 820.\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your firm has received over 180 complaints from your United States customers since 2019 and none of the complaints have been evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report and if the incidences require a failure investigation. For example:\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Complaints (2 total) from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cdiv>&nbsp;\u003C\u002Fdiv>\n\n\u003Cdiv>\n\u003Ctable>\n\t\u003Cthead>\n\t\t\u003Ctr>\n\t\t\t\u003Cth>Customer Complaint #\u003C\u002Fth>\n\t\t\t\u003Cth>Complaint Description\u003C\u002Fth>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Fthead>\n\t\u003Ctbody>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Ftd>\n\t\t\t\u003Ctd>sensitive CRPS patient had red mark on skin for a few days\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Ftd>\n\t\t\t\u003Ctd>failure of liquid cooling unit\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\u003C\u002Fdiv>\n\n\u003Cp>\u003Cu>Complaints (184 total) from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cdiv>\n\u003Ctable>\n\t\u003Cthead>\n\t\t\u003Ctr>\n\t\t\t\u003Cth>Customer Complaint #\u003C\u002Fth>\n\t\t\t\u003Cth>Complaint Description\u003C\u002Fth>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Fthead>\n\t\u003Ctbody>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Ftd>\n\t\t\t\u003Ctd>CP23-017 I have been having problems getting my DeyMed to boot up…\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Ftd>\n\t\t\t\u003Ctd>CP23-013 The client said that a patient felt a mild shock when using the system.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Ftd>\n\t\t\t\u003Ctd>CP22-020 It looks like the device is no longer working. It appears to be a little swollen. Possibly the battery I am assuming.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\u003C\u002Fdiv>\n\n\u003Cp>\u003Cbr>\nWe reviewed your firm’s responses dated August 17, 2023, and September 15, 2023, and determined that the adequacy of your firm’s response cannot be determined at this time. We acknowledge that your firm opened “CAPA2023\u002F04 Customer Complaints”, revised \u003Cstrong>(b)(4)\u003C\u002Fstrong> Customer Complaints (filename “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”) and completed personnel training on the new procedures and processes, which includes revised procedures for complaint recording, evaluating, and reporting, including use of the Customer Complaint (CC) form by complaint handling unit members and the documentation of complaints on a complaint register. However, your firm has not completed a retrospective review of all complaints received from your U.S. customers since 2019 and a failure investigation (if required) per the revised procedure provided in your firm’s response. Being that your retrospective review for the cited nonconformance has not been completed, the adequacy of your firm’s response cannot be determined at this time. Please provide documentation of your retrospective review.\u003C\u002Fp>\n\n\u003Cp>3. Failure to develop, conduct, control, and monitor production processes to ensure that a device conforms to its specifications, as required by 21 CFR 820.70(a). Specifically, your firm has yet to establish procedures for the manufacturing of the various Printed Circuit Board Assembly (PCBA) for the TruScan LT, using the automated pick and place machines (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\n\n\u003Cp>The TruScan LT Neurofeedback has a total of \u003Cstrong>(b)(6)\u003C\u002Fstrong> Printed Circuit Boards (PCBs) in each unit. However, your firm has yet to establish procedures or working instructions for the manufacturing of the various PCBs for the TruScan LT using the automated pick and place machines (\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>and \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses dated August 17, 2023, and September 15, 2023, and concluded that your firm’s responses are not adequate. We acknowledge that your firm opened “CAPA2023\u002F05 PCB Manufacturing Process”, revised \u003Cstrong>(b)(4)\u003C\u002Fstrong> Document Controls (filename “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”), revised the new printed circuit board work instruction (filename “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”) and completed personnel training on the new procedures and processes. Your firm stated that it plans to complete the installation and qualification of the new automated pick and place machine and a retrospective review of the production processes for other devices (e.g., DuoMag NL and TruScan Neurofeedback Device). However, it is not clear how your firm intends to ensure that all devices in the US market were manufactured to ensure that the device conforms to its specifications. Therefore, your firm’s response is not adequate.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish and maintain adequate procedures to ensure that device history records for each batch, lot or unit are maintained to demonstrate that the device is manufactured in accordance with the device master record, as required by 21 CFR 820.184.\u003C\u002Fp>\n\n\u003Cp>Specifically, during this inspection, eleven Device History Records (DHRs) from 2023 (pertaining to the TruScan LT) were selected for review. The following deficiencies were noted:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>None of the DHRs included or referred to the location of the primary identification label and labeling used for each production unit; and\u003C\u002Fli>\n\t\u003Cli>None of the DHRs included or referred to the location of the unique device identifiers (UDIs) used for each production unit.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s responses dated August 17, 2023, and September 15, 2023, and concluded that your firm’s responses are not adequate. We acknowledge that your firm opened “CAPA2023\u002F07 DHR to Include Labels and UDIs”, created a new form to record all used device labels into the DHR and revised \u003Cstrong>(b)(4)\u003C\u002Fstrong> Document Controls (filename “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”) so that it clearly contains all required elements stated in 21 CFR 820.184 and completed personnel training on the new procedures and processes. However, your firm did not indicate that previous DHRs for US devices would be retrospectively reviewed and updated to ensure the required information is included. Therefore, your firm’s response is not adequate.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case # 671076 when replying. If you have any questions about the contents of this letter, please contact: Amber Ballard, PhD at Amber.Ballard@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Nina Mezu-Nwaba, PharmD, MPH, MSc\u003Cbr>\nDeputy Director\u003Cbr>\nOHT5: Office of Neurological and Physical\u003Cbr>\nMedicine Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nRobert V. Packard (U.S. Agent)\u003Cbr>\nMedical Device Academy Inc.\u003Cbr>\nShrewsbury, VT US 05738\u003Cbr>\nEmail: Rob@13485cert.Com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nKamil Holub\n\nDeymed Diagnostic s.r.o.\n\nKudrnacova 533\n\nHronov\n\n54931 Nachod CZ\n\nCzechia\n\ninfo@deymed.com\n\nIssuing Office:\n\n\"OHT5: Office of Neurological and Physical Medicine Devices, Office of Product Evaluation and Quality\"\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nCMS # 671076\n\nCC: valsa@deymed.com\n\nNovember 7, 2023\n\nDear Mr. Kamil Holub:\n\nDuring an inspection of your firm Deymed Diagnostic s.r.o., located in Hronov, Nachod, Czech Republic on July 24, 2023, through July 27, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures a variety of Class II, non-sterile, products: 1) BrainFeedback Pro and 2) TruScan LT. Your firm also contract manufactures the following Class II, non-sterile, product: 1) DuoMAG NL. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nWe received two responses from Mr. Kamil Holub, Chief Executive Officer (CEO) of Deymed Diagnostic s.r.o. dated August 17, 2023, and September 15, 2023, addressing our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain adequate design control procedures to control the design of the device in order to ensure that specified requirements are met, as required by 21 CFR 820.30(a)\n\nSpecifically, your firm’s Design and Development Procedure, Document #(b)(4), states that the purpose of this procedure is to describe control of product development from establishing of requirements on product till transfer to production and following product changes. However, your firm has yet to subject the Class II BrainFeedback PRO to the design control process. Your firm has been shipping these units to the United States (U.S.) since 2015.\n\nWe reviewed your firm’s responses dated August 17, 2023, and September 15, 2023, and concluded that your firm’s response is not adequate. In your responses, you submitted documentation of your corrective action plan and remediation progress to-date. We acknowledge that your firm opened “CAPA2023\u002F04 BrainFeedback Pro USA Design Controls”, revised (b)(4) Design and Development Procedure so that it specifies design inputs and outputs and a design verification and validation plan, completed personnel training on the new procedures and processes and discontinued the sale of the BrainFeedback Pro in the U.S. In your response dated September 15, 2023, your firm indicates that there are several corrective actions in progress, including but not limited to the following: 1) Test the BrainFeedback Pro for electrical safety according to the latest revision of IEC 60601-1, 2) Make a gap analysis for remaining US devices (TruScan Neurofeedback and DuoMag NL), 3) Complete the Design History File (DHF) for BrainFeedback Pro, 4) Delete BrainFeedback Pro proprietary name in FDA Unified Registration and Listing Systems (FURLS) Database and 5) Delete Unique Device Identifier (UDI) 08592566001017 from the Global Unique Device Identification (GUDID) Database. However, as of October 31, 2023, it does not appear that your firm has deleted its entry in the GUDID Database, and it is not clear what your firm intends to do to ensure that BrainFeedback Pro devices that were previously sold in the US are in compliance with the Quality System Regulation. For this reason, your firm’s response is inadequate.\n\n2. Failure to establish and maintain adequate procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a)\n\nSpecifically, under Section 2.4.1 (page 2) of your firm’s Customer Complaints Procedure - Doc #(b)(4), a complaint is defined as follows:\n\nComplaint – …written, electronic or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, usability, safety, or performance of a medical device that has been released from the organization’s control or related to a service that affects the performance of such medical devices, according to ISO 13485.\n\n…any written, electronic, or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or performance of a device after it is released for distribution, according to FDA 21 CFR Part 820.\n\nYour firm has received over 180 complaints from your United States customers since 2019 and none of the complaints have been evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report and if the incidences require a failure investigation. For example:\n\nComplaints (2 total) from (b)(4)\n\nCustomer Complaint #\nComplaint Description\n\n(b)(6)\nsensitive CRPS patient had red mark on skin for a few days\n\n(b)(6)\nfailure of liquid cooling unit\n\nComplaints (184 total) from (b)(4)\n\nCustomer Complaint #\nComplaint Description\n\n(b)(6)\nCP23-017 I have been having problems getting my DeyMed to boot up…\n\n(b)(6)\nCP23-013 The client said that a patient felt a mild shock when using the system.\n\n(b)(6)\nCP22-020 It looks like the device is no longer working. It appears to be a little swollen. Possibly the battery I am assuming.\n\nWe reviewed your firm’s responses dated August 17, 2023, and September 15, 2023, and determined that the adequacy of your firm’s response cannot be determined at this time. We acknowledge that your firm opened “CAPA2023\u002F04 Customer Complaints”, revised (b)(4) Customer Complaints (filename “(b)(4)”) and completed personnel training on the new procedures and processes, which includes revised procedures for complaint recording, evaluating, and reporting, including use of the Customer Complaint (CC) form by complaint handling unit members and the documentation of complaints on a complaint register. However, your firm has not completed a retrospective review of all complaints received from your U.S. customers since 2019 and a failure investigation (if required) per the revised procedure provided in your firm’s response. Being that your retrospective review for the cited nonconformance has not been completed, the adequacy of your firm’s response cannot be determined at this time. Please provide documentation of your retrospective review.\n\n3. Failure to develop, conduct, control, and monitor production processes to ensure that a device conforms to its specifications, as required by 21 CFR 820.70(a). Specifically, your firm has yet to establish procedures for the manufacturing of the various Printed Circuit Board Assembly (PCBA) for the TruScan LT, using the automated pick and place machines ((b)(4) and (b)(4)).\n\nThe TruScan LT Neurofeedback has a total of (b)(6) Printed Circuit Boards (PCBs) in each unit. However, your firm has yet to establish procedures or working instructions for the manufacturing of the various PCBs for the TruScan LT using the automated pick and place machines ((b)(4) and (b)(4)).\n\nWe reviewed your firm’s responses dated August 17, 2023, and September 15, 2023, and concluded that your firm’s responses are not adequate. We acknowledge that your firm opened “CAPA2023\u002F05 PCB Manufacturing Process”, revised (b)(4) Document Controls (filename “(b)(4)”), revised the new printed circuit board work instruction (filename “(b)(4)”) and completed personnel training on the new procedures and processes. Your firm stated that it plans to complete the installation and qualification of the new automated pick and place machine and a retrospective review of the production processes for other devices (e.g., DuoMag NL and TruScan Neurofeedback Device). However, it is not clear how your firm intends to ensure that all devices in the US market were manufactured to ensure that the device conforms to its specifications. Therefore, your firm’s response is not adequate.\n\n4. Failure to establish and maintain adequate procedures to ensure that device history records for each batch, lot or unit are maintained to demonstrate that the device is manufactured in accordance with the device master record, as required by 21 CFR 820.184.\n\nSpecifically, during this inspection, eleven Device History Records (DHRs) from 2023 (pertaining to the TruScan LT) were selected for review. The following deficiencies were noted:\n\nNone of the DHRs included or referred to the location of the primary identification label and labeling used for each production unit; and\n\nNone of the DHRs included or referred to the location of the unique device identifiers (UDIs) used for each production unit.\n\nWe reviewed your firm’s responses dated August 17, 2023, and September 15, 2023, and concluded that your firm’s responses are not adequate. We acknowledge that your firm opened “CAPA2023\u002F07 DHR to Include Labels and UDIs”, created a new form to record all used device labels into the DHR and revised (b)(4) Document Controls (filename “(b)(4)”) so that it clearly contains all required elements stated in 21 CFR 820.184 and completed personnel training on the new procedures and processes. However, your firm did not indicate that previous DHRs for US devices would be retrospectively reviewed and updated to ensure the required information is included. Therefore, your firm’s response is not adequate.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case # 671076 when replying. If you have any questions about the contents of this letter, please contact: Amber Ballard, PhD at Amber.Ballard@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nCAPT Nina Mezu-Nwaba, PharmD, MPH, MSc\n\nDeputy Director\n\nOHT5: Office of Neurological and Physical\n\nMedicine Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nRobert V. Packard (U.S. Agent)\n\nMedical Device Academy Inc.\n\nShrewsbury, VT US 05738\n\nEmail: Rob@13485cert.Com","Deymed Diagnostic s.r.o.","deymed-diagnostic-sro-671076-11072023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdeymed-diagnostic-sro-671076-11072023","2026-10-26T08:08:23.948748+00:00","Closed Out","2024-01-09","671076","2025-08-12","\"OHT5: Office of Neurological and Physical Medicine Devices, Office of Product Evaluation and Quality\"","Kamil Holub","2026-08-20T00:23:06.472+00:00","2023-11-07",{"id":115,"raw":116,"subject":98,"body_html":120,"body_text":121,"firm_name":122,"letter_id":123,"created_at":124,"fei_number":19,"letter_url":125,"updated_at":126,"action_type":22,"case_status":23,"posted_date":127,"marcs_cms_no":128,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":129,"body_fetched_at":130,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":131,"medical_device_id":19,"response_letter_date":19},255,[117,118,119,11,98,13,13,13],"\u003Ctime datetime=\"2026-03-24T04:00:00Z\">03\u002F24\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-02-26T05:00:00Z\">02\u002F26\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flonghorn-vaccines-and-diagnostics-llc-721702-02262026\">Longhorn Vaccines and Diagnostics LLC \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jeffrey D. Fischer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Longhorn Vaccines and Diagnostics LLC \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7272 Wisconsin Avenue, Ste 900\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bethesda\u003C\u002Fspan>, \u003Cspan>MD\u003C\u002Fspan> \u003Cspan>20814\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jeff@lhnvd.com\"> jeff@lhnvd.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS # 721702\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>February 26, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Jeffrey D. Fischer:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Bethesda, MD from October 20, 2025 through October 30, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm is a specification developer of the PrimeStore® MTM (Molecular Transport Medium) device intended for the stabilization, transportation, and inactivation of infectious unprocessed nasal washes suspected of containing Influenza A virus RNA as well as unprocessed sputum samples suspected of containing \u003Cem>Mycobacterium tuberculosis\u003C\u002Fem> DNA from human samples. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Col>\u003Cli>Failure to maintain complaint files and establish and maintain procedures for receiving,reviewing, and evaluating complaints by a formally designated unit to ensure that allcomplaints are processed in a uniform and timely manner; oral complaints are documentedupon receipt; and complaints are evaluated to determine whether the complaint represents anevent which is required to be reported to FDA under part 803 of this chapter, Medical DeviceReporting, as required by 21 CFR 820.198(a) and 21 CFR 820.198(a)(1) through820.198(a)(3).\u003C\u002Fli>\u003C\u002Fol>\u003Cp>Specifically:\u003C\u002Fp>\u003Cp>A. Complaints files are not adequately maintained, as required by 21 CFR 820.198(a). For example, alleged deficiencies of your PrimeStore® MTM devices received via thirteen (13) emails between 2020 and 2022 were not documented in controlled records.\u003C\u002Fp>\u003Cp>B. Your firm did not have a procedure for complaint handling (QSP-COM-001; Rev. 1.0; Effective: 10\u002F27\u002F25), until during the inspection. This procedure lacks requirements for:\u003C\u002Fp>\u003Cp>1) Uniform and timely processing of complaints, as required by 21 CFR 820.198(a)(1);\u003C\u002Fp>\u003Cp>2) Documentation of oral complaints upon receipt, as required by 21 CFR 820.198(a)(2); and\u003C\u002Fp>\u003Cp>3) Evaluation of complaints to determine whether the complaint represents an event which is required to be reported to FDA under 21 CFR 803 (Medical Device Reporting), as required by 21 CFR 820.198(a)(3). For example, your firm failed to evaluate complaints for medical device reportability received for your PrimeStore® MTM devices regarding leakage of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” between 2020 and 2022; two (2) incidents of ingestion in 2022; two (2) incidents of skin exposure in 2021; and FDA notification of cyanide release in 2020 due to usage on incompatible systems consisting of a bleach step (RES 86189).\u003C\u002Fp>\u003Cp>2. Failure to review and evaluate all complaints to determine whether an investigation is necessary. When no investigation is made, the manufacturer shall maintain a record that includes the reason no investigation was made and the name of the individual responsible for the decision not to investigate, as required by 21 CFR 820.198(b).\u003C\u002Fp>\u003Cp>For example, your firm did not review and evaluate whether the two (2) complaints of ingestion in 2022 and two (2) complaints of skin exposure in 2021 required investigations or document reasons for why no investigations were necessary.\u003C\u002Fp>\u003Cp>3. Failure to investigate any complaint involving the possible failure of a device, labeling or packaging to meet any of its specifications, unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 CFR 820.198(c).\u003C\u002Fp>\u003Cp>Specifically, your firm does not have any documented investigations for the following complaints which involve the possible failure of your PrimeStore® MTM device, labeling, or packaging to meet any of its specifications:\u003C\u002Fp>\u003Cul>\u003Cli>Leakage of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” between 2020 and 2022;\u003C\u002Fli>\u003Cli>Release of cyanide after usage of device on incompatible systems (RES 86189)\u003C\u002Fli>\u003C\u002Ful>\u003Cp>4. Failure to establish and maintain procedures for implementing corrective and preventive action, including requirements for analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems using appropriate statistical methodology; investigating the cause of nonconformities relating to product, processes, and the quality system; identifying the action(s) needed to correct and prevent recurrence of nonconforming product and other quality problems; and verifying or validating the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a) and 21 CFR 820.100(a)(1) through 820.100(a)(4).\u003C\u002Fp>\u003Cp>Specifically:\u003C\u002Fp>\u003Cp>A. Your firm did not have a procedure for implementing corrective and preventive action (CAPA) (QSP-CAPA-001; Rev. 1.0; Effective: 10\u002F27\u002F25), until during this inspection, as required by 21 CFR 820.100(a).\u003C\u002Fp>\u003Cp>B. Your firm failed to analyze your processes, work operations, complaints, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a)(1).\u003C\u002Fp>\u003Cp>C. Your firm failed to investigate the cause and identify actions needed to prevent recurrence along with the verification or validation of the effectiveness of such actions, as required by 21 CFR 820.100(a)(2) through 21 CFR 820.100(a)(4), for the following known, systemic issues:\u003C\u002Fp>\u003Cul>\u003Cli>Field correction RES 86189 initiated on June 3, 2020 urging users to apply labels to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> PrimeStore® MTM devices which had been distributed without a label and avoid contact with bleach to prevent the release of cyanide gas.\u003C\u002Fli>\u003Cli>Complaints received for leakage of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” between 2020 and 2022.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>5. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met to demonstrate that the design was developed in accordance with the design control requirements, as required by 21 CFR 820.30(a) through 820.30(j).\u003C\u002Fp>\u003Cp>Specifically:\u003C\u002Fp>\u003Cp>A. Your firm did not have procedures to control the design of your PrimeStore® MTM devices (“PrimeStore® MTM – Design Control Document” created October 18, 2025), until during this inspection, as required by 21 CFR 820.30(a).\u003C\u002Fp>\u003Cp>B. Your firm did not have a design and development plan in place for your PrimeStore® MTM devices (“Design and Development***” section of “PrimeStore® MTM – Design History File (DHF)” [Rev. 1.0; Effective: 10\u002F21\u002F25]), until during this inspection, as required by 21 CFR 820.30(b). Although the “Design and Development Plan” section of this document contains a historical summary of product development, it fails to define responsibility for implementation and identify and describe the interfaces with different groups or activities that provide, or result in, input to the design and development process.\u003C\u002Fp>\u003Cp>C. Your firm did not have a design input procedure (“Design Inputs***” section of “PrimeStore® MTM – Design Control Document” created October 18, 2025 which was superseded by “Design Input Procedure***” [SOP-DV-004; Rev. 1.0; Effective: 10\u002F27\u002F25]), until during this inspection, as required by 21 CFR 820.30(c). Although the design input section of the “PrimeStore® MTM – Design Control Document” states “***\u003Cstrong>(b)(4)\u003C\u002Fstrong>***,” it fails to include a mechanism for addressing incomplete, ambiguous, or conflicting requirements.\u003C\u002Fp>\u003Cp>For example, the following design inputs, created as a part of the “PrimeStore® MTM – Design History File (DHF)” (Rev. 1.0; Effective: 10\u002F21\u002F25) at the time the “PrimeStore® MTM – Design Control Document” procedure was in effect, are ambiguous in that they lack or fail to make reference to clearly defined requirements:\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>D. Your firm did not have a design output procedure (“Design Outputs” section of “PrimeStore® MTM – Design Control Document” created on October 18, 2025 which was superseded by “Design Output Procedure***” [SOP-DV-005; Rev. 1.0; Effective: 10\u002F27\u002F25]), until during this inspection, as required by 21 CFR 820.30(d). Although the design output section of the “PrimeStore® MTM – Design Control Document” states “***\u003Cstrong>(b)(4)\u003C\u002Fstrong>***,” it fails to require that acceptance criteria be included or referenced and that those design outputs that are essential for the proper functioning of the device are identified.\u003C\u002Fp>\u003Cp>For example, the following design outputs, created as a part of the “PrimeStore® MTM – Design History File (DHF)” (Rev. 1.0; Effective: 10\u002F21\u002F25) at the time the “PrimeStore® MTM – Design Control Document” procedure was in effect, fail to contain or make reference to acceptance criteria or identify outputs that are essential for proper functioning of your PrimeStore® MTM devices:\u003C\u002Fp>\u003Cul>\u003Cli>The “Tube system” design output only states “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” with no further references to output documentation.\u003C\u002Fli>\u003Cli>The “Label set” design output only states “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” with no further references to output documentation.\u003C\u002Fli>\u003Cli>The “Manufacturing documents” design output only states “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” with no further references to output documentation.\u003C\u002Fli>\u003Cli>The “Packaging” design output only states “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” with no further references to output documentation.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>E. Your firm did not have a design review procedure (“Design Reviews” section of “PrimeStore® MTM – Design Control Document” created on October 18, 2025 which was superseded by “Design Review Procedure***” [SOP-DV-006; Rev. 1.0; Effective: 10\u002F27\u002F25]), until during this inspection, as required by 21 CFR 820.30(e).\u003C\u002Fp>\u003Cp>F. Your firm did not have a design verification procedure (“Design Verification***” section of “PrimeStore® MTM – Design Control Document” created on October 18, 2025 which was superseded by “Design Verification Procedure ***” [SOP-DV-007; Rev. 1.0; Effective: 10\u002F27\u002F25]), until during this inspection, as required by 21 CFR 820.30(f).\u003C\u002Fp>\u003Cp>G. Your firm did not have a design validation procedure (“Design Validation***” section of “PrimeStore® MTM – Design Control Document” created October 18, 2025 which was superseded by “Design Validation Procedure***” [SOP-DV-008; Rev. 1.0; Effective: 10\u002F27\u002F25]), until during this inspection, as required by 21 CFR 820.30(g).\u003C\u002Fp>\u003Cp>H. Your firm did not have a design transfer procedure (“Design Transfer to Production” section of “PrimeStore® MTM – Design Control Document” created on October 18, 2025 which was superseded by “Design Transfer Procedure***” [SOP-DV-009; Rev. 1.0; Effective: 10\u002F27\u002F25]), until during this inspection, as required by 21 CFR 820.30(h).\u003C\u002Fp>\u003Cp>I. Your firm did not have a design change procedure (“Change Control***” section of “PrimeStore® MTM – Design Control Document” created October 18, 2025 which was superseded by “Design Change Control Procedure***” [SOP-CC-001; Rev. 1.0; Effective: 10\u002F27\u002F25]), until during this inspection, as required by 21 CFR 820.30(i). Although the “Change Control” section of the “PrimeStore® MTM – Design Control Document” requires “***\u003Cstrong>(b)(4)\u003C\u002Fstrong>***” and “***\u003Cstrong>(b)(4)\u003C\u002Fstrong>***,” there is no requirement for validation or where appropriate verification, review, and approval of design changes before their implementation.\u003C\u002Fp>\u003Cp>For example, your firm was unable to provide validation or verification (where appropriate), evidence of review and approval, and assessment for the need of a new premarket authorization submission for the following design changes of your PrimeStore® MTM devices prior to implementation:\u003C\u002Fp>\u003Cul>\u003Cli>Additional tube sizes and fill volume (2mL tube with a 1mL fill volume; 5mL tube with a 1.5mL fill volume; 12mL tube with a 2mL fill volume; and 12mL tube with a 3mL fill volume)\u003C\u002Fli>\u003Cli>Change in shelf life prior to use from 24 months to 30 months\u003C\u002Fli>\u003Cli>Changes in the tube\u003C\u002Fli>\u003C\u002Ful>\u003Cp>J. Your firm failed to define and document a design history file (DHF) (“PrimeStore® MTM – Design History File (DHF)” (Rev. 1.0; Effective: 10\u002F21\u002F25) and “DHF – History” dated 10\u002F23\u002F25) for your PrimeStore® MTM device, until during this inspection, as required by 21 CFR 820.30(j).\u003C\u002Fp>\u003Cp>6. Failure to establish and maintain procedures to control product that does not conform to specified requirements, including the identification, documentation, evaluation, segregation, and disposition of nonconforming product. The evaluation of nonconformance shall include a determination of the need for an investigation and notification of the persons or organizations responsible for the nonconformance. The evaluation and any investigation shall be documented, as required by 21 CFR 820.90(a).\u003C\u002Fp>\u003Cp>Specifically, your firm did not have a procedure to control product that does not conform to specified requirements (QSP-NC-001; Rev. 1; Effective: 10\u002F27\u002F25), until during this inspection. Additionally, your firm failed to identify, document, and evaluate the nonconformances noted in the email dated \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> from your contract manufacturers regarding \u003Cstrong>(b)(4)\u003C\u002Fstrong> underfilled (Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and an unknown quantity of discolored (Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>) PrimeStore® MTM devices, respectively, to determine the need for an investigation. In addition, your firm did not evaluate the need for investigations for the nonconformances associated with 2 leaky caps, 43 specks, and 21 floaters (misc.) of PrimeStore® MTM devices (Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>) which were reworked between \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>7. Failure to establish and maintain procedures for rework, to include retesting and reevaluation of the nonconforming product after rework, to ensure that the product meets its current approved specifications and documentation of rework and reevaluation activities, including determination of any adverse effect from the rework upon the product, in the device history record (DHR), as required by 21 CFR 820.90(b)(2).\u003C\u002Fp>\u003Cp>Specifically, your firm did not have a procedure for rework (QSP-RWK-001; Rev. 1; Effective: 10\u002F27\u002F25), until during this inspection. For example, your firm failed to conduct retesting and reevaluation of the reworks conducted between July 15, 2025 and July 16, 2025 for nonconformances associated with 2 leaky caps, 43 specks, and 21 floaters (or misc.) for your PrimeStore® MTM devices (Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>), to ensure that the product meets its current approved specifications, including a determination of any adverse effect from these reworks.\u003C\u002Fp>\u003Cp>8. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50.\u003C\u002Fp>\u003Cp>Specifically, your firm did not have a procedure to ensure that all suppliers conform to specified requirements (QSP-SUP-001; Rev. 1.0; Effective: 10\u002F27\u002F25), until during this inspection. Additionally:\u003C\u002Fp>\u003Cp>A. Your firm does not establish and maintain requirements, including quality requirements, that must be met by your suppliers, as required by 21 CFR 820.50(a). For example:\u003C\u002Fp>\u003Cp>1) Your firm does not have documented evaluations that confirm the ability of \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> of your suppliers to meet requirements, including quality requirements, as required by 21 CFR 820.50(a)(1). This includes suppliers of the bulk liquid media and plastic components as well as finished device contract manufacturers of your PrimeStore® MTM devices.\u003C\u002Fp>\u003Cp>2) Your firm does not define the type as well as extent of controls to be exercised over your suppliers based on the results of supplier evaluations, as required by 21 CFR 820.50(a)(2).\u003C\u002Fp>\u003Cp>3) Your firm did not have records of acceptable suppliers (“Longhorn Supplier List” dated 10\u002F28\u002F25), until during this inspection, as required by 21 CFR 820.50(a)(3).\u003C\u002Fp>\u003Cp>B. Your firm does not have a purchasing agreement in place for \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the finished device contract manufacturers of your PrimeStore® MTM devices which involves an agreement to notify you of changes so that you may determine whether the changes affect the quality of your finished device, as required by 21 CFR 820.50(b).\u003C\u002Fp>\u003Cp>9. Failure of management with executive responsibility to review the suitability and effectiveness of the quality system at defined intervals and with sufficient frequency according to established procedures to ensure that the quality system satisfies the requirements of this part and the manufacturer's established quality policy and objectives, as required by 21 CFR 820.20(c).\u003C\u002Fp>\u003Cp>Specifically, your firm did not have a procedure which requires that the management with executive responsibility review the suitability and effectiveness of the quality system at defined intervals and with sufficient frequency to ensure that your quality system satisfies the requirement of the regulation and your quality policy and objectives (QP-MR-001; Rev. 1.0; Effective: 10\u002F27\u002F25), until during this inspection. For example, the management review records retrospectively created for 2022, 2023, and 2024 from emails and memory during the inspection were inadequate because they were non-contemporaneous and based on data from incomplete quality metrics (e.g., nonconforming products, CAPAs, supplier and purchasing controls, etc.).\u003C\u002Fp>\u003Cp>10. Failure to establish procedures for quality audits and conduct such audits to assure that the quality system is in compliance with the established quality system requirements and to determine the effectiveness of the quality system, as required by 21 CFR 820.22.\u003C\u002Fp>\u003Cp>Specifically, your firm does not have a quality audit procedure and has not conducted quality audits to assure that your quality system is in compliance with established quality system requirements and to determine the effectiveness of your quality system.\u003C\u002Fp>\u003Cp>On February 2, 2024, the FDA issued a \u003Cu>final rule\u003C\u002Fu> amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection from October 20, 2025 through October 30, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection also revealed that your firm’s PrimeStore® MTM devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection also revealed that the PrimeStore® MTM device is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k) and 21 CFR 807.81(a)(3)(ii). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>The PrimeStore® MTM was granted marketing authorization following FDA’s review of your firm’s De Novo request under \u003Cu>DEN170029\u003C\u002Fu> with the following indications for use:\u003C\u002Fp>\u003Cp>\u003Cem>PrimeStore MTM is intended for the stabilization, transportation and inactivation of infectious unprocessed nasal washes suspected of containing Influenza A virus RNA. PrimeStore MTM is also intended for the stabilization, transportation and inactivation of infectious unprocessed sputum samples suspected of containing Mycobacterium tuberculosis DNA from human samples.\u003C\u002Fem>\u003C\u002Fp>\u003Cp>However, your website contains statements and information demonstrating that the PrimeStore MTM is intended for the stabilization and inactivation of numerous additional microorganisms, for the use of numerous additional specimen types and to improve sensitivity in low copy samples outside of the authorized indications. Your website and product brochure also show an intent to market the device for the detection of antimicrobial resistance (AMR) genes. These statements and representations constitute major changes or modifications to the device’s intended use, for which your firm lacks clearance or approval. Examples from your firm’s website include:\u003C\u002Fp>\u003Cp>1. A list of additional organisms for which your device is intended for stabilization and inactivation, including Crimean-Congo hemorrhagic fever virus, Eastern equine encephalitis virus, Ebola virus, Mpox, as well as many other organisms. (https:\u002F\u002Fwww.lhnvd.com\u002Fprimestore-mtm and https:\u002F\u002Fwww.lhnvd.com\u002Fproduct-development))\u003C\u002Fp>\u003Cp>2. A statement, “PrimeStore MTM was optimized (and patented) to provide consistent results from simple samples like nasal swabs to the most challenging samples like tissue and stool.” (https:\u002F\u002Fwww.lhnvd.com\u002Fprimestore-mtm)\u003C\u002Fp>\u003Cp>3. A statement, “The USDA recently expanded its use of PrimeStore MTM beyond SARS-CoV-2 and African Swine Fever to facilitate the tracking and surveillance of the avian influenza strain that is infecting wild bird populations and US poultry flocks.” (https:\u002F\u002Fwww.lhnvd.com\u002Fproduct-development)\u003C\u002Fp>\u003Cp>Examples from your firm’s product brochure for the PrimeStore MTM include:\u003C\u002Fp>\u003Cp>1. A statement “one device for multiple sample types” which lists 14 different sample types including cervical\u002Fvaginal, fecal\u002Fstool, urine, blood\u002Fplasma\u002Fserum, tissue, and genital skin.\u003C\u002Fp>\u003Cp>2. A statement that the PrimeStore MTM can be used to detect “Viruses,” “Parasites,”“Bacteria,” and “Fungi” and to detect “AMR Genes.”\u003C\u002Fp>\u003Cp>3. A statement, “The device can be used for molecular testing and sequencing of blood,plasma, respiratory samples, urine, tissues and stool in human, animal, avian, plant andenvironmental forensics.” (https:\u002F\u002Fwww.lhnvd.com\u002Fproduct-development)\u003C\u002Fp>\u003Cp>These major changes and\u002For modifications to the intended use of your device could significantly affect the safety and effectiveness of your device as they suggest that your device can stabilize, transport, and inactivate these new sample types and targets not previously reviewed in your De Novo request. Failure to stabilize a specimen and\u002For failure to inactivate a specimen can result in inaccurate test results as well as in risks to the user handling clinical specimens without appropriate precautions for the specific pathogen.\u003C\u002Fp>\u003Cp>The performance data provided in your De Novo request indicates the performance of the previously cleared device to inactivate and stabilize nasal washes containing Influenza A virus RNA or unprocessed sputum samples suspected of containing Mycobacterium tuberculosis DNA. However, it does not demonstrate your device’s ability to inactivate and stabilize other infectious agents or to be effective to inactivate or stabilize any infectious agent in sample types not addressed in the De Novo. FDA is not aware of any data demonstrating the safety and effectiveness of your device when intended for use with such infectious diseases and sample types. If you have data demonstrating these performance characteristics, please provide that information to the agency in a new premarket submission.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have QS regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 721702” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara A. Marsden\u003Cbr>Acting Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJeffrey D. Fischer\n\nRecipient Title\n\nPresident\n\nLonghorn Vaccines and Diagnostics LLC\n\n7272 Wisconsin Avenue, Ste 900\n\nBethesda, MD 20814\n\nUnited States\n\njeff@lhnvd.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 721702\nFebruary 26, 2026\nDear Mr. Jeffrey D. Fischer:\nDuring an inspection of your firm located in Bethesda, MD from October 20, 2025 through October 30, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm is a specification developer of the PrimeStore® MTM (Molecular Transport Medium) device intended for the stabilization, transportation, and inactivation of infectious unprocessed nasal washes suspected of containing Influenza A virus RNA as well as unprocessed sputum samples suspected of containing Mycobacterium tuberculosis DNA from human samples. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\nFailure to maintain complaint files and establish and maintain procedures for receiving,reviewing, and evaluating complaints by a formally designated unit to ensure that allcomplaints are processed in a uniform and timely manner; oral complaints are documentedupon receipt; and complaints are evaluated to determine whether the complaint represents anevent which is required to be reported to FDA under part 803 of this chapter, Medical DeviceReporting, as required by 21 CFR 820.198(a) and 21 CFR 820.198(a)(1) through820.198(a)(3).\nSpecifically:\nA. Complaints files are not adequately maintained, as required by 21 CFR 820.198(a). For example, alleged deficiencies of your PrimeStore® MTM devices received via thirteen (13) emails between 2020 and 2022 were not documented in controlled records.\nB. Your firm did not have a procedure for complaint handling (QSP-COM-001; Rev. 1.0; Effective: 10\u002F27\u002F25), until during the inspection. This procedure lacks requirements for:\n1) Uniform and timely processing of complaints, as required by 21 CFR 820.198(a)(1);\n2) Documentation of oral complaints upon receipt, as required by 21 CFR 820.198(a)(2); and\n3) Evaluation of complaints to determine whether the complaint represents an event which is required to be reported to FDA under 21 CFR 803 (Medical Device Reporting), as required by 21 CFR 820.198(a)(3). For example, your firm failed to evaluate complaints for medical device reportability received for your PrimeStore® MTM devices regarding leakage of “(b)(4)” between 2020 and 2022; two (2) incidents of ingestion in 2022; two (2) incidents of skin exposure in 2021; and FDA notification of cyanide release in 2020 due to usage on incompatible systems consisting of a bleach step (RES 86189).\n2. Failure to review and evaluate all complaints to determine whether an investigation is necessary. When no investigation is made, the manufacturer shall maintain a record that includes the reason no investigation was made and the name of the individual responsible for the decision not to investigate, as required by 21 CFR 820.198(b).\nFor example, your firm did not review and evaluate whether the two (2) complaints of ingestion in 2022 and two (2) complaints of skin exposure in 2021 required investigations or document reasons for why no investigations were necessary.\n3. Failure to investigate any complaint involving the possible failure of a device, labeling or packaging to meet any of its specifications, unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 CFR 820.198(c).\nSpecifically, your firm does not have any documented investigations for the following complaints which involve the possible failure of your PrimeStore® MTM device, labeling, or packaging to meet any of its specifications:\nLeakage of “(b)(4)” between 2020 and 2022;\nRelease of cyanide after usage of device on incompatible systems (RES 86189)\n4. Failure to establish and maintain procedures for implementing corrective and preventive action, including requirements for analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems using appropriate statistical methodology; investigating the cause of nonconformities relating to product, processes, and the quality system; identifying the action(s) needed to correct and prevent recurrence of nonconforming product and other quality problems; and verifying or validating the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a) and 21 CFR 820.100(a)(1) through 820.100(a)(4).\nSpecifically:\nA. Your firm did not have a procedure for implementing corrective and preventive action (CAPA) (QSP-CAPA-001; Rev. 1.0; Effective: 10\u002F27\u002F25), until during this inspection, as required by 21 CFR 820.100(a).\nB. Your firm failed to analyze your processes, work operations, complaints, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a)(1).\nC. Your firm failed to investigate the cause and identify actions needed to prevent recurrence along with the verification or validation of the effectiveness of such actions, as required by 21 CFR 820.100(a)(2) through 21 CFR 820.100(a)(4), for the following known, systemic issues:\nField correction RES 86189 initiated on June 3, 2020 urging users to apply labels to the (b)(4) PrimeStore® MTM devices which had been distributed without a label and avoid contact with bleach to prevent the release of cyanide gas.\nComplaints received for leakage of “(b)(4)” between 2020 and 2022.\n5. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met to demonstrate that the design was developed in accordance with the design control requirements, as required by 21 CFR 820.30(a) through 820.30(j).\nSpecifically:\nA. Your firm did not have procedures to control the design of your PrimeStore® MTM devices (“PrimeStore® MTM – Design Control Document” created October 18, 2025), until during this inspection, as required by 21 CFR 820.30(a).\nB. Your firm did not have a design and development plan in place for your PrimeStore® MTM devices (“Design and Development***” section of “PrimeStore® MTM – Design History File (DHF)” [Rev. 1.0; Effective: 10\u002F21\u002F25]), until during this inspection, as required by 21 CFR 820.30(b). Although the “Design and Development Plan” section of this document contains a historical summary of product development, it fails to define responsibility for implementation and identify and describe the interfaces with different groups or activities that provide, or result in, input to the design and development process.\nC. Your firm did not have a design input procedure (“Design Inputs***” section of “PrimeStore® MTM – Design Control Document” created October 18, 2025 which was superseded by “Design Input Procedure***” [SOP-DV-004; Rev. 1.0; Effective: 10\u002F27\u002F25]), until during this inspection, as required by 21 CFR 820.30(c). Although the design input section of the “PrimeStore® MTM – Design Control Document” states “***(b)(4)***,” it fails to include a mechanism for addressing incomplete, ambiguous, or conflicting requirements.\nFor example, the following design inputs, created as a part of the “PrimeStore® MTM – Design History File (DHF)” (Rev. 1.0; Effective: 10\u002F21\u002F25) at the time the “PrimeStore® MTM – Design Control Document” procedure was in effect, are ambiguous in that they lack or fail to make reference to clearly defined requirements:\n(b)(4)\n(b)(4)\n(b)(4)\n(b)(4)\nD. Your firm did not have a design output procedure (“Design Outputs” section of “PrimeStore® MTM – Design Control Document” created on October 18, 2025 which was superseded by “Design Output Procedure***” [SOP-DV-005; Rev. 1.0; Effective: 10\u002F27\u002F25]), until during this inspection, as required by 21 CFR 820.30(d). Although the design output section of the “PrimeStore® MTM – Design Control Document” states “***(b)(4)***,” it fails to require that acceptance criteria be included or referenced and that those design outputs that are essential for the proper functioning of the device are identified.\nFor example, the following design outputs, created as a part of the “PrimeStore® MTM – Design History File (DHF)” (Rev. 1.0; Effective: 10\u002F21\u002F25) at the time the “PrimeStore® MTM – Design Control Document” procedure was in effect, fail to contain or make reference to acceptance criteria or identify outputs that are essential for proper functioning of your PrimeStore® MTM devices:\nThe “Tube system” design output only states “(b)(4)” with no further references to output documentation.\nThe “Label set” design output only states “(b)(4)” with no further references to output documentation.\nThe “Manufacturing documents” design output only states “(b)(4)” with no further references to output documentation.\nThe “Packaging” design output only states “(b)(4)” with no further references to output documentation.\nE. Your firm did not have a design review procedure (“Design Reviews” section of “PrimeStore® MTM – Design Control Document” created on October 18, 2025 which was superseded by “Design Review Procedure***” [SOP-DV-006; Rev. 1.0; Effective: 10\u002F27\u002F25]), until during this inspection, as required by 21 CFR 820.30(e).\nF. Your firm did not have a design verification procedure (“Design Verification***” section of “PrimeStore® MTM – Design Control Document” created on October 18, 2025 which was superseded by “Design Verification Procedure ***” [SOP-DV-007; Rev. 1.0; Effective: 10\u002F27\u002F25]), until during this inspection, as required by 21 CFR 820.30(f).\nG. Your firm did not have a design validation procedure (“Design Validation***” section of “PrimeStore® MTM – Design Control Document” created October 18, 2025 which was superseded by “Design Validation Procedure***” [SOP-DV-008; Rev. 1.0; Effective: 10\u002F27\u002F25]), until during this inspection, as required by 21 CFR 820.30(g).\nH. Your firm did not have a design transfer procedure (“Design Transfer to Production” section of “PrimeStore® MTM – Design Control Document” created on October 18, 2025 which was superseded by “Design Transfer Procedure***” [SOP-DV-009; Rev. 1.0; Effective: 10\u002F27\u002F25]), until during this inspection, as required by 21 CFR 820.30(h).\nI. Your firm did not have a design change procedure (“Change Control***” section of “PrimeStore® MTM – Design Control Document” created October 18, 2025 which was superseded by “Design Change Control Procedure***” [SOP-CC-001; Rev. 1.0; Effective: 10\u002F27\u002F25]), until during this inspection, as required by 21 CFR 820.30(i). Although the “Change Control” section of the “PrimeStore® MTM – Design Control Document” requires “***(b)(4)***” and “***(b)(4)***,” there is no requirement for validation or where appropriate verification, review, and approval of design changes before their implementation.\nFor example, your firm was unable to provide validation or verification (where appropriate), evidence of review and approval, and assessment for the need of a new premarket authorization submission for the following design changes of your PrimeStore® MTM devices prior to implementation:\nAdditional tube sizes and fill volume (2mL tube with a 1mL fill volume; 5mL tube with a 1.5mL fill volume; 12mL tube with a 2mL fill volume; and 12mL tube with a 3mL fill volume)\nChange in shelf life prior to use from 24 months to 30 months\nChanges in the tube\nJ. Your firm failed to define and document a design history file (DHF) (“PrimeStore® MTM – Design History File (DHF)” (Rev. 1.0; Effective: 10\u002F21\u002F25) and “DHF – History” dated 10\u002F23\u002F25) for your PrimeStore® MTM device, until during this inspection, as required by 21 CFR 820.30(j).\n6. Failure to establish and maintain procedures to control product that does not conform to specified requirements, including the identification, documentation, evaluation, segregation, and disposition of nonconforming product. The evaluation of nonconformance shall include a determination of the need for an investigation and notification of the persons or organizations responsible for the nonconformance. The evaluation and any investigation shall be documented, as required by 21 CFR 820.90(a).\nSpecifically, your firm did not have a procedure to control product that does not conform to specified requirements (QSP-NC-001; Rev. 1; Effective: 10\u002F27\u002F25), until during this inspection. Additionally, your firm failed to identify, document, and evaluate the nonconformances noted in the email dated (b)(4) and (b)(4) from your contract manufacturers regarding (b)(4) underfilled (Lot # (b)(4)) and an unknown quantity of discolored (Lot # (b)(4)) PrimeStore® MTM devices, respectively, to determine the need for an investigation. In addition, your firm did not evaluate the need for investigations for the nonconformances associated with 2 leaky caps, 43 specks, and 21 floaters (misc.) of PrimeStore® MTM devices (Lot # (b)(4)) which were reworked between (b)(4) and (b)(4).\n7. Failure to establish and maintain procedures for rework, to include retesting and reevaluation of the nonconforming product after rework, to ensure that the product meets its current approved specifications and documentation of rework and reevaluation activities, including determination of any adverse effect from the rework upon the product, in the device history record (DHR), as required by 21 CFR 820.90(b)(2).\nSpecifically, your firm did not have a procedure for rework (QSP-RWK-001; Rev. 1; Effective: 10\u002F27\u002F25), until during this inspection. For example, your firm failed to conduct retesting and reevaluation of the reworks conducted between July 15, 2025 and July 16, 2025 for nonconformances associated with 2 leaky caps, 43 specks, and 21 floaters (or misc.) for your PrimeStore® MTM devices (Lot # (b)(4)), to ensure that the product meets its current approved specifications, including a determination of any adverse effect from these reworks.\n8. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50.\nSpecifically, your firm did not have a procedure to ensure that all suppliers conform to specified requirements (QSP-SUP-001; Rev. 1.0; Effective: 10\u002F27\u002F25), until during this inspection. Additionally:\nA. Your firm does not establish and maintain requirements, including quality requirements, that must be met by your suppliers, as required by 21 CFR 820.50(a). For example:\n1) Your firm does not have documented evaluations that confirm the ability of (b)(4) out of (b)(4) of your suppliers to meet requirements, including quality requirements, as required by 21 CFR 820.50(a)(1). This includes suppliers of the bulk liquid media and plastic components as well as finished device contract manufacturers of your PrimeStore® MTM devices.\n2) Your firm does not define the type as well as extent of controls to be exercised over your suppliers based on the results of supplier evaluations, as required by 21 CFR 820.50(a)(2).\n3) Your firm did not have records of acceptable suppliers (“Longhorn Supplier List” dated 10\u002F28\u002F25), until during this inspection, as required by 21 CFR 820.50(a)(3).\nB. Your firm does not have a purchasing agreement in place for (b)(4) out of (b)(4) of the finished device contract manufacturers of your PrimeStore® MTM devices which involves an agreement to notify you of changes so that you may determine whether the changes affect the quality of your finished device, as required by 21 CFR 820.50(b).\n9. Failure of management with executive responsibility to review the suitability and effectiveness of the quality system at defined intervals and with sufficient frequency according to established procedures to ensure that the quality system satisfies the requirements of this part and the manufacturer's established quality policy and objectives, as required by 21 CFR 820.20(c).\nSpecifically, your firm did not have a procedure which requires that the management with executive responsibility review the suitability and effectiveness of the quality system at defined intervals and with sufficient frequency to ensure that your quality system satisfies the requirement of the regulation and your quality policy and objectives (QP-MR-001; Rev. 1.0; Effective: 10\u002F27\u002F25), until during this inspection. For example, the management review records retrospectively created for 2022, 2023, and 2024 from emails and memory during the inspection were inadequate because they were non-contemporaneous and based on data from incomplete quality metrics (e.g., nonconforming products, CAPAs, supplier and purchasing controls, etc.).\n10. Failure to establish procedures for quality audits and conduct such audits to assure that the quality system is in compliance with the established quality system requirements and to determine the effectiveness of the quality system, as required by 21 CFR 820.22.\nSpecifically, your firm does not have a quality audit procedure and has not conducted quality audits to assure that your quality system is in compliance with established quality system requirements and to determine the effectiveness of your quality system.\nOn February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection from October 20, 2025 through October 30, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\nMedical Device Reporting (MDR) Violations\nOur inspection also revealed that your firm’s PrimeStore® MTM devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\nFailure to develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17.\nUnapproved Device Violations\nOur inspection also revealed that the PrimeStore® MTM device is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k) and 21 CFR 807.81(a)(3)(ii). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nThe PrimeStore® MTM was granted marketing authorization following FDA’s review of your firm’s De Novo request under DEN170029 with the following indications for use:\nPrimeStore MTM is intended for the stabilization, transportation and inactivation of infectious unprocessed nasal washes suspected of containing Influenza A virus RNA. PrimeStore MTM is also intended for the stabilization, transportation and inactivation of infectious unprocessed sputum samples suspected of containing Mycobacterium tuberculosis DNA from human samples.\nHowever, your website contains statements and information demonstrating that the PrimeStore MTM is intended for the stabilization and inactivation of numerous additional microorganisms, for the use of numerous additional specimen types and to improve sensitivity in low copy samples outside of the authorized indications. Your website and product brochure also show an intent to market the device for the detection of antimicrobial resistance (AMR) genes. These statements and representations constitute major changes or modifications to the device’s intended use, for which your firm lacks clearance or approval. Examples from your firm’s website include:\n1. A list of additional organisms for which your device is intended for stabilization and inactivation, including Crimean-Congo hemorrhagic fever virus, Eastern equine encephalitis virus, Ebola virus, Mpox, as well as many other organisms. (https:\u002F\u002Fwww.lhnvd.com\u002Fprimestore-mtm and https:\u002F\u002Fwww.lhnvd.com\u002Fproduct-development))\n2. A statement, “PrimeStore MTM was optimized (and patented) to provide consistent results from simple samples like nasal swabs to the most challenging samples like tissue and stool.” (https:\u002F\u002Fwww.lhnvd.com\u002Fprimestore-mtm)\n3. A statement, “The USDA recently expanded its use of PrimeStore MTM beyond SARS-CoV-2 and African Swine Fever to facilitate the tracking and surveillance of the avian influenza strain that is infecting wild bird populations and US poultry flocks.” (https:\u002F\u002Fwww.lhnvd.com\u002Fproduct-development)\nExamples from your firm’s product brochure for the PrimeStore MTM include:\n1. A statement “one device for multiple sample types” which lists 14 different sample types including cervical\u002Fvaginal, fecal\u002Fstool, urine, blood\u002Fplasma\u002Fserum, tissue, and genital skin.\n2. A statement that the PrimeStore MTM can be used to detect “Viruses,” “Parasites,”“Bacteria,” and “Fungi” and to detect “AMR Genes.”\n3. A statement, “The device can be used for molecular testing and sequencing of blood,plasma, respiratory samples, urine, tissues and stool in human, animal, avian, plant andenvironmental forensics.” (https:\u002F\u002Fwww.lhnvd.com\u002Fproduct-development)\nThese major changes and\u002For modifications to the intended use of your device could significantly affect the safety and effectiveness of your device as they suggest that your device can stabilize, transport, and inactivate these new sample types and targets not previously reviewed in your De Novo request. Failure to stabilize a specimen and\u002For failure to inactivate a specimen can result in inaccurate test results as well as in risks to the user handling clinical specimens without appropriate precautions for the specific pathogen.\nThe performance data provided in your De Novo request indicates the performance of the previously cleared device to inactivate and stabilize nasal washes containing Influenza A virus RNA or unprocessed sputum samples suspected of containing Mycobacterium tuberculosis DNA. However, it does not demonstrate your device’s ability to inactivate and stabilize other infectious agents or to be effective to inactivate or stabilize any infectious agent in sample types not addressed in the De Novo. FDA is not aware of any data demonstrating the safety and effectiveness of your device when intended for use with such infectious diseases and sample types. If you have data demonstrating these performance characteristics, please provide that information to the agency in a new premarket submission.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have QS regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 721702” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara A. Marsden\nActing Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Longhorn Vaccines and Diagnostics LLC","longhorn-vaccines-and-diagnostics-llc-721702-02262026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flonghorn-vaccines-and-diagnostics-llc-721702-02262026","2026-10-26T08:09:16.196996+00:00","2026-03-24","721702","Jeffrey D. Fischer","2026-08-19T04:50:18.186+00:00","2026-02-26",{"id":133,"raw":134,"subject":98,"body_html":138,"body_text":139,"firm_name":140,"letter_id":141,"created_at":142,"fei_number":19,"letter_url":143,"updated_at":144,"action_type":22,"case_status":23,"posted_date":145,"marcs_cms_no":146,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":147,"body_fetched_at":148,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":149,"medical_device_id":19,"response_letter_date":19},2501,[135,136,137,11,98,13,13,13],"\u003Ctime datetime=\"2022-08-23T04:00:00Z\">08\u002F23\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-16T04:00:00Z\">08\u002F16\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjas-diagnosticsdrew-scientific-inc-634208-08162022\">JAS Diagnostics\u002FDrew Scientific, Inc. \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jean Felix LaCroix\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u002FCEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>JAS Diagnostics\u002FDrew Scientific, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14100 NW 57th Ct\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Miami Lakes\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33014-3107\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Flacroix@JASdrew.com\"> Flacroix@JASdrew.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS# (634208)\u003C\u002Fp>\u003Cp>August 16, 2022\u003C\u002Fp>\u003Cp>Dear Mr. LaCroix:\u003C\u002Fp>\u003Cp>During an inspection of your firm located at 14100 NW 57th Ct, Miami Lakes, FL 33014-3107 on April 15, 2022 through April 28, 2022, investigators from the United States Food and Drug Administration (FDA) determined that your firm is a medical device manufacturer and repackager\u002Frelabeler of \u003Cem>in vitro\u003C\u002Fem> diagnostic (IVD) Chemistry, Hematology Reagents. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received responses from Mr. Felix LaCroix, CEO dated May 13, 2022 and June 10, 2022 concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR 820.198(a). Specifically, you have not adequately implemented your complaint handling procedure titled “\u003Cem>Customer Complaint Handling”, Doc. # EQA 6.2\u003C\u002Fem>, in that complaints were not adequately documented, investigated, and evaluated for Medical Device Reportable (MDR) events.\u003Cbr>For example,\u003C\u002Fp>\u003Cp>A. Complaints received alleging deficiencies to damaged products during shipping are not documented, evaluated, and investigated according to your complaint handling procedure “\u003Cem>Customer Complaint Handling\u003C\u002Fem>”, Doc. # EQA 6.2. Your firm received 25 complaints in 2021-2022 associated with products arriving damaged, leaking, or controls out-of-temperature which were documented in a spreadsheet log titled “Customer Complaint Log”. Nineteen (19) of these complaints were associated with reagents and controls for your Drew3 analyzer, while 6 complaints were associated to the veterinary \u003Cstrong>(b)(4)\u003C\u002Fstrong> analyzer. Only one of these complaints, C21-04-01, was documented as per EQA 6.3, evaluated for MDR, and investigated. Further, your firm did not maintain records for these “non-technical” complaints for 2020.\u003C\u002Fp>\u003Cp>B. Your complaint handling procedure Doc. # EQA 6.2 states that instrument complaints will be handled according to procedure “Instrument Service and Complaints”, Doc. # IESD 1.0. Instrument complaints are entered into \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a “case”. Your firm does not maintain adequate documentation of communications received regarding the performance of the Drew3 analyzer instruments that include an evaluation to determine whether an investigation is necessary, and the evaluation of potential adverse events associated with the reported event. 119 of 277 \u003Cstrong>(b)(4)\u003C\u002Fstrong> cases entered from January 2020 - April 2022 were associated to troubleshooting and service activities for the Drew3 Analyzer system. We reviewed 52 cases associated to the Drew3 Analyzer and found 48 did not have the MDR event evaluation, and 50 did not have the results of the investigation. Of the 4 reports with an MDR evaluation, two were not reviewed and signed off by Quality Assurance as per “Customer Complaint Handling”, Doc. # EQA 6.2.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response indicates that you plan to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also stated that \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\u003C\u002Fp>\u003Cp>2. Failure to adequately establish CAPA procedures as required by 21 CFR 820.100(a). Specifically,\u003C\u002Fp>\u003Cp>A. The investigations of failures were not extended to evaluate the adequacy of the root cause analysis process and to identify other products potentially affected by the root cause, and CAPAs were closed without identifying root cause or completing actions. For example,\u003C\u002Fp>\u003Cp>i. CAPA 21-002 was initiated on 09\u002F19\u002F2021 to investigate multiple complaints from different customers reporting boxes of products arriving broken\u002Fdamaged\u002Fwet, leaking bottles, and kits that appeared to have been hastily put together during April – July 2021. Your investigation root cause stated \u003Cstrong>(b)(4)\u003C\u002Fstrong> mishandled the packages during transit, without an adequate investigation to determine this conclusion. As a result, no corrective actions were implemented, and the Verification of Effectiveness (VOE) failed as additional complaints for damaged and leaking products were received from November 2021 - February 2022. Furthermore, your firm failed to extend the investigation to determine if the design change of the caps for the Enzymatic Cleaner and Lytic Reagent, its design change validation, and its process validation, were adequate. Six of the complaints received from 06\u002F8\u002F2021 – 07\u002F14\u002F2021 were associated to Drew3 Pac Reagent Kit, Lots #\u003Cstrong>(b)(4)\u003C\u002Fstrong> and #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, which were produced with the new caps for these two reagents. No further actions have been taken for this CAPA after it failed VOE and the CAPA has remained open without further actions since 11\u002F24\u002F2021.\u003C\u002Fp>\u003Cp>ii. CAPA 21-001 was initiated on 04\u002F16\u002F2021 to investigate complaints related to high background counts on various lots of FS-Pak Test Kits for your veterinary hematology device \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your root cause for CAPA 21-001 indicated that the laboratory analysis identified presence of particles in the diluent of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> composition which your firm attributed to the set parameters of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> induction sealer which produced excessive heat and melting of the polymer layer of the FS- Pak Test Kits caps. However, these settings had been validated and in use since \u003Cstrong>(b)(4)\u003C\u002Fstrong> under validation protocol # VP-015-005 and had passed your tests. Validation protocol #VP-015- 005 also validated this \u003Cstrong>(b)(4)\u003C\u002Fstrong> induction sealer for the Drew3-Pac 5L Diluent Reagent. Our review of the validation #VP-015-005 identified inadequate process validation to test the seal integrity. This CAPA 21-001 failed to extend the investigation to the Drew3-Pac 5L Diluent to determine if the \u003Cstrong>(b)(4)\u003C\u002Fstrong> induction sealing parameters for the Drew3-Pac 5L Diluent bottles also affected this product and may have also contributed to the particles that were found in the diluent that were attributed to the Recall # Z-1576-2016 for high background counts as your previous CAPA 16-006 did not characterize the material of the particles found in those bottles. This CAPA remains open.\u003C\u002Fp>\u003Cp>iii. CAPA 19-010 was initiated on \u003Cstrong>(b)(4)\u003C\u002Fstrong> due to two complaints received for Alanine Aminotransferase (ALT), Lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, reporting ABSLim error. The CAPA found the ABSLim error appeared to be related to the decrease of the reagent absorbance but could not identify the reason for the absorbance not reaching specifications at 12 months expiration. Your firm closed this CAPA 19-010 within two months without a root cause on 07\u002F26\u002F2019 with a recommendation to monitor the performance of the reagent by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. A new CAPA 19-012 was opened two months later on 09\u002F13\u002F2019 due to the failed VOE of CAPA 19-010 to continue to investigate the ABSLim error and decrease of absorbance of the Alanine Aminotransferase (ALT). However, this CAPA 19-012 was also closed on 11\u002F30\u002F2020 without completion of an investigation. Further, no adequate evaluation or actions were conducted to address the impacted lots of products in commercial distribution.\u003C\u002Fp>\u003Cp>iv. CAPA 19-011 was initiated on \u003Cstrong>(b)(4)\u003C\u002Fstrong> due to corrective actions that failed Verification of Effectiveness to address an internal audit nonconformance ANR#16-005. This CAPA was closed on 11\u002F19\u002F2021 citing those corrective actions had not been completed as the employees responsible for Facilities &amp; Maintenance and implementation of the CAPA were no longer with the company. It also stated that a new Action Item will be added to your firm’s Quality Plan, Doc. # QP-2020-01, Rev. 2, to review the structure of your departments and ensure all managers have trained employees to act as back-up to continue to conduct activities when an employee is absent. We found continued deficiencies in Facilities &amp; Maintenance in that the current Equipment Inspection Log for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system continues to demonstrate lack of good documentation practices and the records for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system monitoring showed \u003Cstrong>(b)(4)\u003C\u002Fstrong> was not sampled and tested from 02\u002F25\u002F2019 through 09\u002F21\u002F2021 and from 02\u002F10\u002F2022 through 04\u002F04\u002F2022 due to absence of personnel.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>CAPA deficiencies were previously communicated to your firm in our 2014 FDA 483, 2019 FDA 483, and 2020 Untitled Letter.\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>B. You are not adequately trending quality indicators such as complaints, services, nonconformances, laboratory out-of-specification results, and manufacturing rejection rates, using appropriate statistical methodology where necessary to detect recurring quality problems. For example, your current trending report only trends the number of services and preventive maintenance performed and does not include cases of troubleshooting. Your review also fails to trend by product, issue, device identification number, or other factors as needed to detect recurring problems. No other quality data trending is performed.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response indicates that you plan to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It also states your intention to \u003Cstrong>(b)(4)\u003C\u002Fstrong> and describes that you gathered data for complaints, services, non-conformances, out-of-specification lab results, manufacturing deviations, troubleshooting, and preventive maintenance for review and trend analysis. The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\u003C\u002Fp>\u003Cp>3. Failure to adequately establish a process whose results cannot be fully verified by subsequent inspection and test according to established procedures as required by 21 CFR 820.75(a). Specifically, you have not adequately implemented your process validation procedure, “\u003Cem>Validation Procedure”, Doc # EMF 1.0\u003C\u002Fem>. For example,\u003C\u002Fp>\u003Cp>A. Your firm has no documented evidence of the process validation for the mixing, filling, and capping of the Drew3-Pac Diluent and Enzymatic Cleaner reagents and the mixing validation for the Lysing reagent currently manufactured at your facility which compose the Drew3-Pac kit for use with your Drew3 Analyzer. Further, your firm has not completed the process validations for the JAS Chemistry IVDs including \u003Cstrong>(b)(4), (b)(4), (b)(4), (b)(4), (b)(4), (b)(4), (b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>B. Your firm did not adequately conduct the process validation for the new \u003Cstrong>(b)(4)\u003C\u002Fstrong> induction sealer used for the Drew3-Pac Diluent 5L bottle caps, Validation # VP-021-007. The following deficiencies were noted:\u003C\u002Fp>\u003Cp>i. The Operational Qualification (OP) “Heat Seal Integrity Test” consisted of only visual inspection of the seal and visual inspection for leaks of \u003Cstrong>(b)(4)\u003C\u002Fstrong> bottles filled with \u003Cstrong>(b)(4)\u003C\u002Fstrong>. There was no justification for the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and for the sample size to be representative of a production lot of Drew3-Pac Diluent which consists of \u003Cstrong>(b)(4)\u003C\u002Fstrong> bottles.\u003Cbr>ii. The Product Performance Qualification (PPQ) states it was conducted with only one production lot of Drew3-Pac Diluent, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The Device History Record (DHR) for Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> does not indicate that the diluent bottles were sealed with your new magnetic induction sealer being validated, instead, the DHR for Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> indicates the bottle caps were sealed using your previous \u003Cstrong>(b)(4)\u003C\u002Fstrong> heat sealer, ID #\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>iii. The conveyor belt speed parameter was set to 4.8-5, but your OQ states it was set and run at 5.2.\u003C\u002Fp>\u003Cp>C. Your firm did not adequately conduct the process validation for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> heat induction sealer, ID #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, Validation # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, used for the D3 Diluent 5L bottles until Lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, last filled on 09\u002F24\u002F2021. The “heat seal integrity test” consisted of only visual inspection of the seal and visual inspection for leaks of \u003Cstrong>(b)(4)\u003C\u002Fstrong> bottles. There was no justification for the sample size of \u003Cstrong>(b)(4)\u003C\u002Fstrong> bottles to be representative of a production lot of Drew3-Pac Diluent which consists of \u003Cstrong>(b)(4)\u003C\u002Fstrong> bottles. Your visual inspection of the heat seal integrity test indicated that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> bottles passed at sealer parameters of 100% power and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, a documented deviation indicated that Lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong> and the following two production lots were found to have a small number of caps\u002Fseals leaking which was not evident initially. As a result, your firm adjusted the sealer time from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> but repeated the same visual test again on only \u003Cstrong>(b)(4)\u003C\u002Fstrong> additional bottles.\u003C\u002Fp>\u003Cp>D. Your firm has not conducted validation of the off-the-shelf \u003Cstrong>(b)(4)\u003C\u002Fstrong> software used to manage warehouse activities (in-coming, inventory, status, distribution), BOM preparation, and service orders to verify the software meets your needs and intended uses.\u003C\u002Fp>\u003Cp>E. You have not validated the microbial test method performed on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system using the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>Process validation deficiencies were previously communicated to your firm in our 2014 FDA 483, 2019 FDA 483, and 2020 Untitled Letter.\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>We reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response states your intent to review and revise your validation procedure and includes a Retrospective Validation Report for your DREW3-PAC. It also indicates that you are planning to create a validation protocol for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> software and are gathering documentation and data to amend the validation summary reports for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> induction sealer and \u003Cstrong>(b)(4)\u003C\u002Fstrong> heat induction sealer. You also promised to perform an in-house verification for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> test method. The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\u003C\u002Fp>\u003Cp>4. Failure to establish design control procedures as required by 21 CFR 820.30(a). Specifically, you have not adequately implemented your design control procedure “\u003Cem>Design Controls”, Doc. # ER&amp;D 4.1\u003C\u002Fem> in that your firm has not adequately completed implementation of corrections to observations cited during previous inspections associated to Design History File (DHF), design reviews, risk assessment, and shipping validation. For example,\u003C\u002Fp>\u003Cp>A. Your firm has not adequately maintained a Design History File (DHF) for the Drew3 Analyzer system that includes design inputs, design outputs, design reviews, design verification, design validation, and design changes for the system which includes the analyzer, controls, calibrators, and reagents. Your firm conducted a retroactive review of a DHF as correction to previous observations. However, the file presented to us was a DHF exclusively for the Drew3-Pac kit reagents (Diluent, Enzymatic Cleaner, Lysing reagents). Furthermore, we found the retrospective review was inadequate in that the DHF did not include the design input and design output specifications for product packaging including the reagent bottles, caps, and packaging components as well as no documentation of the design change evaluation to the bottle caps of the Diluent, Lysing reagent, and Enzymatic Cleaner and their new specifications.\u003C\u002Fp>\u003Cp>B. The design change validation for the new caps of the 5L Diluent, Doc. #VP-020-001, and validation for the new caps for the Lysing Reagent and Enzymatic Cleaner bottles, Doc. #VP- 021-001, were inadequate:\u003C\u002Fp>\u003Cp>i. Doc. #VP-021-001: The validation did not evaluate the impact to the capper, magnetic induction sealer, and torque requirements for the new caps which had different specifications from the previous caps, there is no rationale for the sampling size of \u003Cstrong>(b)(4)\u003C\u002Fstrong> bottles from a lot of \u003Cstrong>(b)(4)\u003C\u002Fstrong> bottles, and the leak test consisting of visual examination and no defined pressure applied is inadequate. Your firm received five complaints for product damaged and\u002For leaking on D3-Pac Reagent kits Lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong> and one complaint for Lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong> between 06\u002F08\u002F2021 and 07\u002F14\u002F2021 after implementation of the new caps.\u003C\u002Fp>\u003Cp>ii. Doc. #VP-020-001: The validation did not evaluate the impact to the capper, heat induction sealer, and torque requirements, there is no rationale for the sampling size of \u003Cstrong>(b)(4)\u003C\u002Fstrong> from a lot of \u003Cstrong>(b)(4)\u003C\u002Fstrong> bottles, and the leak test consisting of visual examination and no defined pressure applied is inadequate.\u003C\u002Fp>\u003Cp>C. Your firm has not conducted shipping validation for the EX-TROL controls and EX-CAL calibrators that require \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C storage. Your firm documented at least five complaints for “hot” or “damaged” controls received between March 2021 – September 2021.\u003C\u002Fp>\u003Cp>D. Your firm has not evaluated the instructions on the Operator’s Manual for the dilution of the sodium hypochlorite. For example, according to the current \u003Cem>Operator’s Manual, M- Drew3-US- OP, Rev. 1.07, September 2019\u003C\u002Fem>, the user is to perform this cleaning per scheduled maintenance recommendation (monthly or more frequent if processing more than 50 samples per day) or as necessary when there is excessive rejection (*, R-CL, W-CL) for one measured parameter using a Sodium Hypochlorite solution (bleach) at 12% in chloride. However, your firm identified that the bleach solution you use must be a particular grocery chain brand with 7.5% sodium hypochlorite further diluted to approximately 3% in chloride. We also identified complaints that required the use of 50% bleach solution and running the bleach cycle up to 3 times as part of the troubleshooting. Your firm has not validated the use of the Sodium Hypochlorite solution concentration and the frequency of use stated in the Operator’s Manual.\u003C\u002Fp>\u003Cp>E. Your firm failed to adequately implement risk management procedure “\u003Cem>Risk Management Process”, Doc. # EQA 4.2\u003C\u002Fem>. Your complaint handling procedure Doc. # EQA 6.2 states that risk assessment must be performed in accordance with EQA 4.2 for each complaint to determine possible impact to safety, new hazards\u002Fhazardous situations, and\u002For increased risks from existing hazards. However, none of the complaints reviewed found this risk assessment is being performed for each complaint. Furthermore, we identified hazards noted in complaints that were not listed in your risk analysis files. For example, the risk analysis for the Drew3 analyzer, “\u003Cem>Risk Analysis Project”, D3, Version 9, dated 12\u002F22\u002F2014\u003C\u002Fem>, does not include the following hazardous situations:\u003C\u002Fp>\u003Cp>i. Needle mis-positioning and possible needle plunging twice into the same chamber\u003Cbr>ii. Sample needle leaking during sampling\u003Cbr>iii. Counting chamber broken with reported problem with hemoglobin (HGB) count\u003Cbr>iv. Pressure default errors\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>Design Control deficiencies were previously communicated to your firm in our 2009 FDA 483, 2014 FDA 483, 2019 FDA 483, and 2020 Untitled Letter.\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>We reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response states your intent to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It also states that you plan to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\u003C\u002Fp>\u003Cp>5. Failure to adequately establish procedures for the control of product that does not conform to specified requirements as required by 21 CFR 820.30(a). Specifically, you have not adequately implemented your non-conforming product procedures. For example,\u003C\u002Fp>\u003Cp>A. Your firm did not adequately implement “\u003Cem>Nonconforming Material Control and Material Review Board Procedures”, Doc. # EQA 5.0\u003C\u002Fem>. On 04\u002F05\u002F2022, we observed two pallets of 5L bottles, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, used for the Drew3-Pac Diluent in your filling room labeled as “Do Not Use”. Your firm indicated that the bottles of these two pallets had been found to have defects including holes on the handles which caused leakage of the Diluent during the filling process. One pallet was received on \u003Cstrong>(b)(4)\u003C\u002Fstrong> and another on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm did not document this non-conformance as per EQA 5.0, failed to document an evaluation of the affected product lots filled with this lot of bottles, and failed to document the disposition of those filled bottles. The Device History Records (DHR) also had no record of this non-conformance.\u003C\u002Fp>\u003Cp>B. Your firm is not adequately implementing the laboratory procedure “Out of Specification (OOS) Investigations”, Doc. # \u003Cem>EQC 2.0\u003C\u002Fem>, for documenting and investigating Out of Specification results obtained during quality testing of your products. For example,\u003C\u002Fp>\u003Cp>EX-TROL Control Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Low, Normal, and High) exhibited results out-of-range on various instruments during June 2021. Examples include the following:\u003C\u002Fp>\u003Cp>i. 06\u002F21\u002F2021: \u003Cstrong>(b)(4)\u003C\u002Fstrong> in instrument serial numbers \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4) \u003C\u002Fstrong>and \u003Cstrong>(b)(4)\u003C\u002Fstrong> in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>ii. 06\u002F23\u002F2021: \u003Cstrong>(b)(4)\u003C\u002Fstrong> in instrument serial numbers \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4) \u003C\u002Fstrong>and \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>iii. 06\u002F28\u002F2021: \u003Cstrong>(b)(4)\u003C\u002Fstrong> in instrument serial numbers \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4) \u003C\u002Fstrong>and \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your laboratory was unable to provide information if any samples were processed on the above- mentioned days, possible reason for these failures observed for Control \u003Cstrong>(b)(4)\u003C\u002Fstrong> in three separate instruments on the same days, or any actions taken.\u003C\u002Fp>\u003Cp>C. You are not adequately implementing your procedure “\u003Cem>DREW3 Lysing Reagent Bulk Testing and Disposition”, Doc. # EQC 4.0\u003C\u002Fem>. The low control \u003Cstrong>(b)(4)\u003C\u002Fstrong> exhibited inadequate readings during the quality control run performed prior to the Drew3-Pac Lysing Reagent Bulk \u003Cstrong>(b)(4)\u003C\u002Fstrong> sample on 06\u002F09\u002F2021 in instrument S\u002FN \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, this control \u003Cstrong>(b)(4)\u003C\u002Fstrong> was re-run and obtained a passing result which was included in the manufacturing record, but the out-of- specification result was not documented in the DHR.\u003C\u002Fp>\u003Cp>D. You are not adequately implementing your procedure \u003Cem>EQC 3.3 “Test and Disposition for DREW-3 PAC Reagents Kits\u003C\u002Fem>” which states that sections 6.8.2 the Background (3 Diluents) and 6.8.3 Kit Recovery (Controls Low, Normal, and High, and 3 samples) do not meet acceptance criteria, the kit shall \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) and recorded in a new FEQC 3.31 form. We observed this procedure not being adequately implemented in that there is no documentation for the following missing results or sequences of samples missing in between samples. For example,\u003C\u002Fp>\u003Cp>Finished Drew3-Pac kits, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003C\u002Fp>\u003Cp>i. Kit #1 is missing the results for Diluent #3, Control \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Control \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and sequence \u003Cstrong>(b)(4)\u003C\u002Fstrong> between Sample 1 and Sample 2 in instrument S\u002FN \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>ii. Kit #2 is missing sequences 8240-8244 between Diluent 1 and Diluent 2 and sequences 8251-8252 between Sample 1 and Sample 2 in instrument S\u002FN \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>iii. Kit #3 is missing sequences 10859-10860 between Diluent 1 and Diluent 2 and sequences \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Sample 1 in instrument S\u002FN \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>iv. Kit #4 is missing the results of Diluent 2, Diluent 3, Controls L, N, H and sequence 27855 between Sample 2 and Sample 3 in instrument S\u002FN \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>v. Kit #5 is missing sequences 42381-42384 between Sample 1 and Sample 2 in instrument S\u002FN \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Finished Drew3-Pac, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003C\u002Fp>\u003Cp>i. Kit #1 is missing sequence 7602, 7604 and 7607 between Controls in instrument S\u002FN \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The Quality Control Report for the Controls shows Control L (low) and Control N (normal) were out-of-range.\u003C\u002Fp>\u003Cp>ii. Kit #2 is missing sequence 8621 between Diluent 1 and Diluent 2, sequence 8627 between Control Low and Sample 1 and sequence 8629 in between samples in instrument S\u002FN \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>iii. Kit #3 is missing sequence 7020 between Control L and Sample 1, and sequence 7022 between Sample 1 and Sample 2 in instrument S\u002FN \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The Quality Control Report for the controls shows Control L (low) was out-of-range.\u003C\u002Fp>\u003Cp>iv. Kit #5 is missing sequence 28220 between Control N and Control H, and sequence 28222 between Control H and Sample 1, and sequence 28224 between Sample 1 and Sample 2 in instrument S\u002FN \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The Quality Control Report for the controls shows Control L (low) and Control (normal) were out-of-range.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response to the 483 regarding Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> states that you issued a SCAR to the supplier and are investigating\u002Fgathering all documentation regarding Lot “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”. You also promised to investigate and document OOS results correctly and revise or amend all missing sequences or data listed in Observation 5D for the affected lots. The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\u003C\u002Fp>\u003Cp>6. Failure to adequately establish procedures for acceptance as required by 21 CFR 820.80(a). Specifically, your firm is not adequately implementing incoming quality control procedure “\u003Cem>Procedure for the Inspection, QC Verification, and Release of Hematology Controls”, Doc # EQC 16.0\u003C\u002Fem>, to test and release new lots of Hematology Controls received at your facility. EQC 16.0 requires running each type of control (low, normal, high) three times using two hematology analyzers, however, your firm ran each type of control only once in two analyzers for Lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response states your intent to conduct a deviation investigation for Lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong> and provide justification. The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\u003C\u002Fp>\u003Cp>7. Failure to adequately establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements. Specifically,\u003C\u002Fp>\u003Cp>A. You have not adequately implemented your supplier control procedure “\u003Cem>Supplier\u002FService Provider Qualification Program\u003C\u002Fem>”, \u003Cem>Doc. # EQA 7.0\u003C\u002Fem>. For example,\u003C\u002Fp>\u003Cp>i. Your approved supplier list does not include the list of all your approved suppliers, contractors, and consultant(s) as per your procedure.\u003C\u002Fp>\u003Cp>ii. You have not documented the evaluation of your quality consultant and your supplier that supplies your bleach used to service Drew3 Analyzers and as raw material for your Hema- Clenz.\u003C\u002Fp>\u003Cp>iii. Your evaluation of your contract manufacturers is inadequate in that you have not ensured that your contract manufacturers have adequately validated their manufacturing process such as the injection molding process of the 5L diluent bottles.\u003C\u002Fp>\u003Cp>iv. You did not ensure that appropriate corrective actions were taken by your supplier. For example, your firm issued a request via e-mail for investigation and corrective action to your supplier of your 5L bottles after bottles were found to have holes. This action was not documented as a Supplier Corrective Action Request (SCAR) as per your procedure. The contract manufacturer provided their Corrective Action Report, date completed 02\u002F04\u002F2021, with an inadequate investigation and indicated possible root cause due to the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Their corrective action states that they would \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your firm did not ensure that the contract manufacturer of the bottles verified or validated this corrective action and adequately implemented this action. Your firm received another pallet of defective bottles of the same lot on 04\u002F01\u002F2021 after implementation of this correction.\u003C\u002Fp>\u003Cp>B. Your supplier control procedure “Supplier\u002FService Provider Qualification Program”, Doc. # EQA 7.0, does not define when an on-site audit is necessary.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>Purchasing Control deficiencies were previously communicated to your firm in our 2019 FDA 483 and 2020 Untitled Letter.\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>We reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response states your intent to review and revise your supplier qualification procedure and reevaluate all suppliers to ensure they remain qualified. You also promised to revise your master vendor list. The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Additionally, the following has also been noted about your firm and corrective actions should be addressed in your response:\u003C\u002Fp>\u003Cp>8. On your webpage (https:\u002F\u002Fwww.drewscientific.com\u002Fd3) for the D3 hematology analyzer, in the “Performance” segment, under “Part Code” section, the following information about the instrumentation and its description are incorrect and should be removed.\u003C\u002Fp>\u003Cdiv>\u003Ctable>\u003Ctbody>\u003Ctr>\u003Ctd>\u003Cstrong>Part Code\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>Description\u003C\u002Fstrong>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>BAR-9000-221\u003C\u002Ftd>\u003Ctd>2280 Hematology analyzer with computer &amp; barcode reader\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>BAR-9001-221\u003C\u002Ftd>\u003Ctd>2280 Hematology analyzer without computer &amp; barcode reader\u003C\u002Ftd>\u003C\u002Ftr>\u003C\u002Ftbody>\u003C\u002Ftable>\u003C\u002Fdiv>\u003Cp>9. On the webpage (https:\u002F\u002Fwww.drewscientific.com\u002Fd5) describing the D5 analyzer, it says, “FDA Clearance in Process” and “For Export Only”. The phrase “FDA Clearance in Process” should be removed.\u003C\u002Fp>\u003Cp>10. On the D5 analyzer webpage (https:\u002F\u002Fwww.drewscientific.com\u002Fd5), the D3 analyzer informational video is embedded. This should be removed.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent to: Melissa Michurski, Director of Compliance Branch, at oradevices2firmresponse@fda.hhs.gov. Refer to CMS # (634208) when replying. If you have any questions about the contents of this letter, please contact: Compliance Officer, Wendy Blame 334-273-4789 Ext 101 or at wendy.blame@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Blake Bevill, M.S.\u003Cbr>Program Division Director\u003Cbr>Office of Medical Device and Radiological Health Operations\u003Cbr>Division 2 Central\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Jean Felix LaCroix\n\nRecipient Title\n\nOwner\u002FCEO\n\nJAS Diagnostics\u002FDrew Scientific, Inc.\n\n14100 NW 57th Ct\n\nMiami Lakes, FL 33014-3107\n\nUnited States\n\nFlacroix@JASdrew.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS# (634208)\nAugust 16, 2022\nDear Mr. LaCroix:\nDuring an inspection of your firm located at 14100 NW 57th Ct, Miami Lakes, FL 33014-3107 on April 15, 2022 through April 28, 2022, investigators from the United States Food and Drug Administration (FDA) determined that your firm is a medical device manufacturer and repackager\u002Frelabeler of in vitro diagnostic (IVD) Chemistry, Hematology Reagents. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received responses from Mr. Felix LaCroix, CEO dated May 13, 2022 and June 10, 2022 concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to the following:\n1. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR 820.198(a). Specifically, you have not adequately implemented your complaint handling procedure titled “Customer Complaint Handling”, Doc. # EQA 6.2, in that complaints were not adequately documented, investigated, and evaluated for Medical Device Reportable (MDR) events.\nFor example,\nA. Complaints received alleging deficiencies to damaged products during shipping are not documented, evaluated, and investigated according to your complaint handling procedure “Customer Complaint Handling”, Doc. # EQA 6.2. Your firm received 25 complaints in 2021-2022 associated with products arriving damaged, leaking, or controls out-of-temperature which were documented in a spreadsheet log titled “Customer Complaint Log”. Nineteen (19) of these complaints were associated with reagents and controls for your Drew3 analyzer, while 6 complaints were associated to the veterinary (b)(4) analyzer. Only one of these complaints, C21-04-01, was documented as per EQA 6.3, evaluated for MDR, and investigated. Further, your firm did not maintain records for these “non-technical” complaints for 2020.\nB. Your complaint handling procedure Doc. # EQA 6.2 states that instrument complaints will be handled according to procedure “Instrument Service and Complaints”, Doc. # IESD 1.0. Instrument complaints are entered into (b)(4) as a “case”. Your firm does not maintain adequate documentation of communications received regarding the performance of the Drew3 analyzer instruments that include an evaluation to determine whether an investigation is necessary, and the evaluation of potential adverse events associated with the reported event. 119 of 277 (b)(4) cases entered from January 2020 - April 2022 were associated to troubleshooting and service activities for the Drew3 Analyzer system. We reviewed 52 cases associated to the Drew3 Analyzer and found 48 did not have the MDR event evaluation, and 50 did not have the results of the investigation. Of the 4 reports with an MDR evaluation, two were not reviewed and signed off by Quality Assurance as per “Customer Complaint Handling”, Doc. # EQA 6.2.\nWe reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response indicates that you plan to (b)(4). You also stated that (b)(4). The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\n2. Failure to adequately establish CAPA procedures as required by 21 CFR 820.100(a). Specifically,\nA. The investigations of failures were not extended to evaluate the adequacy of the root cause analysis process and to identify other products potentially affected by the root cause, and CAPAs were closed without identifying root cause or completing actions. For example,\ni. CAPA 21-002 was initiated on 09\u002F19\u002F2021 to investigate multiple complaints from different customers reporting boxes of products arriving broken\u002Fdamaged\u002Fwet, leaking bottles, and kits that appeared to have been hastily put together during April – July 2021. Your investigation root cause stated (b)(4) mishandled the packages during transit, without an adequate investigation to determine this conclusion. As a result, no corrective actions were implemented, and the Verification of Effectiveness (VOE) failed as additional complaints for damaged and leaking products were received from November 2021 - February 2022. Furthermore, your firm failed to extend the investigation to determine if the design change of the caps for the Enzymatic Cleaner and Lytic Reagent, its design change validation, and its process validation, were adequate. Six of the complaints received from 06\u002F8\u002F2021 – 07\u002F14\u002F2021 were associated to Drew3 Pac Reagent Kit, Lots #(b)(4) and #(b)(4), which were produced with the new caps for these two reagents. No further actions have been taken for this CAPA after it failed VOE and the CAPA has remained open without further actions since 11\u002F24\u002F2021.\nii. CAPA 21-001 was initiated on 04\u002F16\u002F2021 to investigate complaints related to high background counts on various lots of FS-Pak Test Kits for your veterinary hematology device (b)(4). Your root cause for CAPA 21-001 indicated that the laboratory analysis identified presence of particles in the diluent of (b)(4), (b)(4), and (b)(4) composition which your firm attributed to the set parameters of the (b)(4) induction sealer which produced excessive heat and melting of the polymer layer of the FS- Pak Test Kits caps. However, these settings had been validated and in use since (b)(4) under validation protocol # VP-015-005 and had passed your tests. Validation protocol #VP-015- 005 also validated this (b)(4) induction sealer for the Drew3-Pac 5L Diluent Reagent. Our review of the validation #VP-015-005 identified inadequate process validation to test the seal integrity. This CAPA 21-001 failed to extend the investigation to the Drew3-Pac 5L Diluent to determine if the (b)(4) induction sealing parameters for the Drew3-Pac 5L Diluent bottles also affected this product and may have also contributed to the particles that were found in the diluent that were attributed to the Recall # Z-1576-2016 for high background counts as your previous CAPA 16-006 did not characterize the material of the particles found in those bottles. This CAPA remains open.\niii. CAPA 19-010 was initiated on (b)(4) due to two complaints received for Alanine Aminotransferase (ALT), Lot #(b)(4), reporting ABSLim error. The CAPA found the ABSLim error appeared to be related to the decrease of the reagent absorbance but could not identify the reason for the absorbance not reaching specifications at 12 months expiration. Your firm closed this CAPA 19-010 within two months without a root cause on 07\u002F26\u002F2019 with a recommendation to monitor the performance of the reagent by (b)(4). A new CAPA 19-012 was opened two months later on 09\u002F13\u002F2019 due to the failed VOE of CAPA 19-010 to continue to investigate the ABSLim error and decrease of absorbance of the Alanine Aminotransferase (ALT). However, this CAPA 19-012 was also closed on 11\u002F30\u002F2020 without completion of an investigation. Further, no adequate evaluation or actions were conducted to address the impacted lots of products in commercial distribution.\niv. CAPA 19-011 was initiated on (b)(4) due to corrective actions that failed Verification of Effectiveness to address an internal audit nonconformance ANR#16-005. This CAPA was closed on 11\u002F19\u002F2021 citing those corrective actions had not been completed as the employees responsible for Facilities & Maintenance and implementation of the CAPA were no longer with the company. It also stated that a new Action Item will be added to your firm’s Quality Plan, Doc. # QP-2020-01, Rev. 2, to review the structure of your departments and ensure all managers have trained employees to act as back-up to continue to conduct activities when an employee is absent. We found continued deficiencies in Facilities & Maintenance in that the current Equipment Inspection Log for the (b)(4) system continues to demonstrate lack of good documentation practices and the records for the (b)(4) system monitoring showed (b)(4) was not sampled and tested from 02\u002F25\u002F2019 through 09\u002F21\u002F2021 and from 02\u002F10\u002F2022 through 04\u002F04\u002F2022 due to absence of personnel.\nCAPA deficiencies were previously communicated to your firm in our 2014 FDA 483, 2019 FDA 483, and 2020 Untitled Letter.\nB. You are not adequately trending quality indicators such as complaints, services, nonconformances, laboratory out-of-specification results, and manufacturing rejection rates, using appropriate statistical methodology where necessary to detect recurring quality problems. For example, your current trending report only trends the number of services and preventive maintenance performed and does not include cases of troubleshooting. Your review also fails to trend by product, issue, device identification number, or other factors as needed to detect recurring problems. No other quality data trending is performed.\nWe reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response indicates that you plan to (b)(4). It also states your intention to (b)(4) and describes that you gathered data for complaints, services, non-conformances, out-of-specification lab results, manufacturing deviations, troubleshooting, and preventive maintenance for review and trend analysis. The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\n3. Failure to adequately establish a process whose results cannot be fully verified by subsequent inspection and test according to established procedures as required by 21 CFR 820.75(a). Specifically, you have not adequately implemented your process validation procedure, “Validation Procedure”, Doc # EMF 1.0. For example,\nA. Your firm has no documented evidence of the process validation for the mixing, filling, and capping of the Drew3-Pac Diluent and Enzymatic Cleaner reagents and the mixing validation for the Lysing reagent currently manufactured at your facility which compose the Drew3-Pac kit for use with your Drew3 Analyzer. Further, your firm has not completed the process validations for the JAS Chemistry IVDs including (b)(4), (b)(4), (b)(4), (b)(4), (b)(4), (b)(4), (b)(4), and (b)(4).\nB. Your firm did not adequately conduct the process validation for the new (b)(4) induction sealer used for the Drew3-Pac Diluent 5L bottle caps, Validation # VP-021-007. The following deficiencies were noted:\ni. The Operational Qualification (OP) “Heat Seal Integrity Test” consisted of only visual inspection of the seal and visual inspection for leaks of (b)(4) bottles filled with (b)(4). There was no justification for the use of (b)(4) and for the sample size to be representative of a production lot of Drew3-Pac Diluent which consists of (b)(4) bottles.\nii. The Product Performance Qualification (PPQ) states it was conducted with only one production lot of Drew3-Pac Diluent, Lot (b)(4). The Device History Record (DHR) for Lot (b)(4) does not indicate that the diluent bottles were sealed with your new magnetic induction sealer being validated, instead, the DHR for Lot (b)(4) indicates the bottle caps were sealed using your previous (b)(4) heat sealer, ID #(b)(4).\niii. The conveyor belt speed parameter was set to 4.8-5, but your OQ states it was set and run at 5.2.\nC. Your firm did not adequately conduct the process validation for the (b)(4) heat induction sealer, ID #(b)(4), Validation # (b)(4), used for the D3 Diluent 5L bottles until Lot #(b)(4), last filled on 09\u002F24\u002F2021. The “heat seal integrity test” consisted of only visual inspection of the seal and visual inspection for leaks of (b)(4) bottles. There was no justification for the sample size of (b)(4) bottles to be representative of a production lot of Drew3-Pac Diluent which consists of (b)(4) bottles. Your visual inspection of the heat seal integrity test indicated that the (b)(4) bottles passed at sealer parameters of 100% power and (b)(4). However, a documented deviation indicated that Lot #(b)(4) and the following two production lots were found to have a small number of caps\u002Fseals leaking which was not evident initially. As a result, your firm adjusted the sealer time from (b)(4) to (b)(4) but repeated the same visual test again on only (b)(4) additional bottles.\nD. Your firm has not conducted validation of the off-the-shelf (b)(4) software used to manage warehouse activities (in-coming, inventory, status, distribution), BOM preparation, and service orders to verify the software meets your needs and intended uses.\nE. You have not validated the microbial test method performed on the (b)(4) system using the (b)(4).\nProcess validation deficiencies were previously communicated to your firm in our 2014 FDA 483, 2019 FDA 483, and 2020 Untitled Letter.\nWe reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response states your intent to review and revise your validation procedure and includes a Retrospective Validation Report for your DREW3-PAC. It also indicates that you are planning to create a validation protocol for your (b)(4) software and are gathering documentation and data to amend the validation summary reports for your (b)(4) induction sealer and (b)(4) heat induction sealer. You also promised to perform an in-house verification for the (b)(4) test method. The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\n4. Failure to establish design control procedures as required by 21 CFR 820.30(a). Specifically, you have not adequately implemented your design control procedure “Design Controls”, Doc. # ER&D 4.1 in that your firm has not adequately completed implementation of corrections to observations cited during previous inspections associated to Design History File (DHF), design reviews, risk assessment, and shipping validation. For example,\nA. Your firm has not adequately maintained a Design History File (DHF) for the Drew3 Analyzer system that includes design inputs, design outputs, design reviews, design verification, design validation, and design changes for the system which includes the analyzer, controls, calibrators, and reagents. Your firm conducted a retroactive review of a DHF as correction to previous observations. However, the file presented to us was a DHF exclusively for the Drew3-Pac kit reagents (Diluent, Enzymatic Cleaner, Lysing reagents). Furthermore, we found the retrospective review was inadequate in that the DHF did not include the design input and design output specifications for product packaging including the reagent bottles, caps, and packaging components as well as no documentation of the design change evaluation to the bottle caps of the Diluent, Lysing reagent, and Enzymatic Cleaner and their new specifications.\nB. The design change validation for the new caps of the 5L Diluent, Doc. #VP-020-001, and validation for the new caps for the Lysing Reagent and Enzymatic Cleaner bottles, Doc. #VP- 021-001, were inadequate:\ni. Doc. #VP-021-001: The validation did not evaluate the impact to the capper, magnetic induction sealer, and torque requirements for the new caps which had different specifications from the previous caps, there is no rationale for the sampling size of (b)(4) bottles from a lot of (b)(4) bottles, and the leak test consisting of visual examination and no defined pressure applied is inadequate. Your firm received five complaints for product damaged and\u002For leaking on D3-Pac Reagent kits Lot #(b)(4) and one complaint for Lot #(b)(4) between 06\u002F08\u002F2021 and 07\u002F14\u002F2021 after implementation of the new caps.\nii. Doc. #VP-020-001: The validation did not evaluate the impact to the capper, heat induction sealer, and torque requirements, there is no rationale for the sampling size of (b)(4) from a lot of (b)(4) bottles, and the leak test consisting of visual examination and no defined pressure applied is inadequate.\nC. Your firm has not conducted shipping validation for the EX-TROL controls and EX-CAL calibrators that require (b)(4)°C storage. Your firm documented at least five complaints for “hot” or “damaged” controls received between March 2021 – September 2021.\nD. Your firm has not evaluated the instructions on the Operator’s Manual for the dilution of the sodium hypochlorite. For example, according to the current Operator’s Manual, M- Drew3-US- OP, Rev. 1.07, September 2019, the user is to perform this cleaning per scheduled maintenance recommendation (monthly or more frequent if processing more than 50 samples per day) or as necessary when there is excessive rejection (*, R-CL, W-CL) for one measured parameter using a Sodium Hypochlorite solution (bleach) at 12% in chloride. However, your firm identified that the bleach solution you use must be a particular grocery chain brand with 7.5% sodium hypochlorite further diluted to approximately 3% in chloride. We also identified complaints that required the use of 50% bleach solution and running the bleach cycle up to 3 times as part of the troubleshooting. Your firm has not validated the use of the Sodium Hypochlorite solution concentration and the frequency of use stated in the Operator’s Manual.\nE. Your firm failed to adequately implement risk management procedure “Risk Management Process”, Doc. # EQA 4.2. Your complaint handling procedure Doc. # EQA 6.2 states that risk assessment must be performed in accordance with EQA 4.2 for each complaint to determine possible impact to safety, new hazards\u002Fhazardous situations, and\u002For increased risks from existing hazards. However, none of the complaints reviewed found this risk assessment is being performed for each complaint. Furthermore, we identified hazards noted in complaints that were not listed in your risk analysis files. For example, the risk analysis for the Drew3 analyzer, “Risk Analysis Project”, D3, Version 9, dated 12\u002F22\u002F2014, does not include the following hazardous situations:\ni. Needle mis-positioning and possible needle plunging twice into the same chamber\nii. Sample needle leaking during sampling\niii. Counting chamber broken with reported problem with hemoglobin (HGB) count\niv. Pressure default errors\nDesign Control deficiencies were previously communicated to your firm in our 2009 FDA 483, 2014 FDA 483, 2019 FDA 483, and 2020 Untitled Letter.\nWe reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response states your intent to (b)(4). It also states that you plan to (b)(4). The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\n5. Failure to adequately establish procedures for the control of product that does not conform to specified requirements as required by 21 CFR 820.30(a). Specifically, you have not adequately implemented your non-conforming product procedures. For example,\nA. Your firm did not adequately implement “Nonconforming Material Control and Material Review Board Procedures”, Doc. # EQA 5.0. On 04\u002F05\u002F2022, we observed two pallets of 5L bottles, Lot (b)(4), used for the Drew3-Pac Diluent in your filling room labeled as “Do Not Use”. Your firm indicated that the bottles of these two pallets had been found to have defects including holes on the handles which caused leakage of the Diluent during the filling process. One pallet was received on (b)(4) and another on (b)(4). Your firm did not document this non-conformance as per EQA 5.0, failed to document an evaluation of the affected product lots filled with this lot of bottles, and failed to document the disposition of those filled bottles. The Device History Records (DHR) also had no record of this non-conformance.\nB. Your firm is not adequately implementing the laboratory procedure “Out of Specification (OOS) Investigations”, Doc. # EQC 2.0, for documenting and investigating Out of Specification results obtained during quality testing of your products. For example,\nEX-TROL Control Lot # (b)(4) (Low, Normal, and High) exhibited results out-of-range on various instruments during June 2021. Examples include the following:\ni. 06\u002F21\u002F2021: (b)(4) in instrument serial numbers (b)(4), (b)(4) and (b)(4) in (b)(4)\nii. 06\u002F23\u002F2021: (b)(4) in instrument serial numbers (b)(4), (b)(4) and (b)(4)\niii. 06\u002F28\u002F2021: (b)(4) in instrument serial numbers (b)(4), (b)(4) and (b)(4)\nYour laboratory was unable to provide information if any samples were processed on the above- mentioned days, possible reason for these failures observed for Control (b)(4) in three separate instruments on the same days, or any actions taken.\nC. You are not adequately implementing your procedure “DREW3 Lysing Reagent Bulk Testing and Disposition”, Doc. # EQC 4.0. The low control (b)(4) exhibited inadequate readings during the quality control run performed prior to the Drew3-Pac Lysing Reagent Bulk (b)(4) sample on 06\u002F09\u002F2021 in instrument S\u002FN (b)(4). However, this control (b)(4) was re-run and obtained a passing result which was included in the manufacturing record, but the out-of- specification result was not documented in the DHR.\nD. You are not adequately implementing your procedure EQC 3.3 “Test and Disposition for DREW-3 PAC Reagents Kits” which states that sections 6.8.2 the Background (3 Diluents) and 6.8.3 Kit Recovery (Controls Low, Normal, and High, and 3 samples) do not meet acceptance criteria, the kit shall (b)(4) ((b)(4)) and recorded in a new FEQC 3.31 form. We observed this procedure not being adequately implemented in that there is no documentation for the following missing results or sequences of samples missing in between samples. For example,\nFinished Drew3-Pac kits, Lot (b)(4):\ni. Kit #1 is missing the results for Diluent #3, Control (b)(4), Control (b)(4), and sequence (b)(4) between Sample 1 and Sample 2 in instrument S\u002FN (b)(4)\nii. Kit #2 is missing sequences 8240-8244 between Diluent 1 and Diluent 2 and sequences 8251-8252 between Sample 1 and Sample 2 in instrument S\u002FN (b)(4)\niii. Kit #3 is missing sequences 10859-10860 between Diluent 1 and Diluent 2 and sequences (b)(4) and (b)(4) for Sample 1 in instrument S\u002FN (b)(4)\niv. Kit #4 is missing the results of Diluent 2, Diluent 3, Controls L, N, H and sequence 27855 between Sample 2 and Sample 3 in instrument S\u002FN (b)(4)\nv. Kit #5 is missing sequences 42381-42384 between Sample 1 and Sample 2 in instrument S\u002FN (b)(4)\nFinished Drew3-Pac, Lot (b)(4):\ni. Kit #1 is missing sequence 7602, 7604 and 7607 between Controls in instrument S\u002FN (b)(4). The Quality Control Report for the Controls shows Control L (low) and Control N (normal) were out-of-range.\nii. Kit #2 is missing sequence 8621 between Diluent 1 and Diluent 2, sequence 8627 between Control Low and Sample 1 and sequence 8629 in between samples in instrument S\u002FN (b)(4)\niii. Kit #3 is missing sequence 7020 between Control L and Sample 1, and sequence 7022 between Sample 1 and Sample 2 in instrument S\u002FN (b)(4). The Quality Control Report for the controls shows Control L (low) was out-of-range.\niv. Kit #5 is missing sequence 28220 between Control N and Control H, and sequence 28222 between Control H and Sample 1, and sequence 28224 between Sample 1 and Sample 2 in instrument S\u002FN (b)(4). The Quality Control Report for the controls shows Control L (low) and Control (normal) were out-of-range.\nWe reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response to the 483 regarding Lot (b)(4) states that you issued a SCAR to the supplier and are investigating\u002Fgathering all documentation regarding Lot “(b)(4)”. You also promised to investigate and document OOS results correctly and revise or amend all missing sequences or data listed in Observation 5D for the affected lots. The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\n6. Failure to adequately establish procedures for acceptance as required by 21 CFR 820.80(a). Specifically, your firm is not adequately implementing incoming quality control procedure “Procedure for the Inspection, QC Verification, and Release of Hematology Controls”, Doc # EQC 16.0, to test and release new lots of Hematology Controls received at your facility. EQC 16.0 requires running each type of control (low, normal, high) three times using two hematology analyzers, however, your firm ran each type of control only once in two analyzers for Lot #(b)(4).\nWe reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response states your intent to conduct a deviation investigation for Lot #(b)(4) and provide justification. The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\n7. Failure to adequately establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements. Specifically,\nA. You have not adequately implemented your supplier control procedure “Supplier\u002FService Provider Qualification Program”, Doc. # EQA 7.0. For example,\ni. Your approved supplier list does not include the list of all your approved suppliers, contractors, and consultant(s) as per your procedure.\nii. You have not documented the evaluation of your quality consultant and your supplier that supplies your bleach used to service Drew3 Analyzers and as raw material for your Hema- Clenz.\niii. Your evaluation of your contract manufacturers is inadequate in that you have not ensured that your contract manufacturers have adequately validated their manufacturing process such as the injection molding process of the 5L diluent bottles.\niv. You did not ensure that appropriate corrective actions were taken by your supplier. For example, your firm issued a request via e-mail for investigation and corrective action to your supplier of your 5L bottles after bottles were found to have holes. This action was not documented as a Supplier Corrective Action Request (SCAR) as per your procedure. The contract manufacturer provided their Corrective Action Report, date completed 02\u002F04\u002F2021, with an inadequate investigation and indicated possible root cause due to the (b)(4). Their corrective action states that they would (b)(4). However, your firm did not ensure that the contract manufacturer of the bottles verified or validated this corrective action and adequately implemented this action. Your firm received another pallet of defective bottles of the same lot on 04\u002F01\u002F2021 after implementation of this correction.\nB. Your supplier control procedure “Supplier\u002FService Provider Qualification Program”, Doc. # EQA 7.0, does not define when an on-site audit is necessary.\nPurchasing Control deficiencies were previously communicated to your firm in our 2019 FDA 483 and 2020 Untitled Letter.\nWe reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response states your intent to review and revise your supplier qualification procedure and reevaluate all suppliers to ensure they remain qualified. You also promised to revise your master vendor list. The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nAdditionally, the following has also been noted about your firm and corrective actions should be addressed in your response:\n8. On your webpage (https:\u002F\u002Fwww.drewscientific.com\u002Fd3) for the D3 hematology analyzer, in the “Performance” segment, under “Part Code” section, the following information about the instrumentation and its description are incorrect and should be removed.\nPart CodeDescription\nBAR-9000-2212280 Hematology analyzer with computer & barcode reader\nBAR-9001-2212280 Hematology analyzer without computer & barcode reader\n\n9. On the webpage (https:\u002F\u002Fwww.drewscientific.com\u002Fd5) describing the D5 analyzer, it says, “FDA Clearance in Process” and “For Export Only”. The phrase “FDA Clearance in Process” should be removed.\n10. On the D5 analyzer webpage (https:\u002F\u002Fwww.drewscientific.com\u002Fd5), the D3 analyzer informational video is embedded. This should be removed.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent to: Melissa Michurski, Director of Compliance Branch, at oradevices2firmresponse@fda.hhs.gov. Refer to CMS # (634208) when replying. If you have any questions about the contents of this letter, please contact: Compliance Officer, Wendy Blame 334-273-4789 Ext 101 or at wendy.blame@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nBlake Bevill, M.S.\nProgram Division Director\nOffice of Medical Device and Radiological Health Operations\nDivision 2 Central","JAS Diagnostics\u002FDrew Scientific, Inc.","jas-diagnosticsdrew-scientific-inc-634208-08162022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjas-diagnosticsdrew-scientific-inc-634208-08162022","2026-10-26T08:09:02.919481+00:00","2022-08-23","634208","Mr. Jean Felix LaCroix","2026-08-20T01:38:34.418+00:00","2022-08-16",{"id":151,"raw":152,"subject":98,"body_html":156,"body_text":157,"firm_name":158,"letter_id":159,"created_at":80,"fei_number":19,"letter_url":160,"updated_at":161,"action_type":22,"case_status":23,"posted_date":162,"marcs_cms_no":163,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":164,"body_fetched_at":165,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":166,"medical_device_id":19,"response_letter_date":19},1503,[153,154,155,11,98,13,13,13],"\u003Ctime datetime=\"2024-04-30T13:20:00Z\">04\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-05-11T04:00:00Z\">05\u002F11\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffuture-diagnostics-solutions-bv-653493-05112023\">Future Diagnostics Solutions B.V.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Frank Martel\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Future Diagnostics Solutions B.V.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Nieuweweg 279\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Wijchen\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>6603 BN\u003C\u002Fspan> \u003Cspan>Gelderland\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Netherlands\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:martel.f@future-diagnostics.nl\"> martel.f@future-diagnostics.nl\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>May 11, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Frank Martel,\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Gelderland, Netherlands on January 16 through 19, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures STAT-IntraOperative-Intact PTH (Parathyroid Hormone) Immunoassay Kits (STAT-IO-I-PTH). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to verify or validate corrective and preventive actions (CAPA) to ensure that such actions are effective and do not adversely affect the finished device, as required by 21 CFR 820.100(a)(4).\u003C\u002Fp>\n\n\u003Cp>For example, CAPAs 2021-4, 2021-13, and 2021-16 were initiated to address production non-conformities associated with the STAT-IntraOperative-Intact-PTH Immunoassay Kit. Each report indicates that corrective actions were found to be effective, implemented, and the CAPAs were closed. During the inspection, the investigator requested to review the firm’s documentation of the verification or validation of the corrective action to ensure the action is effective and does not adversely affect the finished device. However, the firm’s Operations Manager, Mr. Jochem van Woezik, stated there was no objective evidence available for review.\u003C\u002Fp>\n\n\u003Cp>2. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements, including, the identification, documentation, evaluation, segregation, and disposition of nonconforming product, and to ensure that the evaluation includes a determination of the need for an investigation, as required by 21 CFR 820.90(a).\u003C\u002Fp>\n\n\u003Cp>For example, the relative humidity for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> compartment, used to&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> and are used during the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was found to be out of specification when re for calibration. Specifically, the calibration report documented that the following relative humidity readings were out of range:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The relative humidity reading was measured at \u003Cstrong>(b)(4)\u003C\u002Fstrong>% (outside the stated tolerance of \u003Cstrong>(b)(4)\u003C\u002Fstrong>%RV)\u003C\u002Fli>\n\t\u003Cli>The relative humidity reading was measured at \u003Cstrong>(b)(4)\u003C\u002Fstrong>% (outside the stated tolerance of \u003Cstrong>(b)(4)\u003C\u002Fstrong>%RV)\u003C\u002Fli>\n\t\u003Cli>The relative humidity reading was measured at \u003Cstrong>(b)(4)\u003C\u002Fstrong>% (outside the stated tolerance of \u003Cstrong>(b)(4)\u003C\u002Fstrong>%RV).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>During the inspection, the investigator determined that a non-conformance report was not initiated. Your operation Manager, Mr. van Woezik, confirmed that the evaluation of the nonconformance was not documented.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish and maintain procedures for identifying valid statistical techniques and to ensure that sampling plans are adequate for their intended use, as required by 21 CFR 820.250.\u003C\u002Fp>\n\n\u003Cp>For example, for recall Z-1016-2023, your firm documented the investigation in Investigation report NCP2022-14, dated 29 November 2022. The report documents, among other things, experiments to investigate the problems with the seals and accusphere integrity. \u003Cstrong>(b)(4)\u003C\u002Fstrong> RTU plates out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> plates from lot M78493 were tested. During the inspection, the investigator asked about your firm’s justification for selecting&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> plates. Your Head of Research &amp; Science, Dr. Lindhout, stated there is no statistical basis for selecting a sample size of five plates. In addition, your firm’s Operations Manager, Mr. van Woezik, stated that your firm does not have procedures pertaining to statistical techniques.\u003C\u002Fp>\n\n\u003Cp>4. Failure to adequately establish procedures for quality audits and conduct such audits to ensure that the quality system is in compliance with the established quality system requirements and to determine the effectiveness of the quality system, as required by 21 CFR 820.22.\u003C\u002Fp>\n\n\u003Cp>For example, your firm's procedure, SOP-048, \u003Cem>Internal Audit\u003C\u002Fem>, version 30, effective 10 Nov 2022 states, \"The audit frequency will be such that at least once a year a total facility audit will be performed.\" Previous versions, version 29, effective 4 Jul 2022 and version 28, effective 24 Jun 2020 include the same requirement. A list of audit topics for 2020, 2021, and 2022 was reviewed but it did not include Management responsibility, Design controls, or Corrective and Preventive Actions subsystems. Additionally, your Operations Manager, Mr. van Woezik, stated that your firm has never conducted internal audits of these subsystems.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s STAT-IntraOperative-Intact-PTH (STAT-IO-IPTH) Immunoassay kits is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately develop, maintain, and implement written Medical Device Reporting (MDR) procedures as required by 21 CFR 803.17(a). For example, during the inspection, your firm identified the document titled “SOP Medical Device Reporting,” SOP-087, Rev. 14, dated 11\u002F7\u002F2022, as its MDR procedure. After reviewing the procedure, the following deficiencies were noted:\u003C\u002Fp>\n\n\u003Cp>a. The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\u003C\u002Fp>\n\n\u003Cp>i. The procedure omits definitions of the terms “become aware” and “caused or contributed” from 21 CFR Part 803.3, and the definition of the term “reasonably suggest” found in 803.20(c)(1). The exclusion of the definitions for these terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003Cbr>\nii. The procedure, as written, combines language from the requirements of other regulatory or competent authorities with the requirements in 21 CFR Part 803 in a manner that will result in incomplete, inadequate, or even nonreporting of adverse events that meet the reportability requirements under 21 CFR Part 803.\u003Cbr>\niii. The procedure does not include instructions for how your firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\u003C\u002Fp>\n\n\u003Cp>b. The procedure does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example:\u003C\u002Fp>\n\n\u003Cp>i. There are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event.\u003Cbr>\nii. Although the procedure includes instructions for how your firm will evaluate information about an event to make a reportability decision, it fails to include instructions for making determinations in a timely manner.\u003C\u002Fp>\n\n\u003Cp>c. The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the procedure does not include:\u003C\u002Fp>\n\n\u003Cp>i. Instructions for how to obtain and complete the FDA 3500A form.\u003Cbr>\nii. A process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review and archive in accordance with 21 CFR 803.12(a).\u003C\u002Fp>\n\n\u003Cp>2. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003C\u002Fp>\n\n\u003Cp>For example, the information included for Complaints NCP 2022-14 and NCP 2020-29 reasonably suggests that your firm’s STAT-IntraOperative-Intact-PTH (STAT-IO-I-PTH) Immunoassay Kit malfunctioned (i.e., defective component resulting in high coefficients of variation) while in use. Although the information from the complaints state that there was no indication of patient impact, your firm should evaluate each malfunction for reportability. Your firm-initiated recall Z-1016-2023 for a malfunction that results in high coefficients of variation. Per the Preamble, in the Medical Devices; Medical User Facility and Manufacturer Reporting, Certification and Registration; Final Rule, 60 Fed. Reg. 63585 (December 11, 1995), Comment 12, a malfunction is reportable if the manufacturer takes or would be required to take an action under sections 518 or 519(g) of the act as a result of the malfunction of the device or other similar devices. There is no information included for the complaints that indicates that the high coefficients of variation were not the result of the referenced component failure and whether it would not be likely to cause or contribute to a death or serious injury if it were to recur. Your firm became aware of one event described in NCP 2022-14, from \u003Cstrong>(b)(4)\u003C\u002Fstrong> hospital (Texas) on 11\u002F17\u002F2022, two from \u003Cstrong>(b)(4)\u003C\u002Fstrong> Hospital (Pennsylvania) on 11\u002F21\u002F2022, and two more events from Hospital \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>(Spain) on 12\u002F1\u002F2022. Additionally, your firm became aware of one event from&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> hospital (Arizona) identified in NCP 2020-29 on 11\u002F10\u002F2020. However, your firm failed to submit an MDR for each of the six referenced events within the required 30-calendar day timeframe at the conclusion of the inspection.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov&nbsp;\u003Cstrong>Refer to CMS case #653493 when replying\u003C\u002Fstrong>. If you have any questions about the contents of this letter, please contact: Helen Yousefi at helen.yousefi@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Timothy T. Stenzel, M.D., Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT 7: Office of In Vitro Diagnostics\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nMichael Van Der Woude\u003Cbr>\nUS Agent\u003Cbr>\nUSAgent@Ul.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Frank Martel\n\nRecipient Title\n\nManaging Director\n\nFuture Diagnostics Solutions B.V.\n\nNieuweweg 279\n\nWijchen\n\n6603 BN Gelderland\n\nNetherlands\n\nmartel.f@future-diagnostics.nl\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nMay 11, 2023\n\nDear Mr. Frank Martel,\n\nDuring an inspection of your firm located in Gelderland, Netherlands on January 16 through 19, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures STAT-IntraOperative-Intact PTH (Parathyroid Hormone) Immunoassay Kits (STAT-IO-I-PTH). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\n\n1. Failure to verify or validate corrective and preventive actions (CAPA) to ensure that such actions are effective and do not adversely affect the finished device, as required by 21 CFR 820.100(a)(4).\n\nFor example, CAPAs 2021-4, 2021-13, and 2021-16 were initiated to address production non-conformities associated with the STAT-IntraOperative-Intact-PTH Immunoassay Kit. Each report indicates that corrective actions were found to be effective, implemented, and the CAPAs were closed. During the inspection, the investigator requested to review the firm’s documentation of the verification or validation of the corrective action to ensure the action is effective and does not adversely affect the finished device. However, the firm’s Operations Manager, Mr. Jochem van Woezik, stated there was no objective evidence available for review.\n\n2. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements, including, the identification, documentation, evaluation, segregation, and disposition of nonconforming product, and to ensure that the evaluation includes a determination of the need for an investigation, as required by 21 CFR 820.90(a).\n\nFor example, the relative humidity for (b)(4), the (b)(4) compartment, used to (b)(4) and are used during the (b)(4), was found to be out of specification when re for calibration. Specifically, the calibration report documented that the following relative humidity readings were out of range:\n\nThe relative humidity reading was measured at (b)(4)% (outside the stated tolerance of (b)(4)%RV)\n\nThe relative humidity reading was measured at (b)(4)% (outside the stated tolerance of (b)(4)%RV)\n\nThe relative humidity reading was measured at (b)(4)% (outside the stated tolerance of (b)(4)%RV).\n\nDuring the inspection, the investigator determined that a non-conformance report was not initiated. Your operation Manager, Mr. van Woezik, confirmed that the evaluation of the nonconformance was not documented.\n\n3. Failure to establish and maintain procedures for identifying valid statistical techniques and to ensure that sampling plans are adequate for their intended use, as required by 21 CFR 820.250.\n\nFor example, for recall Z-1016-2023, your firm documented the investigation in Investigation report NCP2022-14, dated 29 November 2022. The report documents, among other things, experiments to investigate the problems with the seals and accusphere integrity. (b)(4) RTU plates out of (b)(4) plates from lot M78493 were tested. During the inspection, the investigator asked about your firm’s justification for selecting (b)(4) plates. Your Head of Research & Science, Dr. Lindhout, stated there is no statistical basis for selecting a sample size of five plates. In addition, your firm’s Operations Manager, Mr. van Woezik, stated that your firm does not have procedures pertaining to statistical techniques.\n\n4. Failure to adequately establish procedures for quality audits and conduct such audits to ensure that the quality system is in compliance with the established quality system requirements and to determine the effectiveness of the quality system, as required by 21 CFR 820.22.\n\nFor example, your firm's procedure, SOP-048, Internal Audit, version 30, effective 10 Nov 2022 states, \"The audit frequency will be such that at least once a year a total facility audit will be performed.\" Previous versions, version 29, effective 4 Jul 2022 and version 28, effective 24 Jun 2020 include the same requirement. A list of audit topics for 2020, 2021, and 2022 was reviewed but it did not include Management responsibility, Design controls, or Corrective and Preventive Actions subsystems. Additionally, your Operations Manager, Mr. van Woezik, stated that your firm has never conducted internal audits of these subsystems.\n\nOur inspection also revealed that your firm’s STAT-IntraOperative-Intact-PTH (STAT-IO-IPTH) Immunoassay kits is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n\n1. Failure to adequately develop, maintain, and implement written Medical Device Reporting (MDR) procedures as required by 21 CFR 803.17(a). For example, during the inspection, your firm identified the document titled “SOP Medical Device Reporting,” SOP-087, Rev. 14, dated 11\u002F7\u002F2022, as its MDR procedure. After reviewing the procedure, the following deficiencies were noted:\n\na. The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\n\ni. The procedure omits definitions of the terms “become aware” and “caused or contributed” from 21 CFR Part 803.3, and the definition of the term “reasonably suggest” found in 803.20(c)(1). The exclusion of the definitions for these terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\n\nii. The procedure, as written, combines language from the requirements of other regulatory or competent authorities with the requirements in 21 CFR Part 803 in a manner that will result in incomplete, inadequate, or even nonreporting of adverse events that meet the reportability requirements under 21 CFR Part 803.\n\niii. The procedure does not include instructions for how your firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\n\nb. The procedure does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example:\n\ni. There are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event.\n\nii. Although the procedure includes instructions for how your firm will evaluate information about an event to make a reportability decision, it fails to include instructions for making determinations in a timely manner.\n\nc. The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the procedure does not include:\n\ni. Instructions for how to obtain and complete the FDA 3500A form.\n\nii. A process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review and archive in accordance with 21 CFR 803.12(a).\n\n2. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\n\nFor example, the information included for Complaints NCP 2022-14 and NCP 2020-29 reasonably suggests that your firm’s STAT-IntraOperative-Intact-PTH (STAT-IO-I-PTH) Immunoassay Kit malfunctioned (i.e., defective component resulting in high coefficients of variation) while in use. Although the information from the complaints state that there was no indication of patient impact, your firm should evaluate each malfunction for reportability. Your firm-initiated recall Z-1016-2023 for a malfunction that results in high coefficients of variation. Per the Preamble, in the Medical Devices; Medical User Facility and Manufacturer Reporting, Certification and Registration; Final Rule, 60 Fed. Reg. 63585 (December 11, 1995), Comment 12, a malfunction is reportable if the manufacturer takes or would be required to take an action under sections 518 or 519(g) of the act as a result of the malfunction of the device or other similar devices. There is no information included for the complaints that indicates that the high coefficients of variation were not the result of the referenced component failure and whether it would not be likely to cause or contribute to a death or serious injury if it were to recur. Your firm became aware of one event described in NCP 2022-14, from (b)(4) hospital (Texas) on 11\u002F17\u002F2022, two from (b)(4) Hospital (Pennsylvania) on 11\u002F21\u002F2022, and two more events from Hospital (b)(4) (Spain) on 12\u002F1\u002F2022. Additionally, your firm became aware of one event from (b)(4) hospital (Arizona) identified in NCP 2020-29 on 11\u002F10\u002F2020. However, your firm failed to submit an MDR for each of the six referenced events within the required 30-calendar day timeframe at the conclusion of the inspection.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov Refer to CMS case #653493 when replying. If you have any questions about the contents of this letter, please contact: Helen Yousefi at helen.yousefi@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D.\n\nDirector\n\nOHT 7: Office of In Vitro Diagnostics\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nMichael Van Der Woude\n\nUS Agent\n\nUSAgent@Ul.com","Future Diagnostics Solutions B.V.","future-diagnostics-solutions-bv-653493-05112023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffuture-diagnostics-solutions-bv-653493-05112023","2026-10-26T08:08:44.259812+00:00","2024-04-30","653493","Mr. Frank Martel","2026-08-20T00:09:13.206+00:00","2023-05-11",{"id":168,"raw":169,"subject":173,"body_html":174,"body_text":175,"firm_name":176,"letter_id":177,"created_at":178,"fei_number":19,"letter_url":179,"updated_at":180,"action_type":22,"case_status":23,"posted_date":181,"marcs_cms_no":182,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":183,"body_fetched_at":184,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":185,"medical_device_id":19,"response_letter_date":19},3223,[170,171,172,11,173,13,13,13],"\u003Ctime datetime=\"2021-08-10T13:20:00Z\">08\u002F10\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-07-09T04:00:00Z\">07\u002F09\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fush-diagnostics-inccovidinstanttestnet-612084-07092021\">USH Diagnostics, Inc.\u002Fcovidinstanttest.net\u003C\u002Fa>","Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Chris Ormiston\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>USH Diagnostics, Inc.\u002Fcovidinstanttest.net\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3456 E. 155th St.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Kansas City\u003C\u002Fspan>, \u003Cspan>MO\u003C\u002Fspan> \u003Cspan>64147\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:co@ushealthdiagnostics.com\"> co@ushealthdiagnostics.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:cormiston@ushealthdiagnostics.com\"> cormiston@ushealthdiagnostics.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@covidinstanttest.net\"> support@covidinstanttest.net\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: July 9, 2021\u003C\u002Fp>\n\n\u003Cp>TO:&nbsp;\u003Cbr>\ncovidinstanttest.net\u003Cbr>\n205 E. Osborn Rd.\u003Cbr>\nPhoenix, AZ 85012\u003Cbr>\nsupport@ushealthdiagnostics.com\u003Cbr>\nsupport@americanmedicalsuppliers.com\u003C\u002Fp>\n\n\u003Cp>RE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your websites at the Internet addresses https:\u002F\u002Fcovidinstanttest.net and https:\u002F\u002Fushealthdiagnostics.com\u002F on March 30, 2021, and April 9, 2021. We also reviewed your social media websites at https:\u002F\u002Ffacebook.com\u002Fcovid19instanttest, https:\u002F\u002Ftwitter.com\u002Fcovidathometest, and https:\u002F\u002Fwww.instagram.com\u002Fcovid19instanttest, where you direct consumers to your website, https:\u002F\u002Fcovidinstanttest.net, to purchase your products. The FDA has observed that your websites https:\u002F\u002Fcovidinstanttest.net and https:\u002F\u002Fushealthdiagnostics.com\u002F offer for sale a “Rapid Dual Antibody Test” (which your website also refers to as the “COVID-19 Instant Test,” “Dual Antibody Rapid Test,” “COVID-19 Dual Antibody Test,” “Rapid 15 Minute Antibody,” “Dual IgG\u002FIgM Screening Test for COVID-19,” “15-Minute COVID-19 Screening Test,” “COVID-19 IgM\u002FIgG Rapid Test Device,” “COVID-19 Antibody Test Kit,” and “Dual Antibody Test”) (hereafter referred to as the “COVID-19 Antibody Test Kit”), a “Rapid 10 Minute Antigen Test” (which your website also refers to as the “Antigen Rapid Test,” “COVID-19 Antigen Test Kit,” “Access Bio COVID-19 Antigen Test,” and “COVID-19 Instant Antigen Test”) (hereafter referred to as the “COVID-19 Rapid Antigen Test”), and a “Saliva Test Kit” (all hereafter referred to as “COVID-19 Test Kits”) in the United States. Based on our review, the COVID-19 Test Kits are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, they are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>The COVID-19 Test Kits are offered for sale in the United States to consumers for at-home testing without marketing approval, clearance, or authorization from FDA.\u003Csup>\u003Cem>\u003Cstrong>2,3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Accordingly, your products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described above, you sell products that are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>We also note that different and potentially serious public health risks are presented with specimen collection and testing in the home versus using a test in a healthcare setting. Risks may include, but are not limited to, whether a lay person has the ability to collect their specimen, run the test, and interpret the test result accurately. Your websites, https:\u002F\u002Fcovidinstanttest.net and https:\u002F\u002Fushealthdiagnostics.com\u002F, as well as social media websites, indicate that your firm’s COVID-19 Test Kits may be purchased by consumers and are intended to be used for at-home testing for COVID-19, including:\u003C\u002Fp>\n\n\u003Cp>• “THE MOST RAPID COVID-19 TESTS ON THE INTERNET. PERIOD…\u003Cbr>\nThe Fastest Home Tests on the Market Receive Your Test Next Day, Results Available in Minutes!” [https:\u002F\u002Fcovidinstanttest.net\u002F]\u003C\u002Fp>\n\n\u003Cp>• “COVID-19 INSTANT ANTIGEN TEST\u003Cbr>\nThis diagnostic test is used to get into sporting events, board flights, and meeting other mandatory testing requirements FDA EUA AUTHORIZED LOWER NASAL COVID 10 MIN RAPID TEST Coronavirus (COVID-19) Rapid Test with Telehealth Consultation. The test is administered over a video appointment from the comfort of your home with results in 10 minutes. [https:\u002F\u002Fcovidinstanttest.net\u002Fantigen]\u003C\u002Fp>\n\n\u003Cp>• “COVID-19 At Home Instant Test #COVID19…How does our Coronavirus (COVID-19) Rapid At Home Test work? Learn more: covidinstanttest.net\u003Cbr>\n#CoronaVirus #COVID #COVID19 #SARSCoV2 #COVIDInstantTest\u003Cbr>\n#COVIDRapidTest #COVIDAtHome #RapidTesting #InstantTest”\u003Cbr>\n[Pinned Tweet from November 24, 2020, at https:\u002F\u002Ftwitter.com\u002Fcovidathometest]\u003C\u002Fp>\n\n\u003Cp>• “COVID-19 At Home Instant Test\u003Cbr>\nOur #COVID19 Rapid Tests have received an Emergency Use Authorization from the FDA.\u003Cbr>\ncovidinstanttest.net”\u003Cbr>\n[https:\u002F\u002Fwww.instagram.com\u002Fcovid19instanttest\u002F]\u003Cbr>\n\u003Cbr>\n• “Saliva Test Kit\u003Cbr>\nFDA Submitted\u002FEUA Approved\u003Cbr>\nResults in 24-48 hours\u003Cbr>\nApproved for In-Home Use!\u003Cbr>\n&nbsp; &nbsp; o 100% Accuracy with zero false negatives\u003Cbr>\n&nbsp; &nbsp; o ZERO false positives with 100% Overall Accuracy\u003Cbr>\n&nbsp; &nbsp; o Determines if the patient is currently infected.”\u003Cbr>\n[https:\u002F\u002Fushealthdiagnostics.com]\u003C\u002Fp>\n\n\u003Cp>• “15-Minute COVID-19 Screening Test\u003Cbr>\nSelf contained test can be administered at home or business under the supervision of a Telehealth professional with results in 15 minutes” [https:\u002F\u002Fcovidinstanttest.net\u002Fdual-antibody-test\u002F]\u003C\u002Fp>\n\n\u003Cp>Your products are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because your websites represent that the COVID-19 Test Kits are “FDA Submitted\u002FEUA Approved,” “FDA EUA Authorized,” or “EUA\u002FFDA Certified.” These representations create a false impression that your products have been approved or authorized for emergency use by FDA and are misleading. As discussed above, your COVID-19 Test Kits have not been approved or authorized for emergency use by FDA. In addition, your website, https:\u002F\u002Fushealthdiagnostics.com, displays the FDA logo positioned near images of and information about the COVID-19 Antibody Test Kit and Saliva Test Kit. The FDA logo is for the official use of the FDA and not for use on private sector materials.\u003Csup>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Such use may send a misleading message that the FDA favors or endorses your products. Unauthorized use of the FDA logo may violate federal law and subject those responsible to civil and\u002For criminal liability.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”\u003Csup>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act. This list can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Timothy T. Stenzel, M.D., Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT7: Office of In Vitro Diagnostics and\u003Cbr>\nRadiological Health\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>__________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The “COVID-19 Antibody Test Kit” offered for sale on your website appears to be the RightSign COVID-19 IgG\u002FIgM Rapid Test Cassette manufactured by Hangzhou Biotest Biotech Co., Ltd. On December 21, 2020, FDA reissued an Emergency Use Authorization (EUA) pursuant to section 564 of the Act, 21 U.S.C. § 360bbb-3, to permit emergency use of Hangzhou Biotest Biotech Co., Ltd.’s RightSign COVID-19 IgG\u002FIgM Rapid Test Cassette. The test is indicated for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform moderate and high complexity tests for the qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in human venous whole blood (sodium heparin, potassium EDTA, and sodium citrate), serum, and plasma (sodium heparin, potassium EDTA, and sodium citrate), and, by laboratories certified under CLIA, 42 U.S.C. § 263a, to perform high, moderate, or waived complexity tests, for the qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in fingerstick whole blood specimens. Testing of fingerstick whole blood specimens is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.The test is intended for use as an aid in identifying individuals with an adaptive immune response toSARS-CoV-2, indicating recent or prior infection. However, this EUA does not authorize the sale of the Hangzhou Biotest Biotech Co., Ltd., RightSign COVID-19 IgG\u002FIgM Rapid Test Cassette to consumers for at-home testing.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> The “COVID-19 Rapid Antigen Test” offered for sale on your website appears to be the CareStart COVID-19 Antigen test manufactured by Access Bio, Inc. On April 12, 2021, FDA reissued an EUA pursuant to section 564 of the Act, 21 U.S.C. § 360bbb-3, to permit emergency use of Access Bio, Inc.’s CareStart COVID-19 Antigen test. The test is indicated for for use by laboratories certified under CLIA, 42 U.S.C. § 263a, to perform high, moderate, or waived complexity tests and in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation, for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in nasopharyngeal or anterior nasal swab specimens directly collected from individuals suspected of COVID-19 by their healthcare provider within five days of symptom onset, or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests. However, this EUA does not authorize the sale of the Access Bio, Inc. CareStart COVID-19 Antigen test to consumers for at-home testing.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services Alex M. Azar II, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020 and subsequently renewed), \u003Cem>available at\u003C\u002Fem> \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> FDA Logo Policy (available at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy\">https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy\u003C\u002Fa>).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> Accessible at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Chris Ormiston\n\nUSH Diagnostics, Inc.\u002Fcovidinstanttest.net\n\n3456 E. 155th St.\n\nKansas City, MO 64147\n\nUnited States\n\nco@ushealthdiagnostics.com\n\ncormiston@ushealthdiagnostics.com\n\nsupport@covidinstanttest.net\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDate: July 9, 2021\n\nTO:\n\ncovidinstanttest.net\n\n205 E. Osborn Rd.\n\nPhoenix, AZ 85012\n\nsupport@ushealthdiagnostics.com\n\nsupport@americanmedicalsuppliers.com\n\nRE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your websites at the Internet addresses https:\u002F\u002Fcovidinstanttest.net and https:\u002F\u002Fushealthdiagnostics.com\u002F on March 30, 2021, and April 9, 2021. We also reviewed your social media websites at https:\u002F\u002Ffacebook.com\u002Fcovid19instanttest, https:\u002F\u002Ftwitter.com\u002Fcovidathometest, and https:\u002F\u002Fwww.instagram.com\u002Fcovid19instanttest, where you direct consumers to your website, https:\u002F\u002Fcovidinstanttest.net, to purchase your products. The FDA has observed that your websites https:\u002F\u002Fcovidinstanttest.net and https:\u002F\u002Fushealthdiagnostics.com\u002F offer for sale a “Rapid Dual Antibody Test” (which your website also refers to as the “COVID-19 Instant Test,” “Dual Antibody Rapid Test,” “COVID-19 Dual Antibody Test,” “Rapid 15 Minute Antibody,” “Dual IgG\u002FIgM Screening Test for COVID-19,” “15-Minute COVID-19 Screening Test,” “COVID-19 IgM\u002FIgG Rapid Test Device,” “COVID-19 Antibody Test Kit,” and “Dual Antibody Test”) (hereafter referred to as the “COVID-19 Antibody Test Kit”), a “Rapid 10 Minute Antigen Test” (which your website also refers to as the “Antigen Rapid Test,” “COVID-19 Antigen Test Kit,” “Access Bio COVID-19 Antigen Test,” and “COVID-19 Instant Antigen Test”) (hereafter referred to as the “COVID-19 Rapid Antigen Test”), and a “Saliva Test Kit” (all hereafter referred to as “COVID-19 Test Kits”) in the United States. Based on our review, the COVID-19 Test Kits are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people, and thus, they are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nThe COVID-19 Test Kits are offered for sale in the United States to consumers for at-home testing without marketing approval, clearance, or authorization from FDA.2,3 Accordingly, your products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.4 In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.5 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described above, you sell products that are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nWe also note that different and potentially serious public health risks are presented with specimen collection and testing in the home versus using a test in a healthcare setting. Risks may include, but are not limited to, whether a lay person has the ability to collect their specimen, run the test, and interpret the test result accurately. Your websites, https:\u002F\u002Fcovidinstanttest.net and https:\u002F\u002Fushealthdiagnostics.com\u002F, as well as social media websites, indicate that your firm’s COVID-19 Test Kits may be purchased by consumers and are intended to be used for at-home testing for COVID-19, including:\n\n• “THE MOST RAPID COVID-19 TESTS ON THE INTERNET. PERIOD…\n\nThe Fastest Home Tests on the Market Receive Your Test Next Day, Results Available in Minutes!” [https:\u002F\u002Fcovidinstanttest.net\u002F]\n\n• “COVID-19 INSTANT ANTIGEN TEST\n\nThis diagnostic test is used to get into sporting events, board flights, and meeting other mandatory testing requirements FDA EUA AUTHORIZED LOWER NASAL COVID 10 MIN RAPID TEST Coronavirus (COVID-19) Rapid Test with Telehealth Consultation. The test is administered over a video appointment from the comfort of your home with results in 10 minutes. [https:\u002F\u002Fcovidinstanttest.net\u002Fantigen]\n\n• “COVID-19 At Home Instant Test #COVID19…How does our Coronavirus (COVID-19) Rapid At Home Test work? Learn more: covidinstanttest.net\n\n#CoronaVirus #COVID #COVID19 #SARSCoV2 #COVIDInstantTest\n\n#COVIDRapidTest #COVIDAtHome #RapidTesting #InstantTest”\n\n[Pinned Tweet from November 24, 2020, at https:\u002F\u002Ftwitter.com\u002Fcovidathometest]\n\n• “COVID-19 At Home Instant Test\n\nOur #COVID19 Rapid Tests have received an Emergency Use Authorization from the FDA.\n\ncovidinstanttest.net”\n\n[https:\u002F\u002Fwww.instagram.com\u002Fcovid19instanttest\u002F]\n\n• “Saliva Test Kit\n\nFDA Submitted\u002FEUA Approved\n\nResults in 24-48 hours\n\nApproved for In-Home Use!\n\no 100% Accuracy with zero false negatives\n\no ZERO false positives with 100% Overall Accuracy\n\no Determines if the patient is currently infected.”\n\n[https:\u002F\u002Fushealthdiagnostics.com]\n\n• “15-Minute COVID-19 Screening Test\n\nSelf contained test can be administered at home or business under the supervision of a Telehealth professional with results in 15 minutes” [https:\u002F\u002Fcovidinstanttest.net\u002Fdual-antibody-test\u002F]\n\nYour products are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because your websites represent that the COVID-19 Test Kits are “FDA Submitted\u002FEUA Approved,” “FDA EUA Authorized,” or “EUA\u002FFDA Certified.” These representations create a false impression that your products have been approved or authorized for emergency use by FDA and are misleading. As discussed above, your COVID-19 Test Kits have not been approved or authorized for emergency use by FDA. In addition, your website, https:\u002F\u002Fushealthdiagnostics.com, displays the FDA logo positioned near images of and information about the COVID-19 Antibody Test Kit and Saliva Test Kit. The FDA logo is for the official use of the FDA and not for use on private sector materials.6 Such use may send a misleading message that the FDA favors or endorses your products. Unauthorized use of the FDA logo may violate federal law and subject those responsible to civil and\u002For criminal liability.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”7 provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D.\n\nDirector\n\nOHT7: Office of In Vitro Diagnostics and\n\nRadiological Health\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n__________________________________\n\n1 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 The “COVID-19 Antibody Test Kit” offered for sale on your website appears to be the RightSign COVID-19 IgG\u002FIgM Rapid Test Cassette manufactured by Hangzhou Biotest Biotech Co., Ltd. On December 21, 2020, FDA reissued an Emergency Use Authorization (EUA) pursuant to section 564 of the Act, 21 U.S.C. § 360bbb-3, to permit emergency use of Hangzhou Biotest Biotech Co., Ltd.’s RightSign COVID-19 IgG\u002FIgM Rapid Test Cassette. The test is indicated for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform moderate and high complexity tests for the qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in human venous whole blood (sodium heparin, potassium EDTA, and sodium citrate), serum, and plasma (sodium heparin, potassium EDTA, and sodium citrate), and, by laboratories certified under CLIA, 42 U.S.C. § 263a, to perform high, moderate, or waived complexity tests, for the qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in fingerstick whole blood specimens. Testing of fingerstick whole blood specimens is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.The test is intended for use as an aid in identifying individuals with an adaptive immune response toSARS-CoV-2, indicating recent or prior infection. However, this EUA does not authorize the sale of the Hangzhou Biotest Biotech Co., Ltd., RightSign COVID-19 IgG\u002FIgM Rapid Test Cassette to consumers for at-home testing.\n\n3 The “COVID-19 Rapid Antigen Test” offered for sale on your website appears to be the CareStart COVID-19 Antigen test manufactured by Access Bio, Inc. On April 12, 2021, FDA reissued an EUA pursuant to section 564 of the Act, 21 U.S.C. § 360bbb-3, to permit emergency use of Access Bio, Inc.’s CareStart COVID-19 Antigen test. The test is indicated for for use by laboratories certified under CLIA, 42 U.S.C. § 263a, to perform high, moderate, or waived complexity tests and in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation, for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in nasopharyngeal or anterior nasal swab specimens directly collected from individuals suspected of COVID-19 by their healthcare provider within five days of symptom onset, or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests. However, this EUA does not authorize the sale of the Access Bio, Inc. CareStart COVID-19 Antigen test to consumers for at-home testing.\n\n4 Secretary of Health and Human Services Alex M. Azar II, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020 and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n5 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\n\n6 FDA Logo Policy (available at: https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy).\n\n7 Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload.","USH Diagnostics, Inc.\u002Fcovidinstanttest.net","ush-diagnostics-inccovidinstanttestnet-612084-07092021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fush-diagnostics-inccovidinstanttestnet-612084-07092021","2026-10-26T08:10:18.664164+00:00","2021-08-10","612084","Mr. Chris Ormiston","2026-08-20T02:43:10.937+00:00","2021-07-09",9,{"510k":188,"classification":189,"enforcement":190,"event":191,"event_backfill":192,"pma":193,"warning_letter":194},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]